
<html lang="en"     class="pb-page"  data-request-id="e931e8f6-456c-4cae-a80d-e93f714e893e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm2007613;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2011.54.issue-18;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)" /></meta><meta name="dc.Creator" content="J. Jean  Cui" /></meta><meta name="dc.Creator" content="Michelle  Tran-Dubé" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Mitchell  Nambu" /></meta><meta name="dc.Creator" content="Pei-Pei  Kung" /></meta><meta name="dc.Creator" content="Mason  Pairish" /></meta><meta name="dc.Creator" content="Lei  Jia" /></meta><meta name="dc.Creator" content="Jerry  Meng" /></meta><meta name="dc.Creator" content="Lee  Funk" /></meta><meta name="dc.Creator" content="Iriny  Botrous" /></meta><meta name="dc.Creator" content="Michele  McTigue" /></meta><meta name="dc.Creator" content="Neil  Grodsky" /></meta><meta name="dc.Creator" content="Kevin  Ryan" /></meta><meta name="dc.Creator" content="Ellen  Padrique" /></meta><meta name="dc.Creator" content="Gordon  Alton" /></meta><meta name="dc.Creator" content="Sergei  Timofeevski" /></meta><meta name="dc.Creator" content="Shinji  Yamazaki" /></meta><meta name="dc.Creator" content="Qiuhua  Li" /></meta><meta name="dc.Creator" content="Helen  Zou" /></meta><meta name="dc.Creator" content="James  Christensen" /></meta><meta name="dc.Creator" content="Barbara  Mroczkowski" /></meta><meta name="dc.Creator" content="Steve  Bender" /></meta><meta name="dc.Creator" content="Robert S.  Kania" /></meta><meta name="dc.Creator" content="Martin P.  Edwards" /></meta><meta name="dc.Description" content="Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of ..." /></meta><meta name="Description" content="Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 18, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm2007613" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm2007613" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm2007613" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm2007613" /></link>
        
    
    

<title>Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm2007613" /></meta><meta property="og:title" content="Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0019.jpeg" /></meta><meta property="og:description" content="Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm2007613"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm2007613">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm2007613&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm2007613&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm2007613&amp;href=/doi/10.1021/jm2007613" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 6342-6363</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm200758k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2007744" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)<a class="ref internalNav" href="#pdb" aria-label=""></a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Jean++Cui">J. Jean Cui</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Tran-Dub%C3%A9">Michelle Tran-Dubé</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mitchell++Nambu">Mitchell Nambu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pei-Pei++Kung">Pei-Pei Kung</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mason++Pairish">Mason Pairish</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Jia">Lei Jia</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jerry++Meng">Jerry Meng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lee++Funk">Lee Funk</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Iriny++Botrous">Iriny Botrous</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele++McTigue">Michele McTigue</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Grodsky">Neil Grodsky</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Ryan">Kevin Ryan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ellen++Padrique">Ellen Padrique</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gordon++Alton">Gordon Alton</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sergei++Timofeevski">Sergei Timofeevski</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shinji++Yamazaki">Shinji Yamazaki</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiuhua++Li">Qiuhua Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Zou">Helen Zou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Christensen">James Christensen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Mroczkowski">Barbara Mroczkowski</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Bender">Steve Bender</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+S.++Kania">Robert S. Kania</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+P.++Edwards">Martin P. Edwards</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info">Phone: 858-638-6333. Fax: 877-481-1783. E-mail: <a href="/cdn-cgi/l/email-protection#7b111e1a1555180e123b0b1d12011e0955181416"><span class="__cf_email__" data-cfemail="355f50545b1b56405c7545535c4f50471b565a58">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm2007613&amp;href=/doi/10.1021%2Fjm2007613" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 6342–6363</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 3, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 June 2011</li><li><span class="item_label"><b>Published</b> online</span>18 August 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm2007613" title="DOI URL">https://doi.org/10.1021/jm2007613</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6342%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJ.%2BJean%2BCui%252C%2BMichelle%2BTran-Dub%25C3%25A9%252C%2BHong%2BShen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D18%26contentID%3Djm2007613%26title%3DStructure%2BBased%2BDrug%2BDesign%2Bof%2BCrizotinib%2B%2528PF-02341066%2529%252C%2Ba%2BPotent%2Band%2BSelective%2BDual%2BInhibitor%2Bof%2BMesenchymal%25E2%2580%2593Epithelial%2BTransition%2BFactor%2B%2528c-MET%2529%2BKinase%2Band%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6363%26publicationDate%3DSeptember%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm2007613"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">18713</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">539</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm2007613" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Tran-Dubé&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Mitchell&quot;,&quot;last_name&quot;:&quot;Nambu&quot;},{&quot;first_name&quot;:&quot;Pei-Pei&quot;,&quot;last_name&quot;:&quot;Kung&quot;},{&quot;first_name&quot;:&quot;Mason&quot;,&quot;last_name&quot;:&quot;Pairish&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Jia&quot;},{&quot;first_name&quot;:&quot;Jerry&quot;,&quot;last_name&quot;:&quot;Meng&quot;},{&quot;first_name&quot;:&quot;Lee&quot;,&quot;last_name&quot;:&quot;Funk&quot;},{&quot;first_name&quot;:&quot;Iriny&quot;,&quot;last_name&quot;:&quot;Botrous&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;McTigue&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Grodsky&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Ryan&quot;},{&quot;first_name&quot;:&quot;Ellen&quot;,&quot;last_name&quot;:&quot;Padrique&quot;},{&quot;first_name&quot;:&quot;Gordon&quot;,&quot;last_name&quot;:&quot;Alton&quot;},{&quot;first_name&quot;:&quot;Sergei&quot;,&quot;last_name&quot;:&quot;Timofeevski&quot;},{&quot;first_name&quot;:&quot;Shinji&quot;,&quot;last_name&quot;:&quot;Yamazaki&quot;},{&quot;first_name&quot;:&quot;Qiuhua&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Christensen&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Mroczkowski&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Bender&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;S. Kania&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;6342-6363&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm2007613&quot;},&quot;abstract&quot;:&quot;Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2007613&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2007613" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2007613&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2007613" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2007613&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2007613" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm2007613&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2007613&amp;href=/doi/10.1021/jm2007613" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm2007613" /></input><a href="/doi/pdf/10.1021/jm2007613" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26pmid%3D21812414%26genre%3Darticle%26aulast%3DCui%26date%3D2011%26atitle%3DStructure%2BBased%2BDrug%2BDesign%2Bof%2BCrizotinib%2B%2528PF-02341066%2529%252C%2Ba%2BPotent%2Band%2BSelective%2BDual%2BInhibitor%2Bof%2BMesenchymal%25E2%2580%2593Epithelial%2BTransition%2BFactor%2B%2528c-MET%2529%2BKinase%2Band%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D18%26spage%3D6342%26epage%3D6363%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jmcmar.2011.54.issue-18/production/jmcmar.2011.54.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of <b>3</b> (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with <b>3</b>. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of <b>3</b> via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span>†</span>  Note</h4><p class="last">PDB codes are the following: <a href="https://" class="ext-link">2wkm</a> for the PHA-665752/c-MET complex; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj">2wgj</a> for the PF-02341066/c-MET complex; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a> for the PF-02341066/ALK complex.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Receptor tyrosine kinases (RTKs) play fundamental roles in cellular processes, including cell proliferation, migration, metabolism, differentiation, and survival. RTK activity is tightly controlled in normal cells. The constitutively enhanced RTK activities from point mutation, amplification, and rearrangement of the corresponding genes have been implicated in the development and progression of many types of cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Successful approval of small molecule tyrosine kinase inhibitors has clinically validated this mode of therapeutic intervention, along with several pathogenic tyrosine kinases as effective molecular targets for cancer therapy. Recent examples include imatinib in gastrointestinal stromal tumors with mutant c-KIT kinase or chronic myelogenous leukemia with BCR-ABL gene translocations, erlotinib in non-small-cell lung cancer (NSCLC) with mutant EGFR, and sunitinib targeting the VHL-dependent VEGF pathway in renal cell carcinoma.</div><div class="NLM_p">Signaling from the receptor tyrosine kinase c-MET, also known as hepatocyte growth factor receptor (HGFR), and its natural ligand hepatocyte growth factor (HGF), also known as scatter factor, plays important roles during normal development, organogenesis, and homeostasis. After activation by HGF, c-MET induces an invasive program consisting of cell proliferation, migration, invasion, survival, and branching morphogenesis. Aberrant c-MET signaling through constitutive activation, gene amplification, and mutations occurs in virtually all types of solid tumors and is implicated in dysregulation of multiple tumor oncogenic processes such as mitogenesis, survival, angiogenesis, invasive growth, and especially the metastatic process.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Furthermore, the overexpression of c-MET and HGF was demonstrated to correlate with poor prognosis or metastatic progression in a number of major human cancers.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> For these reasons c-MET and its ligand HGF have become leading candidates for molecular targeted cancer therapies.</div><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, grouped together with leukocyte tyrosine kinase (LTK) to a subfamily within the insulin receptor (IR) superfamily. ALK was first discovered as a fusion protein, NPM (nucleophosmin)–ALK in anaplastic large cell lymphoma cell lines in 1994.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The transforming ability of NPM–ALK was demonstrated, and the oncogenesis requires the activation of ALK kinase function as a result of oligomerization mediated by the NPM segment.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> ALK with other chromosomal rearrangements have been detected in anaplastic large cell lymphoma (50–60%), inflammatory myofibroblastic tumors (27%), and non-small-cell lung cancer (4–7%).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The ALK fusion proteins have a common structural feature with the amino terminal region of the fusion protein containing an oligomerization domain to cause the oligomerization of the fusion protein and ALK kinase-mediated autophosphorylation. EML4–ALK fusion gene, comprising portions of the echinoderm microtubule associated protein-like 4 (EML4) gene and the ALK gene, was first discovered in non-small-cell lung cancer archived clinical specimens and also cell lines.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> EML4–ALK fusion variants were demonstrated to transform NIH-3T3 fibroblasts and cause lung adenocarcinoma when expressed in transgenic mice, which confirm the potent oncogenic activity of the fusion kinase.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Oncogenic mutations of ALK in both familial and sporadic cases of neuroblastoma have also been reported.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Therefore, ALK is an attractive molecular target for cancer therapeutic intervention.</div><div class="NLM_p last">Herein, we detail the drug design campaign that led to crizotinib (PF-02341066, <b>63</b>), a potent and selective c-MET/ALK dual inhibitor.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Consistent with its mechanism of action, crizotinib demonstrates dose-dependent inhibition of phosphorylation of c-MET, NPM–ALK, and selected variants, as well as targets dependent functions in tumor cells both in vitro and in vivo.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Crizotinib showed antitumor efficacy, including marked cytoreductive antitumor activity, in multiple tumor models implanted in athymic mice that expressed activated c-MET or ALK fusion proteins.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In additional published studies, crizotinib inhibits tumor cell growth of cell lines harboring fusion variants and activating mutations of ALK including Karpas299 (NPM–ALK), SU-DHL-1 (NPM–ALK), Kelly neuroblastoma (active ALK mutation), and NCI-H3122 (EML4–ALK variant 1) with IC<sub>50</sub> values ranging from 74 to 544 nM.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> On the basis of an exceptional attribute profile, crizotinib was advanced into human clinical studies for the treatment of cancer.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Foundations of Structure Based Design</h3><div class="NLM_p">To enable a structure based drug design (SBDD) program, a kinase domain (KD) construct of c-MET, in its nonphosphorylated form, was prepared for utilization in cocrystallization experiments. Fortunately, cell-based activity of the inhibitors prevented RTK autophosphorylation, consistent with inhibitory interaction with the nonphosphorylated form in cells. Inhibition of phosphorylated c-MET KD in purified enzyme biochemical assays confirmed that the inhibitors can inhibit both unactivated and activated c-MET. Overall, there was little divergence between enzyme and cell data, apart from that which could be readily understood by permeability/efflux considerations. Where there was minor divergence, the structural biology was illuminating, as will be discussed below.</div><div class="NLM_p">The search for leads started in a potent class of kinase inhibitors, the 3-substituted indolin-2-ones, where one representative, sunitinib, is now approved for GIST and RCC treatment.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The selectivity of indolin-2-ones for particular kinases is mediated by substituents built onto the indolin-2-one core. Both 4-substituted indolin-2-ones and 5-substituted indolin-2-ones were evaluated for c-MET inhibition and attractive lead matter was found.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> From this starting point, key cocrystal structures guided both prioritization decisions and drug design strategy.</div><div class="NLM_p">To monitor the progress of optimization, lipophilic efficiency (LipE = p<i>K</i><sub>i</sub> (or pIC<sub>50</sub>) – cLogD) was used as a numerical index of binding effectiveness.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Drug design aimed at improvement of LipE results in parallel optimization for desirable ADME and greater likelihood of safe drug profiles, since ligand interactions with most proteins are substantially influenced by lipophilicity.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This convenient numeric index that reflects compound target potency relative to lipophilicity is presented consistently throughout, demonstrating the effectiveness of integrated SBDD and property based drug design.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0021.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> c-MET Leads from the 3-Substituted Indolin-2-one Series</h3><div class="NLM_p">Compound <b>2</b> (SU11274), shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, was identified as a c-MET inhibitor with isolated enzyme IC<sub>50</sub> of 10 nM.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><b>2</b> inhibited HGF-induced c-MET autophosphorylation in a dose dependent manner with complete inhibition at 1 μM in A549 c-MET cellular assay.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Optimization of <b>2</b> led to <b>3</b> (PHA-665752) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), a c-MET RTK inhibitor with a significantly improved cellular potency (IC<sub>50</sub> = 9 nM in GTL-16 cell line) and selectivity (>50-fold for c-MET compared with a panel of diverse tyrosine and serine–threonine kinases).<a onclick="showRef(event, 'cit13c ref17'); return false;" href="javascript:void(0);" class="ref cit13c ref17">(13c, 17)</a><b>3</b> was broadly used in preclinical studies to build confidence in c-MET as a target for cancer therapy and to identify potential patient populations.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In a variety of tumor cells, <b>3</b> potently inhibited HGF stimulated and constitutive c-MET phosphorylation, downstream signal transduction of c-MET, and HGF/c-MET driven phenotypes, e.g., cell growth, cell motility, invasion, and morphology. In vivo, <b>3</b> inhibited c-MET phosphorylation in tumor xenografts, and tumor growth in a dose-dependent manner.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> However, the poor pharmaceutical properties of <b>3</b> limited its further development as a clinic candidate.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0022.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of <b>3</b> bound to the kinase domain of c-MET. The backbone trace of the activation loop is highlighted in cyan, and hydrogen bonds are indicated as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A cocrystal structure of <b>3</b> bound to the unphosphorylated c-MET KD revealed the key binding interactions as presented in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm">2wkm</a>). In the complex of <b>3</b>, the c-MET KD adopts the unique autoinhibitory conformation observed previously in crystal structures of the apo-enzyme and a complex with the staurosporine analogue K252a.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In these c-MET crystal structures, the beginning of the kinase activation loop (residues 1222–1227) forms a turn that wedges between the β-sheet and the αC-helix. Consequently, the activation loop significantly displaces the αC-helix from a catalytically competent position and the downstream activation loop residues (1228–1245) to a position that interferes with ATP and substrate binding. This unusual kinase activation loop conformation creates a unique inhibitor binding pocket which presents an opportunity for the design of selective inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0023.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure overlay of <b>3</b>/c-MET (green/gray) and <b>1</b>/FGFR1K (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As in a previously published cocrystal structure of <b>1</b> (SU5402) with fibroblast growth factor receptor 1 kinase (FGFR1K),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> the oxindole ring N–H and carbonyl oxygen of <b>3</b> form two hydrogen bonds to the protein backbone of the kinase hinge region. Also, similar to the <b>1</b>/FGFR1K complex, the amide substituent off the pyrrole ring extends into the solvent surrounding the kinase hinge segment. For both inhibitors, the oxindole and pyrrole rings are in a coplanar conformation, stabilized by resonance and an intramolecular hydrogen bond between the pyrrole N–H and the oxindole O═C. This flat scaffold provides strong interactions to the adenine binding cleft while fitting its flat dimensions well. Unlike the <b>1</b>/FGFR1K structure, the plane of the oxindole–pyrrole system in <b>3</b> is tilted away from the c-MET glycine-rich loop significantly (down in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), a difference arising from both protein and inhibitor structural differences. This lower inhibitor position in c-MET is permitted by the more flexible (and compressed) Met-1211 and is stabilized by the critical π–π stacking interaction between the benzyl group and Tyr-1230 of the A-loop in its unique conformation (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). A hydrogen bond between the oxygen of the sulfonyl group and the backbone N–H of Asp-1222 is also stabilizing this orientation.</div><div class="NLM_p last">For clarity, it is useful to establish that all the inhibitors discussed herein are believed to bind the above unique A-loop conformation of c-MET and that the phosphorylation state of c-MET protein in different contexts is as follows: (1) c-MET remains nonphosphorylated in cells when inhibited; (2) in crystal structures of nonphosphorylated c-MET the protein adopts a unique conformation to which the inhibitors bind. It is also recognized that phosphorylation of the activation loop is part of the regulatory mechanism that destabilizes the autoinhibited activation loop conformation that is serving as the drug design target. Impacts of this become apparent in small potency trend differences between enzyme and cell assays for certain inhibitor structural types. The differences arise, predictably, from structural features optimized to bind adjacent to the activation loop.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Design of Novel 5-Aryl-3-benzyloxy-2-aminopyridine c-MET Inhibitors</h3><div class="NLM_p">Although <b>3</b> demonstrated potent and selective inhibition of c-MET autophosphorylation and related biological functions in both in vitro and in vivo studies, the poor pharmaceutical properties (low solubility, high metabolic clearance, and poor permeability) limited further development for human clinical studies. With improved pharmaceutical properties as the goal, a key strategy was to design smaller and less lipophilic inhibitors (<b>3</b>, MW = 641.62, measured log <i>D</i> = 3.20 at pH 7.4, c-MET cell IC<sub>50</sub> = 9 nM, LE = 0.25,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> LipE = 4.85) with good kinase selectivity.</div><div class="NLM_p">The cocrystal structure of <b>3</b> with c-MET KD was analyzed to elucidate opportunities to make key interactions with a more efficient use of chemical structure. Starting with fundamental scaffold optimization, one such opportunity was recognized by analyzing the indolin-2-one pyrrole core, which extends the full length of the adenine pocket. In addition to occupying a low tilt position in the adenine pocket (vide supra) the core size requires that the sulfone methylene linker make a U-turn to position the 2,6-dichlorophenyl group for a π–π stacking interaction with Tyr-1230. Consequently, a significant portion of the indolinone ring along with the sulfone linker was identified as inefficient scaffolding for the 2,6-dichlorophenyl group. Compounds were designed with a smaller hinge binder, from which could be positioned an aryl ring to interact with Tyr-1230 in a more direct manner.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0024.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of 5-aryl-3-benzyloxy-2-aminopyridine scaffold for c-MET inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Through re-engineering of the central core rings (three iterations of thinking are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), the novel 5-aryl-3-benzyloxy-2-aminopyridine scaffold was designed. This required a recentering and truncating of the pyrrole–oxindole platform down to a small, adenine-pocket core. Accordingly, the 2-aminopyridine NH and ring nitrogen were expected to make H-bonds to the hinge protein residues Pro-1158 and Met-1160, similar to the oxindole ring of <b>3</b>. The more bold requirement of this design is that the 3-benzyloxy group must take an efficient path, along a new vector, to stack with Tyr-1230. For the shortened linkage to stretch back to the hinge, binding must be accompanied by a scaffold tilt back to the higher adenine pocket position seen with <b>1</b>. Last, the aryl group at the 5-position of this new scaffold is easily anticipated to point toward solvent in the same way oxindole–pyrrole substituents do, providing a handle to modulate lipophilicity.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0025.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. First iteration 2-aminopyridines show c-MET inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The design concept was tested with a small set of compounds shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>. Compound <b>7</b> displayed moderate inhibition against c-MET with an enzymatic <i>K</i><sub>i</sub> of 3.83 μM (LE= 0.29, LipE = 0.35). The introduction of a 2-morpholinoethoxyethyl group in <b>8</b> showed a similar potency against c-MET as <b>7</b>. Although this is less efficient, retained inhibition is consistent with the 5-phenyl group pointing toward solvent and the 2-aminopyridine interacting at the hinge. Compound <b>11a</b> (LE = 0.24, LipE = 3.70), with the same amide group as <b>3</b>, demonstrated improved absolute potency against c-MET and also LipE value, again consistent with a similar binding mode for this novel series. Additionally, given the different vector of the new series, optimal substituents for the novel 2-aminopyridines were not expected to mirror those of the oxindole core. A cocrystal structure of the 2-aminopyridine core making H-bonds to the hinge confirmed the adenine binding orientation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For compounds <b>7</b>, <b>8</b>, and <b>11a</b>, the structural features that are necessary to bind the hinge backbone were incorporated in the monocyclic 2-aminopyridine whereas the <i>O</i>-methylene-2,6-dichlorophenyl was intended to fully and efficiently interact with Tyr-1230 of the A-loop. The trajectory of the solvent exposed group and the electronic effects already observed between <b>8</b> and <b>11a</b> gave reason to expect that optimization from this point would be productive. From this novel series, with greater promise of efficiency, optimization was focused on improving c-MET potency and physical properties in parallel.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Optimization of the 3-Benzyloxy Group</h3><div class="NLM_p">Further optimization of the 2-aminopyridine series was supported by the promising inhibition exhibited by <b>11a</b>, which also served as a convenient scaffold for initial analogues. According to the binding mode of the original design hypothesis, the benzyloxy group at the 3-position is the structural feature that binds to the hydrophobic pocket and interacts with Tyr-1230, a priority area to study structural modifications. Various aryl analogues intended to interact with Tyr-1230 were targeted, with representative results and LipE analysis results summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. The convenience of the graphical plot allows for easy recognition of overall optimization against constant LipE zones, facilitating the mining of structural features that impart movement orthogonal to the LipE lines (e.g., <b>14c</b>, <b>14i</b>, and <b>14j</b> are similarly efficient across broad potency/cLogD space).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship of Substitutes on 3-Benzyloxy Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">cLogD <a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">c-MET <i>K</i><sub>i</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">LipE(<i>K</i><sub>i</sub>) <a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">c-MET cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">LipE(IC<sub>50</sub>) <a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2,6-di-Cl</td><td class="colsep0 rowsep0" align="left">2.64</td><td class="colsep0 rowsep0" align="left">0.46</td><td class="colsep0 rowsep0" align="left">3.70</td><td class="colsep0 rowsep0" align="left">1.79</td><td class="colsep0 rowsep0" align="left">3.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1.44</td><td class="colsep0 rowsep0" align="left">7.92</td><td class="colsep0 rowsep0" align="left">3.66</td><td class="colsep0 rowsep0" align="left">>10.0</td><td class="colsep0 rowsep0" align="left"><3.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">1.49</td><td class="colsep0 rowsep0" align="left">2.82</td><td class="colsep0 rowsep0" align="left">4.08</td><td class="colsep0 rowsep0" align="left">6.62</td><td class="colsep0 rowsep0" align="left">3.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">2.03</td><td class="colsep0 rowsep0" align="left">1.71</td><td class="colsep0 rowsep0" align="left">3.79</td><td class="colsep0 rowsep0" align="left">5.85</td><td class="colsep0 rowsep0" align="left">3.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-CN</td><td class="colsep0 rowsep0" align="left">0.88</td><td class="colsep0 rowsep0" align="left">6.50</td><td class="colsep0 rowsep0" align="left">4.31</td><td class="colsep0 rowsep0" align="left">>10.0</td><td class="colsep0 rowsep0" align="left"><4.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.01</td><td class="colsep0 rowsep0" align="left">2.59</td><td class="colsep0 rowsep0" align="left">3.58</td><td class="colsep0 rowsep0" align="left">7.11</td><td class="colsep0 rowsep0" align="left">3.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-<i>tert</i>-butyl</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">0.98</td><td class="colsep0 rowsep0" align="left">3.15</td><td class="colsep0 rowsep0" align="left">8.53</td><td class="colsep0 rowsep0" align="left">1.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2,4-di-Cl</td><td class="colsep0 rowsep0" align="left">2.64</td><td class="colsep0 rowsep0" align="left">1.03</td><td class="colsep0 rowsep0" align="left">3.35</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">3.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-Cl-6-F</td><td class="colsep0 rowsep0" align="left">1.64</td><td class="colsep0 rowsep0" align="left">5.11</td><td class="colsep0 rowsep0" align="left">4.16</td><td class="colsep0 rowsep0" align="left">8.12</td><td class="colsep0 rowsep0" align="left">3.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14h</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-Cl-3,6-di-F</td><td class="colsep0 rowsep0" align="left">1.87</td><td class="colsep0 rowsep0" align="left">0.88</td><td class="colsep0 rowsep0" align="left">4.18</td><td class="colsep0 rowsep0" align="left">0.56</td><td class="colsep0 rowsep0" align="left">4.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14i</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2-Cl-3,6-di-F</td><td class="colsep0 rowsep0" align="left">2.22</td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">4.37</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">4.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14j</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2,6-di-Cl</td><td class="colsep0 rowsep0" align="left">2.99</td><td class="colsep0 rowsep0" align="left">0.068</td><td class="colsep0 rowsep0" align="left">4.20</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">3.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14k</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2,6-di-Cl-3-F</td><td class="colsep0 rowsep0" align="left">3.10</td><td class="colsep0 rowsep0" align="left">0.012</td><td class="colsep0 rowsep0" align="left">4.82</td><td class="colsep0 rowsep0" align="left">0.020</td><td class="colsep0 rowsep0" align="left">4.60</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat, version 9.3.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and cell IC<sub>50</sub><a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> were determined as described in <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">LipE = p<i>K</i><sub>i</sub> (or pIC<sub>50</sub>) – cLogD.</p></div></div></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. LipE plot highlights <b>14k</b>, <b>14i</b>, and <b>14c</b> as lead compounds and where close analogues reside.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unsubstituted <b>11b</b> serves as a benchmark for c-MET kinase inhibition (<i>K</i><sub>i</sub> = 7.92 μM, LipE = 3.66), establishing a baseline to analyze LipE contributions from different phenyl ring substitution patterns. The relatively conservative phenyl ring derivatives displayed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> have enzymatic LipE values ranging from 3 to 5. The 2-position, monosubstituted phenyl ring compounds <b>14a</b>–<b>d</b> had measurable increases in potency against c-MET, with the exception of nitrile <b>14c</b>. Although with potency similar to that of <b>11b</b>, this nitrile compound had the highest biochemical LipE of 4.31. However, <b>14c</b> was not active in the c-MET cellular assay at 10 μM tested. Compound <b>14e</b>, a 4-position derivative bearing the highly lipophilic <i>tert</i>-butylphenyl group, had improved enzymatic potency against c-MET (<i>K</i><sub>i</sub> = 0.98 μM). However, the lower LipE (3.15), which was even worse when using cell-based numbers, indicated that the potency gain was not attractive relative to lipophilicity cost. The 2,4-dichloro substituted compound <b>14f</b> showed slightly improved enzymatic LipE due to a lower lipophilicity. This translated to greater cell potency with an IC<sub>50</sub> of 0.41 μM and one of the three big jumps in cell LipE observed within this table. Although a number of variables could be contributing, the cell vs biochemical potency of <b>14f</b> was an early indication that SAR between cell and biochemical measures may diverge because of the different binding affinity of the inhibitor to nonphosphorylated c-MET vs phosphorylated c-MET. Importantly, cell/enzyme potency divergence was associated with the benzylic structural feature, which interacts with the unique tyrosine and protein conformation of nonphosphorylated c-MET discussed earlier. Previous work with RTKs reinforced the practice of targeting nonphosphorylated kinase and prioritizing the cell-based data, which is consistent with conformations and interactions seen crystallographically.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The potency contribution of the 3-fluoro substituent on the phenyl ring was demonstrated by <b>14h</b> compared to <b>14g</b>. The addition of the 3-fluoro imparted a 5-fold increase in enzymatic potency (<i>K</i><sub>i</sub> = 0.88 μM) and a 14.5-fold increase of cell potency (IC<sub>50</sub> = 0.56 μM) relative to the 2-chloro-6-fluorophenyl ring of <b>14g</b> (<i>K</i><sub>i</sub> = 5.11 μM and cell IC<sub>50</sub> = 8.12 μM). The improvement of c-MET cell LipE, from 3.45 to 4.38 for <b>14h</b>, reinforced the importance of this single atom change and is the second jump in LipE. Overall, the phenyl group substitution optimization provided moderate improvement to c-MET potency, with notable impacts for 2-chloro and 3-fluoro substitution.</div><div class="NLM_p last">Further optimization came from modification to the linkage between the 2-aminopyridine core and the phenyl ring just discussed. A small lipophilic pocket, visible to the upper left of Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, is adjacent to the putative bound location of the 3-benzyloxy linker. Adding small lipophilic bulk to this structural feature led to enhanced efficiency from an α-methyl group. As demonstrated with compounds <b>14i</b>–<b>k</b>, inclusion of the α-methyl group boosted both enzymatic and cell potencies significantly compared with the desmethyl analogues, justifying the added lipophilicity. By comparison of the α-methyl <b>14j</b> with the desmethyl analogue <b>11a</b>, the enzyme based LipE improves from 3.70 to 4.02 and the cell-based LipE improves from 3.11 to 3.86. Importantly, bringing together the 2,6-dichloro and 3-fluoro and α-methyl into a single compound, <b>14k</b>, resulted in the most potent inhibition against c-MET and the highest LipE values observed within this specific series (enzymatic LipE = 4.80 and cell LipE = 4.60) as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. Of note, these are racemates, and the relative potencies of enantiomers will be discussed later. Accordingly, the phenyl substitution pattern of <b>14k</b> was the focus for further lead optimization of the 2-aminopyridine series, which next focused on 5-position derivation to address remaining drug design goals.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Optimization at the 5-Position of the 2-Aminopyridine Series to Crizotinib</h3><div class="NLM_p">With the potent c-MET inhibitor <b>14k</b> in hand, design strategies focused on ensuring that potency is maintained while more aggressively tuning physical properties to achieve the ADME profile goals needed for a clinical candidate. Across series, both inhibition data and solved cocrystal structures suggested that substituents extending through the narrow hydrophobic cleft formed by Tyr-1159, Ile-1084, and Gly-1163 into solvent were efficient contributors to potency, provided the necessary planar relationship to the core is maintained. Modeling of 2-aminopyridines suggested that the 5-position vector was the best opportunity to deliver polar groups to the solvent, allowing physical property modulation while optimizing potency. To rapidly test this approach, truncated 2-aminopyridine cores and extended basic amine derivatives from readily available materials were evaluated (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Expectedly, only modest inhibition was observed for <b>21</b>, which has no 5-position substituent. Additionally, <b>22</b> and <b>26</b> with 5-bromo and 5-cyano groups had similarly weak potency as did the 5-<i>N</i>-amide <b>25</b>, which introduces polarity too close to the core. Additionally, the 5-phenyl derivative <b>27</b> also resulted in micromolar potency. However, greater potency and LipE were achieved with <b>14k</b> and <b>36</b>–<b>38</b>. A number of factors are potentially contributing to this increase. For these latter compounds, the amide moiety is positioned away from the adenine pocket and into solvent, eliminating the desolvation penalty seen for <b>25</b>. Furthermore, the amide is electron withdrawing, perhaps contributing to greater planarity arising from conjugation to the amino group of the core and possibly modifying the H-bond donating potential as a result. Last, the solvent exposed basic groups, which lower log <i>D</i>, result in enzymatic and cell LipE values that are at attractive levels, as exemplified with <b>14k</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure and Activity Relationship of 5-Substitutes on Racemic 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0014.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat, version 9.3.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and cell IC<sub>50</sub><a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> were determined as described in <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">LipE = p<i>K</i><sub>i</sub> (or pIC<sub>50</sub>) – cLogD.</p></div></div><div></div></div><div class="NLM_p">In order to maximize chances of good ADME properties and improved potencies by attenuating torsion strain associated with planar binding, a set of smaller, less lipophilic 5-heteroaryl analogues were prepared as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The preference of a five-member heteroaryl group at the 5-position of 2-aminopyridine is consistent with coplanarity of the 5-aryl group with the pyridine scaffold upon binding. The five-member heteroaryl groups also lowered cLogD by about 2 units in general from the phenyl containing <b>27</b>. Consequently, compounds <b>24</b> and <b>29</b>–<b>35</b> showed much improved LipE in the kinase assay, with the weakest improvements coming from compounds <b>24</b> and <b>34</b>. The performance of <b>34</b> is expected because of the methyl groups which destabilize a planar arrangement. To help understand <b>24</b>, crystal structures of potent analogues indicate that backbone c-MET protein carbonyl oxygen atoms of residues Met-1160 and Ile-1084 are oriented toward the “ortho” positions of these five-membered heterocycles. Additional residues at the ligand–protein interface disfavor access of bulk water to these positions, requiring the breaking of solvent H-bonds to the nitrogen lone pair of <b>24</b> upon binding. The structural biology, therefore, is consistent with a desolvation penalty and unfavorable electrostatics for compounds such as <b>24</b> that present “ortho” electronegative heteroatoms, with capacity as H-bond acceptors only. In contrast, the 5-pyrazol-4-yl group of <b>33</b> improved enzymatic and cell potency by 10- to 20-fold, resulting in a cell LipE of 2.83, more than a 3 unit improvement over compound <b>27</b>. In this case, the heteroatoms are oriented toward solvent and therefore pay no desolvation penalty. As a result, the pyrazol-4-yl group provided the most potent inhibition against c-MET and the highest LipE value in comparison with other heteroaryl and phenyl groups. Additionally, N-substitution on the pyrazol-4-yl group was well tolerated, as demonstrated by enzymatic and cell potency and an improved cell LipE value of 2.83 for <b>35</b>, indicating an attractive design path forward.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure, Activity, and Lipophilicity Relationships of Racemic 5-Aryl Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0016.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat, version 9.3.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and cell IC<sub>50</sub><a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> were determined as described in <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">LipE = p<i>K</i><sub>i</sub> (or pIC<sub>50</sub>) – cLogD.</p></div></div><div></div></div><div class="NLM_p">For earlier subseries (e.g., <b>36</b>–<b>38</b>), extending polar basic groups into solvent was a strategy that consistently improved potency and efficiency. With knowledge that the pyrazole linker provided an extended conformation and vector that resulted in highly efficient cores, a focused lead optimization effort sought to combine these structural features to achieve both the potency and the pharmaceutical properties being sought. For polar N-substituents on the pyrazole-4-yl ring, the smallest groups were targeted to provide desirable properties. A set of representative examples are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure, Activity, and Property Relationships of N-Substituents on the 5-Pyrazol-4-yl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0017.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0018.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat, version 9.3.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and cell IC<sub>50</sub><a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> were determined as described in <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">LipE = p<i>K</i><sub>i</sub> (or pIC<sub>50</sub>) −cLogD.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Human liver microsome percent remaining was determined as described in <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">Overall, N-substituents on the pyrazol-4-yl group maintained or enhanced c-MET inhibition potency while lowering cLogD by almost 3 full units in some cases. Consequently, the introduced structural features improved LipE along with targeted pharmaceutical properties dramatically. The c-MET cell potency vs cLogD data from this and earlier subseries, all 5-aryl derivatives of the 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine core, are plotted in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a> to graphically illustrate different efficiency zones with constant LipE values. The data points colored blue represent the 5-pyrazol-4-yl subseries which generally occupied higher LipE space over 5-phenyl subseries (red color). Movement up and to the left, crossing LipE lines, was analyzed for structural features that crossed zones and served as the design goal during optimization. Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> indicates that <b>61</b>, a racemic version of crizotinib, is one of the most efficient inhibitors, with a c-MET cell IC<sub>50</sub> of 0.018 μM and a LipE of 5.62. This is also clear from the plot of all 5-aryl derivatives shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. c-MET cell p(IC<sub>50</sub>) vs cLogD (blue for 5-pyrazol-4-yl, red for 5-phenyl, and yellow for other).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is important to note that the prototype 5-aryl subseries suffered high metabolic clearance due, in large part, to the high lipophilicity of the key 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy group on this novel 2-aminopyridine scaffold. Navigating the results across series, using plots such as Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, facilitates drug design for improved LipE, where metabolic stability improvements are achieved in parallel as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Compounds with moderate to stable human metabolic stability were achieved as exemplified by <b>48</b> and <b>61</b>. With overall good pharmaceutical properties, <b>61</b> was chosen for further evaluation.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure and activity of pure enantiomers of <b>61</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds in the tables are racemates. The two pure enantiomeric forms of <b>61</b> were prepared to evaluate the relative c-MET activity (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). The <i>R</i> enantiomer <b>63</b> is significantly more potent, consistent with specific binding as later revealed in a cocrystal structure of crizotinib bound to c-MET (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj">2wgj</a>).</div><div class="NLM_p">The cocrystal structure of crizotinib bound to the nonphosphorylated state of the c-MET kinase domain shows that, as with <b>3</b>, the compound binds to an autoinhibitory kinase conformation in which a portion of the kinase activation loop makes direct interactions with the inhibitor (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The potency of crizotinib in cells, as was discussed for predecessors <b>14f</b> and <b>14k</b>, results from key interactions between the α-methylbenzyloxy unit and the unique c-MET A-loop conformation. The halogenated phenyl group of crizotinib takes a direct and favorable path to form a π–π interaction with Tyr-1230, also achieving better distances and aligned geometry between the aryl groups for stacking compared to the case of <b>3</b>. Another consequence of the more compact linker of crizotinib is noted when comparing cocrystal structures (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). The plane of the novel 2-aminopyridine core in crizotinib binds to the hinge in a position that is more consistent with the oxindole in the <b>1</b>/FGFR1K complex and different from the oxindole in <b>3</b>/c-MET complex, which was noted earlier to be tilted at approximately a 15° angle. This observation is consistent with less conformational strain associated with binding the more compact 3-benzyloxy-2-aminopyridine compared to <b>3</b>. Met-1211 has closer interactions with the phenyl group and 2-aminopyridine core via hydrophobic interactions. Both the 2-chloro and 3-fluoro elements on the 3-benzyloxy group in crizotinib point toward the N–H of Asp-1222, indicating that there may be beneficial electrostatic interactions that replace the sulfonyl oxygen H-bond in <b>3</b>. According to the SAR, the α-methyl and 2,6-dichloro moieties on the 3-benzyloxy group in crizotinib are critical for establishing the low nanomolar cell potency against c-MET. The α-methyl group not only rigidifies the benzyl group but also makes favorable hydrophobic interactions in the pocket surrounded by side chains of residues Val-1092, Leu-1157, Lys-1110, and Ala-1108. As the data and cocrystal structure demonstrate, only the <i>R</i>-configuration of the α-methyl group provides the right fit in this lipophilic pocket.</div><div class="NLM_p">On the other side, the 5-pyrazol-4-yl group is bound through the narrow lipophilic tunnel surrounded by Ile-1084 and Tyr-1159. The terminal piperidine ring, attached to the N1 position of the pyrazol-4-yl, reaches out into the solvent. The cocrystal structure of crizotinib with c-MET confirmed the original design hypotheses, sharing a similar binding mode to <b>3</b>. However, crizotinib binds the c-MET kinase domain more efficiently than <b>3</b>, resulting in much improved cell-based ligand efficacy (LE) and lipophilic efficiency (LipE) (LE = 0.379 and LipE = 6.14 for crizotinib; LE = 0.264 and LipE = 4.81 for <b>3</b>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Cocrystal structure of crizotinib bound to c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of crizotinib and <b>3</b> bound to c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Kinase Selectivity Profile of Crizotinib</h3><div class="NLM_p">To investigate kinase selectivity, crizotinib was evaluated against a panel of more than 120 human kinases from Upstate Inc. Of these, 13 kinases were inhibited with enzymatic potency within a 100-fold selectivity window of crizotinib enzymatic c-MET potency. To fully account for the unique binding mode accessed by crizotinib, cell-based autophosphorylation assays were employed to determine a more accurate picture of kinase selectivity in the whole cell contest. Compared with c-MET cell potency, crizotinib was found to be greater than 1000-fold selective against VEGFR2 and PDGFRβ split-RTKs (cell IC<sub>50</sub> > 10 μM), with other cell potency results within the 10 μM limit summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Selectivity is greater than 200-fold for IR and LCK and approximately 40- to 60-fold for AXL, TIE2, TRKA, and TRKB. Crizotinib selectivity is 10-fold for the c-MET subfamily member RON, which shares 63% sequence identity in the KD and many biological functions with c-MET.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> RON receptor tyrosine kinase is overexpressed and activated in many cancers including breast, colon, and lung and plays important roles in tumor invasive growth and metastasis.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> RON overexpression or coexpression with c-MET correlates with a poor disease free survival in breast, bladder, and gastresophageal cancers.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> RON is an attractive molecular target for cancer therapy. Furthermore, crizotinib demonstrated a potent cell IC<sub>50</sub> of 20 nM against an oncogenic ALK kinase fusion protein, NPM–ALK, in a human lymphoma cell line even though ALK shares only 36% kinase domain sequence identity with c-MET. Similar to BCR-ABL in CML, available literature indicates that ALK fusion proteins are also key disease drivers of anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and non-small cell lung cancer.<a onclick="showRef(event, 'ref7 ref29'); return false;" href="javascript:void(0);" class="ref ref7 ref29">(7, 29)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity of Crizotinib</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="10" align="center">kinase</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">c-MET</th><th class="colsep0 rowsep0" align="center">ALK</th><th class="colsep0 rowsep0" align="center">RON</th><th class="colsep0 rowsep0" align="center">AXL</th><th class="colsep0 rowsep0" align="center">TIE2</th><th class="colsep0 rowsep0" align="center">TRKA</th><th class="colsep0 rowsep0" align="center">TRKB</th><th class="colsep0 rowsep0" align="center">ABL</th><th class="colsep0 rowsep0" align="center">IR</th><th class="colsep0 rowsep0" align="center">LCK</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% inhib (1 μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">97.0</td><td class="colsep0 rowsep0" align="left">99.0</td><td class="colsep0 rowsep0" align="left">97.0</td><td class="colsep0 rowsep0" align="left">93.0</td><td class="colsep0 rowsep0" align="left">97.0</td><td class="colsep0 rowsep0" align="left">99.3</td><td class="colsep0 rowsep0" align="left">99.7</td><td class="colsep0 rowsep0" align="left">91.5</td><td class="colsep0 rowsep0" align="left">67.7</td><td class="colsep0 rowsep0" align="left">96.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"><1.0</td><td class="colsep0 rowsep0" align="left"><1.0</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left"><1.0</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left"><1.0</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">102</td><td class="colsep0 rowsep0" align="left"><1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">294</td><td class="colsep0 rowsep0" align="left">448</td><td class="colsep0 rowsep0" align="left">580</td><td class="colsep0 rowsep0" align="left">399</td><td class="colsep0 rowsep0" align="left">1159</td><td class="colsep0 rowsep0" align="left">2887</td><td class="colsep0 rowsep0" align="left">2741</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Data were obtained from Upstate kinase selectivity screens.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Values are the average of at least two experiments based on the inhibition of autophosphorylation of targets in the corresponding cell lines with <20% variance.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a></p></div></div></div><div class="NLM_p last">In summary, 13 different kinases were inhibited within a 100-fold multiple of c-MET in enzymatic assays. With cellular assays, crizotinib demonstrated potent inhibition of c-MET/ALK, with a 10-fold selectivity window for RON. The high selectivity of crizotinib at the cellular level is related to the unusual binding pocket created by the unique activation loop conformation of nonphosphorylated c-MET as discussed previously. A cocrystal structure of ALK kinase domain complexed with crizotinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2">2xp2</a>) reveals a conformation similar to crizotinib bound to c-MET. The A-loop of ALK shows a notable difference, lacking a π-stacking interaction observed between c-MET Tyr-1230 and crizotinib. The loss of this protein–crizotinib interaction may partially explain the weaker potency observed with ALK. The importance of Tyr-1230–crizotinib interaction in c-MET is further confirmed with Y1230C mutation of c-MET protein, where crizotinib is 10-fold less potent.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These results are consistent with the weaker potency for crizotinib inhibition of RON kinase, which has a leucine residue at the position of c-MET Tyr-1230. One common interaction among these kinases is that of the Met-1211 residue in c-MET. It stabilizes the 2-aminopyridine core, the 3-benzyloxy group, and anchors the scaffold in an L-shape. These important hydrophobic interactions should be retained for RON because of the presence of a methionine residue at the same position. A leucine residue in ALK kinase at the Met-1211 position of c-MET provides similar hydrophobic interactions with crizotinib. Moreover, the high kinase selectivity profile of crizotinib is consistent with pharmacology stemming from a limited set of kinases with potential clinic utility and provides mechanism-based guidance for the expansion of crizotinib to specific additional cancer patient populations.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>7</b>, <b>8</b>, and <b>11</b> were synthesized according to the procedures outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. <b>4</b> was prepared according to the literature procedures.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Selective alkylation of the 3-hydroxyl group was achieved under basic conditions by treating with 1 equiv of benzyl bromide and 1 equiv of Cs<sub>2</sub>CO<sub>3</sub> in DMF at 80 °C for 4 h to give <b>6</b>. Conventional Suzuki coupling conditions provided <b>7</b> and <b>11</b>. Compound <b>8</b> was synthesized via alkylation of <b>7</b>.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4 h; (b) arylboronic ester, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 12 h; (c) 4-(2-chloroethyl)morpholine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4 h; (d) (<i>R</i>)-1-(pyrrolidin-2-ylmethyl)pyrrolidine, HOBt, EDC, DMF, 1 h; (e) Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 12 h.</p></p></figure><div class="NLM_p">For rapid optimization of substituted 3-benzyloxy groups, compounds were synthesized for evaluation as outlined in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. <b>11b</b> was prepared according to the procedure described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. After hydrogenolysis, <b>12</b> was obtained in a quantitative yield and used to couple with <b>13</b> to generate compounds <b>14a</b>–<b>k</b>.</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub> balloon, 10% Pd/C, methanol, 16 h; (b) NaH, DMF, 0 °C to ambient temperature, 2 h; (c) LiAlH<sub>4</sub>, THF, 0 °C to ambient temperature, 3 h; (d) Ph<sub>3</sub>PBr<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><div class="NLM_p">Compounds <b>22</b> and <b>23</b> were prepared according to the procedures in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, in order to access a diversity of 5-substituted analogues to support the optimization efforts. Mitsunobu reaction of <b>16</b> with <b>18</b> provided <b>20</b> in high yield, which was further reduced with iron chips in acetic acid and ethanol under reflux to <b>21</b>. Bromination and iodination of <b>21</b> produced <b>22</b> and <b>23</b>. A variety of aryl groups were introduced at the 5-position via a Suzuki coupling reaction to provide <b>27</b>–<b>35</b>. Compounds <b>24</b> and <b>25</b> were prepared via copper-catalyzed amination reaction under microwave conditions. The cyano group was introduced under palladium-catalyzed condition to give <b>26</b>. Compounds <b>36</b>–<b>38</b> were prepared with the conventional amide coupling conditions.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0008.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>P, DEAD, THF, 0 °C, 4 h; (b) Fe, AcOH/EtOH, reflux, 1 h; (c) NBS, ACN, 0 °C, 15 min; (d) NIS, ACN/AcOH, 0 °C, 4 h; (e) CuI, K<sub>3</sub>PO<sub>4</sub>, dodecane/cyclohexanediamine, DMSO, microwave at 150 °C, 2 h; (f) Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 12 h; (g) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, DPPF, DMF, 100 °C, 3 h; (h) EDC, HOBt, DMF, 4 h.</p></p></figure><div class="NLM_p">A variety of N-substituted pyrazole analogues were prepared as shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a> via the pyrazole boronic ester <b>39</b> or 4-bromopyrazole <b>41</b> which was transferred to boronic ester <b>43</b> under conventional palladium coupling conditions. Suzuki coupling reaction generated compounds <b>44</b>–<b>50</b>. <b>52</b> was prepared with oxosulfonium ylide which was generated in situ from trimethylsulfoxonium iodide using NaH in DMSO solvent and coupled with <b>39</b> to generate compound <b>53</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0009.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 12–16 h; (b) NaH, DMF, microwave at 110 °C, 30 min; (c) Pd(dppf)Cl<sub>2</sub>, KOAc, DMSO, 80 °C, overnight; (d) Pd(dppf)Cl<sub>2</sub> or Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, CsF, DME/H<sub>2</sub>O, microwave at 120 °C, 1 h; (e) Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 85 °C, overnight; (f) trimethylsulfoxonium iodide, NaH, DMSO, 55 °C, 6 h; (g) NaH, DMF, 90 °C, 3 h.</p></p></figure><div class="NLM_p">An alternative route to access N-substituted pyrazole analogues is outlined in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. 2-Amino function was protected as a bis-<i>tert</i>-butyl carbamate <b>54</b> for the preparation of boronic ester <b>56</b> with high yield. Acid deprotection of <b>56</b> produced <b>57</b> which was coupled with <b>42</b> to produce compounds <b>58</b>–<b>61</b>.</div><figure id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0010.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, DMAP, DMF, ambient temperature, 18 h; (b) Pd(dppf)Cl<sub>2</sub>, KOAc, DMSO, 80 °C, overnight; (c) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 12 h; (d) Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 87 °C, 16 h; (e) 4 N HCl in dioxane, MeOH, 1 h.</p></p></figure><div class="NLM_p">A total synthesis of crizotinib is outlined in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Boronic ester <b>68</b> was prepared via alkylation of <b>66</b> with piperidinyl derivative <b>65</b> followed by palladium coupling with <b>55</b>. <b>69</b> was prepared with the same synthetic route as the racemic analogue <b>22</b> as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. (<i>S</i>)-1-(2,6-Dichloro-3-fluorophenyl)ethanol was obtained via a biotransformation method.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Mitsunobu reaction of (<i>S</i>)-1-(2,6-dichloro-3-fluorophenyl)ethanol with <b>18</b> provided (<i>R</i>)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine with >99.5% ee. Suzuki coupling reaction of <b>69</b> with <b>68</b> followed by deprotection with HCl generated crizotinib in good yield.</div><figure id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0011.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Total Synthesis of Crizotinib<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (b) NaH, DMF, 100 °C, overnight; (c) Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, KOAc, DMSO, 80 °C, 2 h; (d) Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 90 °C, 3 h; (e) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 4 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The cocrystal structure of <b>3</b>/c-MET complex revealed a novel binding mode of c-MET, which was used to design the novel 5-aryl-3-benzyloxy-2-aminopyridine series. First iteration 5-aryl-3-benzyloxy-2-aminopyridines were moderate c-MET inhibitors. The series was optimized to a highly potent and selective c-MET/ALK dual inhibitor, with a narrower window of selectivity to RON kinase. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, LipE and structure based drug design led to crizotinib, which has the highest LipE value. Crizotinib potently inhibited c-MET phosphorylation and c-MET-dependent proliferation, migration, and invasion of human tumor cells in vitro (IC<sub>50</sub> of 5–20 nM).<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> In addition, crizotinib potently inhibited HGF-stimulated endothelial cell survival and invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> Crizotinib showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-MET.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> In biochemical and cellular screens, crizotinib was shown to be selective for c-MET and ALK at pharmacologically relevant concentrations across a panel of >120 diverse kinases. Crizotinib demonstrated tumor cell growth inhibitory activity against cell lines harboring fusion variants or activating mutations of ALK including Karpas 299 (NPM–ALK), SU-DHL-1 (NPM–ALK), Kelly neuroblastoma (activating mutation), and NCI-H3122 (EML4–ALK variant 1) with IC<sub>50</sub> values ranging from 74 to 566 nM.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Crizotinib potently inhibited cell proliferation, which was associated with G<sub>1</sub>-S phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC<sub>50</sub> ≈ 30 nM) but not ALK-negative lymphoma cells.<a onclick="showRef(event, 'cit10b'); return false;" href="javascript:void(0);" class="ref cit10b">(10b)</a> Oral administration of crizotinib to severe combined immunodeficient beige mice bearing Karpas 299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 (mg/kg)/day dose within 15 days of initial compound administration.<a onclick="showRef(event, 'cit10b'); return false;" href="javascript:void(0);" class="ref cit10b">(10b)</a> A strong correlation was observed between antitumor response and inhibition of NPM–ALK phosphorylation and induction of apoptosis in tumor tissue.<a onclick="showRef(event, 'cit10b'); return false;" href="javascript:void(0);" class="ref cit10b">(10b)</a> Crizotinib demonstrates desirable oral pharmacokinetics in preclinical species, consistent with target modulation and efficacy, with acceptable pharmacokinetics in patients while being well tolerated.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> Crizotinib has advanced to human clinical trials and demonstrated remarkable efficacy for patients with non-small-cell lung cancer, inflammatory myofibroblastic tumor, and large cell anaplastic lymphoma harboring fusion ALK genes.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Early clinical efficacy was also observed for patients with lung, glioblastoma, and esophagogastric adenocarcinoma with c-MET gene amplification.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods for Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as purchased from commercial sources. Reactions were carried out under nitrogen atmosphere unless otherwise indicated. Silica gel chromatography was done using the appropriate size Biotage prepacked silica filled cartridges. NMR spectra were generated on a Bruker 300 or 400 MHz instrument and obtained as CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> solutions (reported in ppm), using CDCl<sub>3</sub> as the reference standard (7.27 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 ppm). Multiplicities were given as s (singlet), b s (broad singlet), d (doublet), t (triplet), dt (double of triplets), and m (multiplet). Mass spectral data (APCI) were gathered on an Agilent 1100 LC with MSD (Agilent model G1946B upgraded to D model) single-quadrupole mass spec detectors running with atmospheric pressure chemical ionization source. The LC instrument includes a binary pump (Agilent model G1312A) with upper pressure limit of 400 bar attached to an autosampler (Agilent model G1313A) that uses an external tray for sample submission. The column compartment (Agilent model G1316A) is attached to a diode array (Agilent model G1315A). The instrument acquisition and data handling were done with ChemStation, revision B.02.01. The purity measurements were done by measuring peak area at 254 and 224 nm and total ion chromatogram. To evaluate the purity of each peak, UV–vis spectrum from 190 to 700 nm at step size of 2 nm and mass spectrum scan from 150 to 850 amu with cycle time of 0.29 cycle/sec were performed. Retention times (<i>t</i><sub>R</sub>) were in minutes, and purity was calculated as percentage of total area. Two HPLC methods were utilized for purity. Method A consisted of the following: Waters Acquity UPLC BEH C18 column, 1.7 μm, 2.1 mm × 100 mm, column temperature 80 °C; solvent A consisting of water (0.1% formic acid and 0.05% ammonium formate); solvent B consisting of methanol (0.1% formic acid and 0.05% ammonium formate); gradient of 5–95% B in 10 min, 95% B in 10–12 min; flow rate of 0.6 mL/min. Method B consisted of the following: EclipsXDB C8 column, 3.5 μm, 4.6 mm × 50 mm, column temperature 40 °C; solvent A consisting of water (5% ACN, 2 mM ammonium acetate, 0.1% acetic acid); solvent B consisting of ACN (5% H<sub>2</sub>O, 2 mM ammonium acetate, 0.1% acetic acid); gradient of 20–85% B (0.0–2.5 min), 85–95% B (2.5–3.5 min), 95% B (5 min); flow rate of 0.8 mL/min. Compound purity was determined by combustion analysis (Atlantic Microlabs, Inc.) or high pressure liquid chromatography (HPLC) with a confirming purity of ≥95% for all of the final biological testing compounds.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 3-(2,6-Dichlorobenzyloxy)-5-bromopyridin-2-amine (<b>6a</b>)</h3><div class="NLM_p last">To a solution of 2-amino-5-bromopyridin-3-ol (1.000 g, 5.29 mmol) and 2-(bromomethyl)-1,3-dichlorobenzene (1.270 g, 5.29 mmol) in DMF (20 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (1.720 g, 5.29 mmol). The reaction mixture was stirred at 80 °C in an oil bath for 4 h, and LCMS showed the completion of the reaction. The mixture was cooled to ambient temperature, diluted with EtOAc (100 mL), washed with water (30 mL × 5) and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and condensation, the residue was purified with a silica gel column, eluting with EtOAc/heptane (0–50%) to provide <b>6a</b> as an off-white solid (1.120 g, 60.8%): LCMS <i>m</i>/<i>z</i> 347 (62%), 349 (100%), 351 (45%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.62 (d, <i>J</i> = 2.02 Hz, 1H), 7.52–7.59 (m, 2H), 7.44–7.50 (m, 2H), 5.79 (s, 2H), 5.24 (s, 2H). Anal. Calcd for C<sub>12</sub>H<sub>4</sub>BrCl<sub>2</sub>N<sub>2</sub>O: C, 41.41; H, 2.61; N, 8.05. Found: C, 41.50; H, 2.51; N, 8.05.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 4-(5-(2,6-Dichlorobenzyloxy)-6-aminopyridin-3-yl)phenol (<b>7</b>)</h3><div class="NLM_p last">A mixture of 3-(2,6-dichlorobenzyloxy)-5-bromopyridin-2-amine (100 mg, 0.29 mmol), 4-(4,4,5,5-tetramethyl-1,3-2-dioxabordan-2-yl)phenol (86 mg, 0.35 mmol), bis(triphenylphosphine)palladium(II) chloride (8 mg, 0.009 mmol), and sodium carbonate (91 mg, 0.87 mmol) in ethylene glycol dimethyl ether (10 mL) and water (0.5 mL) was degassed and charged with nitrogen three times and then heated in a 80 °C oil bath under nitrogen for 12 h. The mixture was cooled to ambient temperature and diluted with ethyl acetate. The mixture was washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and condensation, the residue was purified on a silica column, eluting with EtOAc/hexane (0–50%) to afford <b>7</b> as a light pink solid (89 mg, 85% yield): LCMS <i>m</i>/<i>z</i> 361 (100%), 363 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.39 (s, 1H), 7.80 (d, <i>J</i> = 1.77 Hz, 1H), 7.53–7.61 (m, 2H), 7.40–7.52 (m, 4H), 6.81 (d, <i>J</i> = 8.59 Hz, 2H), 5.52 (s, 2H), 5.33 (s, 2H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.697, 100%.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 3-(2,6-Dichlorobenzyloxy)-5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-amine (<b>8</b>)</h3><div class="NLM_p last">To a solution of <b>7</b> (100 mg, 0.247 mmol) and 4-(2-chloroethyl)morpholine (37 mg, 0.247 mmol) in DMF (5 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (81 mg, 0.247 mmol). The reaction mixture was heated in a 80 °C oil bath for 4 h. After cooling to ambient temperature, the reaction mixture was filtered and washed with ethyl acetate. The filtrate was condensed and purified on a reversed phase preparative HPLC column, eluting with methanol/water containing 0.1% formic acid. <b>8</b> was obtained as a white amorphous solid (61 mg, 52%): LCMS <i>m</i>/<i>z</i> 474 (100%), 476 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.85 (d, <i>J</i> = 1.77 Hz, 1H), 7.53–7.61 (m, 4H), 7.45–7.52 (m, 2H), 7.00 (d, <i>J</i> = 8.84 Hz, 2H), 5.59 (s, 2H), 5.35 (s, 2H), 4.09–4.15 (m, 2H), 3.56–3.62 (m, 4H), 2.69–2.75 (m, 2H), 2.46 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.004, 100%.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>R</i>)-(2-(Pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone (<b>10</b>)</h3><div class="NLM_p last">To a mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (<b>9</b>, 5.00 g, 20.2 mmol) and (3-(dimethylamino)propyl)ethylcarbodiimide hydrochloride (EDC, 4.88 g, 24.2 mmol) in DMF (100 mL) was added 1,2,3-benzotriazol-1-ol monohydrate (HOBt, 3.57 g, 22.2 mmol). A clear solution was observed after stirring for 30 min, and (<i>R</i>)-1-(pyrrolidin-2-ylmethyl)pyrrolidine (6.22 g, 40.3 mmol) was added to the reaction solution, which was stirred at ambient temperature overnight (12 h). The reaction solution was diluted with EtOAc (500 mL), washed with water (100 mL × 4), saturated Na<sub>2</sub>CO<sub>3</sub> solution, brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, evaporation, and high vacuum drying, <b>10</b> was obtained as a colorless syrup (4.80 g, 62%): LCMS <i>m</i>/<i>z</i> 385 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.70 (d, <i>J</i> = 7.83 Hz, 2H), 7.43 (d, <i>J</i> = 7.83 Hz, 2H), 4.15–4.31 (m, 1H), 3.34–3.50 (m, 2H), 3.14–3.26 (m, 1H), 2.61–2.70 (m, 1H), 2.41–2.59 (m, 4H), 1.77–1.90 (m, 4H), 1.58–1.74 (m, 4H), 1.29 (s, 12H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>R</i>)-(4-(5-(2,6-Dichlorobenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>11a</b>)</h3><div class="NLM_p last">To a solution of <b>6a</b> (150 mg, 0.43 mmol) and <b>9</b> (248 mg, 0.65 mmol) in DME (3 mL) was added the freshly prepared aqueous solution of Cs<sub>2</sub>CO<sub>3</sub> (210 mg, 0.65 mmol) in water (1 mL), followed by the addition of 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride (16.1 mg, 0.022 mmol). The reaction flask was degassed and charged with nitrogen three times and then heated in a 80 °C oil bath overnight (15 h). The reaction solution was diluted with EtOAc, washed with water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified on a reverse phase preparative HPLC column, eluting with methanol/H<sub>2</sub>O containing 0.1% formic acid (10–90%), and <b>11a</b> was obtained as a white amorphous solid (78 mg, 34% yield): LCMS <i>m</i>/<i>z</i> 525 (100%), 527 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.99 (d, <i>J</i> = 1.88 Hz, 1H), 7.64–7.73 (m, 2H), 7.40–7.61 (m, 6H), 5.52 (s, 2H), 5.42 (s, 2H), 4.16–4.27 (m, 1H), 3.43–3.52 (m, 2H), 3.16–3.26 (m, 1H), 2.54–2.66 (m, 2H), 2.24–2.47 (m, 3H), 1.73–2.08 (m, 4H), 1.58–1.71 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.463, 95.7%.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>R</i>)-(4-(5-Benzyloxy-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>11b</b>)</h3><div class="NLM_p last">Compound <b>11b</b> was prepared by using a similar procedure described for the synthesis of <b>11a</b>: LCMS <i>m</i>/<i>z</i> 457 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.88–7.99 (m, 1H), 7.28–7.69 (m, 10H), 5.65 (s, 2H), 5.27 (s, 2H), 4.07–4.32 (m, 1H), 3.38–3.53 (m, 2H), 2.45 (m, 6H), 1.72–2.12 (m, 5H), 1.54–1.71 (m, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.419, 100%.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>R</i>)-(4-(6-Amino-5-hydroxypyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>12</b>)</h3><div class="NLM_p last">To a solution of <b>11b</b> (2.28 g, 5.00 mmol) in methanol (25 mL) was added 10% Pd/C (100 mg). The mixture was degassed and charged with hydrogen three times and then stirred under hydrogen balloon for overnight. The mixture was filtered through a Celite pad, washed with methanol, and condensed. After high vacuum drying, <b>12</b> was obtained as a white solid (1.74 g, 95% yield): LCMS <i>m</i>/<i>z</i> 367 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.79 (s, 1H), 7.54 (m, 3H), 7.46 (m, 2H), 7.14 (s, 1H), 5.68 (s, 2H), 4.22 (m, 1H), 3.45 (m, 2H), 2.66 (m, 1H), 2.52 (m, 4H), 1.96 (m, 2H), 1.84 (m, 3H), 1.64 (m, 4H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-(2,6-Dichloro-3-fluorophenyl)ethanol (<b>16</b>)</h3><div class="NLM_p last">To a solution of 1-(2,6-dichloro-3-fluorophenyl)ethanone (15.00 g, 72 mmol) in anhydrous THF (150 mL) at 0 °C was added lithium aluminum hydride (2.75 g, 72 mmol) slowly. The mixture was stirred at ambient temperature for 3 h and cooled in an ice bath. Water (3 mL) was dropwise added followed by slow addition of 15% NaOH (3 mL). The mixture was stirred at ambient temperature for 30 min. Then 15% NaOH (9 mL) and MgSO<sub>4</sub> were added and the mixture was filtered to remove solids. The solids were washed with THF (50 mL) and the filtrate was concentrated to give <b>16</b> (14.8 g, 95% yield) as a yellow oil: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.42 (m, 1H), 7.32 (m, 1H), 5.42 (m, 2H), 1.45 (d, <i>J</i> = 6.4 Hz, 3H).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 2-(1-Bromoethyl)-1,3-dichloro-4-fluorobenzene (<b>17</b>)</h3><div class="NLM_p last">To a solution of <b>16</b> (10.00 g, 47.8 mmol) in anhydrous dichloromethane was added dibromotriphenylphosphorane (22.2 g, 52.6 mmol) portionwise at ambient temperature. The mixture was stirred for 16 h and then concentrated and purified by a silica gel column chromatography with 10% EtOAc in heptane to provide <b>17</b> as a colorless liquid (10.14 g, 78% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.41 (m, 2H), 5.90–6.09 (m, 1H), 2.2 (d, <i>J</i> = 7.16 Hz, 3H).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>R</i>)-(4-(5-(2-Fluorobenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14a</b>)</h3><div class="NLM_p">To a stirred solution of <b>12</b> (100 mg, 0.27 mmol) in anhydrous DMF (15 mL) at 0 °C was added sodium hydride (60% dispersion in mineral oil, 11 mg, 0.49 mmol). The mixture was allowed to stir at 0 °C for 30 min followed by the addition of 1-(bromomethyl)-2-fluorobenzene (51 mg, 0.27 mmol). The reaction mixture was stirred at room temperature for 2 h, diluted with EtOAc, and partitioned with H<sub>2</sub>O. The aqueous layer was extracted with EtOAc (2 × 25 mL). The organic layers were combined, washed with H<sub>2</sub>O (15 mL), brine (15 mL), and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified on a reverse phase preparative HPLC column, eluting with methanol/H<sub>2</sub>O containing 0.1% formic acid (10–90%), and <b>14a</b> was obtained as a white amorphous solid (58 mg, 45% yield): LCMS <i>m</i>/<i>z</i> 475 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.93–7.99 (m, 1H), 7.48–7.68 (m, 6H), 7.37–7.44 (m, 1H), 7.15–7.28 (m, 2H), 5.64 (br s, 2H), 5.29 (s, 2H), 4.32–4.44 (m, 1H), 3.35–3.57 (m, 3H), 2.03–2.25 (m, 2H), 1.56–2.01 (m, 9H), 1.20–1.36 (m, 2H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.515, 95.5%.</div><div class="NLM_p last">Compounds <b>14b</b>–<b>l</b> were prepared by using a similar procedure described for the synthesis of <b>14a</b>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-(4-(5-(2-Chlorobenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14b</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 491 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.95 (d, <i>J</i> = 1.88 Hz, 1H), 7.68–7.74 (m, 1H), 7.62–7.66 (m, 2H), 7.45–7.54 (m, 4H), 7.33–7.43 (m, 2H), 5.65 (s, 2H), 5.32 (s, 2H), 4.16–4.25 (m, 1H), 3.42–3.50 (m, 2H), 3.20–3.24 (m, 1H), 2.53–2.61 (m, 2H), 2.37–2.45 (m, 3H), 1.73–2.06 (m, 4H), 1.58–1.68 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.812, 98.7%.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>R</i>)-2-((2-Amino-5-(4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)phenyl)pyridin-3-yloxy)methyl)benzonitrile (<b>14c</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 582 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.91–8.00 (m, 2H), 7.81–7.89 (m, 1H), 7.73–7.81 (m, 1H), 7.69 (d, <i>J</i> = 7.91 Hz, 2H), 7.48–7.61 (m, 4H), 5.93 (s, 2H), 5.41 (s, 2H), 4.09–4.37 (m, 1H), 3.45–3.52 (m, 4H), 2.55–2.66 (m, 3H), 2.40–2.47 (m, 1H), 1.85–2.02 (m, 4H), 1.57–1.75 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 5.573, 98.9%.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-(4-(5-(2-Trifluoromethylbenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14d</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 525 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.97 (d, <i>J</i> = 1.88 Hz, 1H), 7.88 (d, <i>J</i> = 7.54 Hz, 1H), 7.70–7.83 (m, 2H), 7.57–7.66 (m, 3H), 7.51 (d, <i>J</i> = 8.29 Hz, 2H), 7.44 (d, <i>J</i> = 1.88 Hz, 1H), 5.54–5.81 (m, 2H), 5.39 (s, 2H), 4.15–4.32 (m, 2H), 3.47 (t, <i>J</i> = 5.75 Hz, 2H), 2.52–2.67 (m, 3H), 2.30–2.47 (m, 2H), 1.75–2.06 (m, 4H), 1.56–1.75 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.400, 100%.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>R</i>)-(4-(5-(4-<i>tert</i>-Butylbenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14e</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 513 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.92 (d, <i>J</i> = 1.88 Hz, 1H), 7.59–7.64 (m, 2H), 7.49 (d, <i>J</i> = 8.10 Hz, 2H), 7.39–7.46 (m, 5H), 5.62 (br s, 2H), 5.21 (s, 2H), 4.17–4.29 (m, 1 H), 3.39–3.51 (m, 3H), 2.51–2.65 (m, 3H), 2.33–2.47 (m, 2H), 1.75–2.06 (m, 4H), 1.62–1.71 (m, 4H), 1.31 (s, 9H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.664, 96.5%.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>R</i>)-(4-(5-(2,4-Dichlorobenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14f</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 525 (100%), 527 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.97 (d, <i>J</i> = 1.88 Hz, 1H), 7.75 (d, <i>J</i> = 8.48 Hz, 1H), 7.60–7.70 (m, 3H), 7.43–7.54 (m, 4H), 5.69 (s, 2H), 5.31 (s, 2H), 4.15–4.29 (m, 1H), 3.41–3.52 (m, 2H), 3.19–3.24 (m, 1H), 2.53–2.61 (m, 2H), 2.34–2.48 (m, 3H), 1.76–2.02 (m, 4H), 1.58–1.69 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.987, 95.95%.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>R</i>)-(4-(5-(2-Chloro-6-fluorobenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14g</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 509 (100%), 510 (32%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.98 (d, <i>J</i> = 2.07 Hz, 1H), 7.62–7.71 (m, 2H), 7.38–7.63 (m, 5H), 7.24–7.36 (m, 1H), 5.53 (s, 2H), 5.34 (d, <i>J</i> = 1.88 Hz, 2H), 4.18–4.30 (m, 1H), 3.46–3.51 (m, 2H), 3.20–3.24 (m, 1H), 2.55–2.61 (m, 2H), 2.32–2.48 (m, 3H), 1.76–2.12 (m, 4H), 1.61–1.70 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.909, 100%.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>R</i>)-(4-(5-(2-Chloro-3,6-difluorobenzyloxy)-6-aminopyridin-3-yl)phenyl)(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14h</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 527 (100%), 529 (32%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.99 (d, <i>J</i> = 1.88 Hz, 1H), 7.68 (d, <i>J</i> = 8.48 Hz, 2H), 7.46–7.62 (m, 4H), 7.31–7.44 (m, 1H), 5.57 (s, 2H), 5.33–5.39 (m, 2H), 4.19–4.31 (m, 1H), 3.45–3.52 (m, 2H), 3.19–3.26 (m, 1H), 2.54–2.61 (m, 2H), 2.35–2.47 (m, 3H), 1.78–2.09 (m, 4H), 1.59–1.70 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.821, 96.3%.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (4-(6-Amino-5-(1-(2-chloro-3,6-difluorophenyl)ethoxy)pyridin-3-yl)phenyl)((<i>R</i>)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14i</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 541 (100%), 543 (32%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.89 (d, <i>J</i> = 1.88 Hz, 1H), 7.34–7.60 (m, 5H), 7.22–7.33 (m, 1H), 7.18 (d, <i>J</i> = 1.88 Hz, 1H), 5.89–6.08 (m, 1H), 5.61 (s, 2H), 4.01–4.29 (m, 1H), 3.28–3.52 (m, 2H), 2.28–2.48 (m, 6H), 1.67–2.13 (m, 8H), 1.51–1.69 (m, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.865, 100%.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (4-(6-Amino-5-(1-(2,6-dichlorophenyl)ethoxy)pyridin-3-yl)phenyl)((<i>R</i>)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14j</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 539 (100%), 541 (64%) (M + H)<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.88 (s, 1H), 7.39–7.51 (m, 6H), 7.24–7.39 (m, 1H), 7.05 (s, 1H), 6.06–6.22 (m, 1H), 5.67 (s, 2H), 4.14–4.30 (m, 1H), 3.39–3.50 (m, 2H), 2.30–2.48 (m, 5H), 1.73–2.10 (m, 8H), 1.60–1.71 (m, 4 H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.329, 100%.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>R</i>)-(4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)phenyl)((<i>R</i>)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)methanone (<b>14k</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 557 (100%), 559 (64%) (M + H)<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ ppm 7.90 (d, <i>J</i> = 1.51 Hz, 1H), 7.50–7.61 (m, 1H), 7.36–7.49 (m, 5H), 7.06 (d, <i>J</i> = 1.88 Hz, 1H), 6.11–6.23 (m, 1H), 5.70 (s, 2H), 4.13–4.26 (m, 1H), 3.46 (t, <i>J</i> = 6.78 Hz, 2H), 2.32–2.49 (m, 6H), 1.75–2.04 (m, 4H), 1.56–1.70 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.010, 100%.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine (<b>20</b>)</h3><div class="NLM_p last">To a stirred solution of triphenylphosphine (8.2 g, 0.03 mol) and DEAD (13.65 mL of a 40% solution in toluene) in THF (200 mL) at 0 °C was added a solution of 1-(2,6-dichloro-3-fluorophenyl)ethanol (4.55 g, 0.021 mol) and 3-hydroxynitropyridine (3.35 g, 0.023 mol) in THF (200 mL). The resulting bright orange solution was stirred under a nitrogen atmosphere at ambient temperature for 4 h at which point all starting materials had been consumed. The solvent was removed, and the crude material was dry loaded onto a silica gel column and eluted with ethyl acetate–hexanes (20:80) to yield <b>20</b> (6.21 g, 0.021 mol, 98%) as an off-white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.08 (dd, <i>J</i> = 4.67, 1.14 Hz, 1H), 7.68 (dd, <i>J</i> = 8.59, 4.55 Hz, 1H), 7.53–7.59 (m, 1H), 7.43–7.51 (m, 2H), 6.27 (q, <i>J</i> = 6.74 Hz, 1H), 1.74 (d, <i>J</i> = 6.57 Hz, 3H).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine (<b>21</b>)</h3><div class="NLM_p last">To a stirred mixture of AcOH (650 mL) and EtOH (500 mL) were suspended <b>20</b> (9.43 g, 0.028 mol) and iron chips (15.7 g, 0.28 mol). The mixture was heated slowly to reflux and allowed to stir for 1 h. The mixture was cooled to room temperature. Then diethyl ether (500 mL) and water (500 mL) were added. The solution was carefully neutralized by the addition of sodium carbonate. The combined organic extracts were washed with saturated NaHCO<sub>3</sub> (2 × 100 mL), H<sub>2</sub>O (2 × 100 mL), and brine (1 × 100 mL) and then dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to dryness under vacuum to yield <b>21</b> (9.04 g, 99%) as an off-white solid: LCMS <i>m</i>/<i>z</i> 301 (100%), 303 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.51–7.58 (m, 1H), 7.40–7.50 (m, 2H), 6.62 (dd, <i>J</i> = 7.83, 1.01 Hz, 1H), 6.38 (dd, <i>J</i> = 7.83, 5.05 Hz, 1H), 5.96 (q, <i>J</i> = 6.65 Hz, 1H), 5.66 (s, 2H), 1.76 (d, <i>J</i> = 6.57 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.185, 99.3%.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 5-Bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine (<b>22</b>)</h3><div class="NLM_p last">A stirring solution of <b>21</b> (9.07 g, 0.03 mol) in acetonitrile was cooled to 0 °C using an ice bath. To this solution was added <i>N</i>-bromosuccinimide (NBS) (5.33 g, 0.03 mol) portionwise. The mixture was stirred at 0 °C for 15 min. The mixture was concentrated to dryness under vacuum. The resulting dark oil was purified via a silica gel column, eluting with ethyl acetate/hexane (1:5), and <b>22</b> was obtained as a white crystalline solid (5.8 g, 51%): LCMS <i>m</i>/<i>z</i> 379 (62%), 381 (100%), 383 (45%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.52–7.62 (m, 2H), 7.43–7.51 (m, 1H), 6.75 (d, <i>J</i> = 1.77 Hz, 1H), 5.94–6.05 (m, 3H), 1.77 (d, <i>J</i> = 6.82 Hz, 3H). Anal. Calcd for C<sub>13</sub>H<sub>10</sub>BrCl<sub>2</sub>FN<sub>2</sub>O: C, 41.09; H, 2.65; N, 7.37. Found: C, 41.20; H, 2.54; N, 7.34.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 5-Iodo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine (<b>23</b>)</h3><div class="NLM_p last">To a solution of <b>21</b> (10.0 g, 33.2 mmol) in acetonitrile (600 mL) and acetic acid (120 mL) was added <i>N</i>-iodosuccinimide (11.2 g, 49.8 mmol). The mixture was stirred at room temperature for 4 h, and the reaction was quenched with Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> solution. After evaporation, the residue was partitioned between ethyl acetate and water. The organic layer was washed with aqueous NaOH solution (2 N), brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude product was purified on a silica gel column, eluting with ethyl acetate/hexane (1:5) to provide <b>23</b> as an off-white solid (7.1 g, 50% yield): LCMS <i>m</i>/<i>z</i> 427 (100%), 429 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.63 (d, <i>J</i> = 1.70 Hz, 1H), 7.51–7.60 (m, 1H), 7.37–7.51 (m, 1H), 6.84 (d, <i>J</i> = 1.70 Hz, 1H), 5.82–6.06 (m, 3H), 1.76 (d, <i>J</i> = 6.59 Hz, 3H). Anal. Calcd for C<sub>13</sub>H<sub>10</sub>Cl<sub>2</sub>FIN<sub>2</sub>O: C, 36.56; H, 2.36; N, 6.56. Found: C, 36.85; H, 2.28; N, 6.42.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1<i>H</i>-pyrazol-1-yl)pyridin-2-amine (<b>24</b>)</h3><div class="NLM_p last">To a stirred solution of <b>23</b> (100 mg, 0.23 mmol) and pyrazole (48 mg, 0.70 mmol) in DMSO (1 mL) were added K<sub>3</sub>PO<sub>4</sub> (101 mg, 0.47 mmol), dodecane (0.015 mL, 0.05 mmol), cyclohexanediamine (0.009 mL, 0.07 mmol), and copper iodide (CuI) (14 mg, 0.07 mmol). The solution was bubbled with nitrogen for 5 min, then irradiated with microwave at 150 °C for 2 h. The mixture was purified by preparative reverse phase HPLC to produce <b>24</b> as an amorphous white solid (38 mg, yield 34%): LCMS <i>m</i>/<i>z</i> 367 (100%), 369 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.21 (d, <i>J</i> = 2.53 Hz, 1H), 7.95 (d, <i>J</i> = 2.02 Hz, 1H), 7.67 (d, <i>J</i> = 1.77 Hz, 1H), 7.57 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.45 (t, <i>J</i> = 8.72 Hz, 1H), 7.29 (d, <i>J</i> = 1.77 Hz, 1H), 6.46–6.52 (m, 1H), 6.16 (t, <i>J</i> = 6.57 Hz, 1H), 1.81 (d, <i>J</i> = 6.57 Hz, 3H).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)benzamide (<b>25</b>)</h3><div class="NLM_p last">Compound <b>25</b> was prepared by using a similar procedure described for the synthesis of compound <b>24</b>: LCMS <i>m</i>/<i>z</i> 420 (100%), 422 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.31 (s, 1H), 7.93 (s, 1H), 7.83 (d, <i>J</i> = 7.33 Hz, 2H), 7.48–7.60 (m, 5H), 7.37 (d, <i>J</i> = 1.52 Hz, 1H), 6.06 (q, <i>J</i> = 6.57 Hz, 1H), 1.75–1.85 (m, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 9.457, 98.0%.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)nicotinonitrile (<b>26</b>)</h3><div class="NLM_p">To a solution of <b>22</b> (5.00 g, 13.15 mmol) in DMF (73 mL) and water (1 mL) were added Zn(CN)<sub>2</sub> (4.50 g, 26.3 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (0.602 g, 0.65 mmol), and DPPF (0.86 g, 1.55 mmol). The mixture was degassed and charged with nitrogen three times and then stirred under nitrogen at 100 °C for 3 h. The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed with a solution of saturated NH<sub>4</sub>Cl–concentrated NH<sub>4</sub>OH–water (4:1:4), then dried over MgSO<sub>4</sub>. The crude product was purified on a silica gel column, eluting with ethyl acetate–hexanes (1:4) to provide <b>26</b> as a white solid (4.15 g, 97% yield): LCMS <i>m</i>/<i>z</i> 326 (100%), 328 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.93 (d, <i>J</i> = 1.77 Hz, 1H), 7.57 (dd, <i>J</i> = 9.09, 5.05 Hz, 1H), 7.46 (t, <i>J</i> = 8.72 Hz, 1H), 6.88 (br s, 2H), 6.75 (d, <i>J</i> = 1.77 Hz, 1H), 6.03 (q, <i>J</i> = 6.57 Hz, 1H), 1.76 (d, <i>J</i> = 6.57 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 9.656, 98.9%.</div><div class="NLM_p last">Compounds <b>27</b>–<b>35</b> were prepared according to a similar procedure described for the synthesis of compound <b>11a</b>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-phenylpyridin-2-amine (<b>27</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 377 (100%), 379 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.82 (d, <i>J</i> = 2.02 Hz, 1H), 7.57 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.40–7.49 (m, 1H), 7.30–7.40 (m, 4H), 7.25 (ddd, <i>J</i> = 5.18, 3.54, 3.41 Hz, 1H), 6.94 (d, <i>J</i> = 2.02 Hz, 1H), 6.07–6.17 (m, 1 H), 5.88 (s, 2H), 1.81 (d, <i>J</i> = 6.82 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 10.094, 98.4%.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)benzoic Acid (<b>28</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 421 (100%), 423 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.80–7.91 (m, 3H), 7.59 (dd, <i>J</i> = 9.09, 5.05 Hz, 1H), 7.40–7.50 (m, 1H), 7.36 (d, <i>J</i> = 8.08 Hz, 2H), 6.99 (d, <i>J</i> = 1.77 Hz, 1H), 6.15 (q, <i>J</i> = 6.57 Hz, 1H), 5.92 (s, 2H), 1.82 (d, <i>J</i> = 6.57 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.335, 95.5%.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)pyridin-2-amine (<b>29</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 381 (100%), 383 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.30–7.39 (m, 3H), 7.22 (t, <i>J</i> = 8.72 Hz, 1H), 6.51 (s, 1H), 6.40 (d, <i>J</i> = 1.77 Hz, 1H), 5.80 (q, <i>J</i> = 6.65 Hz, 1H), 5.73 (s, 2H), 3.18 (s, 3H), 1.55(d, <i>J</i> = 6.57 Hz, 3H). Anal. Calcd for C<sub>17</sub>H<sub>15</sub>N<sub>4</sub>OCl<sub>2</sub>F·0.1H<sub>2</sub>O: C, 53.31; H, 4.00; N, 14.63. Found: C, 53.28; H, 4.08; N, 14.31.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(thiazol-2-yl)pyridin-2-amine (<b>30</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 384 (100%), 386 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.10 (d, <i>J</i> = 1.77 Hz, 1H), 7.76 (d, <i>J</i> = 3.28 Hz, 1H), 7.53–7.64 (m, 2H), 7.45 (t, <i>J</i> = 8.72 Hz, 1H), 7.12 (d, <i>J</i> = 1.77 Hz, 1H), 6.35 (s, 2H), 6.10 (q, <i>J</i> = 6.48 Hz, 1H), 1.82 (d, <i>J</i> = 6.57 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 10.417, 100%.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(isoxazol-4-yl)pyridin-2-amine (<b>31</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 368 (100%), 370 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.68 (s, 1H), 8.50 (s, 1H), 7.64 (s, 1H), 7.36 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.13 (t, <i>J</i> = 8.72 Hz, 1H), 6.87 (s, 1H), 6.11 (q, <i>J</i> = 6.57 Hz, 1H), 1.78 (d, <i>J</i> = 6.82 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 3.441, 100%.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1<i>H</i>-pyrazol-5-yl)pyridin-2-amine (<b>32</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 367 (100%), 369 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.92 (d, <i>J</i> = 1.52 Hz, 1H), 7.68 (s, 1H), 7.49–7.59 (m, 1H), 7.43 (t, <i>J</i> = 8.72 Hz, 2H), 7.12 (s, 1H), 6.41 (s, 1H), 6.06 (s, 1H), 5.90 (s, 2H), 3.32 (s, 4H), 1.78 (d, <i>J</i> = 6.57 Hz, 3H).</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>33</b>)</h3><div class="NLM_p last">Yield: 53.6%. LCMS <i>m</i>/<i>z</i> 367 (100%), 369 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.80 (d, <i>J</i> = 1.52 Hz, 1H), 7.67 (s, 2H), 7.22–7.33 (m, 1H), 6.96–7.06 (m, 1H), 6.89 (d, <i>J</i> = 1.77 Hz, 1H), 6.06 (q, <i>J</i> = 6.57 Hz, 1H), 5.07 (s, 2H), 1.84 (d, <i>J</i> = 6.57 Hz, 3H), 1.60 (s, 1H). Anal. Calcd for C<sub>16</sub>H<sub>13</sub>N<sub>4</sub>OCl<sub>2</sub>F·0.5CH<sub>3</sub>OH·0.1CH<sub>2</sub>Cl<sub>2</sub>: C, 50.90; H, 3.91; N, 14.30. Found: C, 50.60; H, 3.94; N, 14.57.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>34</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 395 (100%), 397 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.36 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.21 (d, <i>J</i> = 1.26 Hz, 1H), 7.11–7.19 (m, 1H), 6.71 (s, 1H), 6.05–6.16 (m, 1H), 2.14 (s, 6H), 1.93 (d, <i>J</i> = 6.57 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.335, 100%.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>35</b>)</h3><div class="NLM_p last">Yield: 68.4%. LCMS <i>m</i>/<i>z</i> 381 (100%), 383 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.74 (d, <i>J</i> = 1.77 Hz, 1H), 7.53 (s, 1H), 7.40 (s, 1H), 7.28 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.03 (m, 1H), 6.84 (d, <i>J</i> = 1.77 Hz, 1H), 6.05 (q, <i>J</i> = 6.57 Hz, 1H), 4.76 (s, 2H), 3.89 (s, 3H), 1.84 (d, <i>J</i> = 6.82 Hz, 3H). Anal. Calcd for C<sub>17</sub>H<sub>15</sub>N<sub>4</sub>OCl<sub>2</sub>F·0.5H<sub>2</sub>O: C, 52.32; H, 4.13; N, 14.36. Found: C, 52.51; H, 4.00; N, 14.30.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> General Procedure A for Amide Formation</h3><div class="NLM_p">To a solution of 6-amino-5-(substituted benzyloxy)pyridin-3-yl]benzoic acid (1 mol equiv), 1-hydroxybenzotriazole hydrate (HOBT, 1.2 mol equiv), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 1.2 mol equiv) in DMF (0.2 M) was added amine (1.2 mol equiv). The reaction solution was stirred at room temperature overnight, then diluted with EtOAc and partitioned with H<sub>2</sub>O. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water, saturated NaHCO<sub>3</sub>, and brine. The solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness under vacuum. The residue was purified using column chromatography (silica gel, 99:1 to 95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). The fractions containing product were concentrated under vacuum to yield the amide product with a yield of ∼50%.</div><div class="NLM_p last">Compounds <b>36</b>–<b>38</b> were prepared according to general procedure B for amide formation.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone (<b>36</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 557 (100%), 559 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.88 (d, <i>J</i> = 1.77 Hz, 1H), 7.57 (dd, <i>J</i> = 9.09, 5.05 Hz, 1H), 7.40–7.50 (m, 3H), 7.33–7.40 (m, 2H), 7.01 (d, <i>J</i> = 1.77 Hz, 1H), 6.15 (q, <i>J</i> = 6.57 Hz, 1H), 5.95 (s, 2H); 4.24 (m, 1H), 3.59 (m, 1H), 2.99–3.12 (m, 2H), 2.40–2.47 (m, 1H), 2.16–2.31 (m, 1H), 1.73–1.97 (m, 5H), 1.62–1.73 (m, 4H);, 1.27–1.45 (m, 2H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.293, 100%.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-<i>N</i>-(2-(pyrrolidin-1-yl)ethyl)benzamide (<b>37</b>)</h3><div class="NLM_p last">Acetic acid salt: LCMS <i>m</i>/<i>z</i> 517 (100%), 519 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.35–8.46 (m, 1H), 7.91 (d, <i>J</i> = 2.02 Hz, 1H), 7.78–7.88 (m, 2H), 7.57 (dd, <i>J</i> = 8.84, 5.05 Hz, 1H), 7.38–7.50 (m, 3H), 6.99 (d, <i>J</i> = 1.52 Hz, 1H), 6.07–6.20 (m, 1H), 6.00 (s, 2H), 3.35–3.41 (m, 4H), 2.57 (t, <i>J</i> = 6.95 Hz, 2H), 2.43–2.48 (m, 2H), 1.90 (s, 3H), 1.82 (d, <i>J</i> = 6.57 Hz, 3H), 1.68 (t, <i>J</i> = 3.28 Hz, 4H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.801, 99.4%.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)phenyl)((3<i>S</i>,5<i>R</i>)-3,5-dimethylpiperazin-1-yl)methanone (<b>38</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 516, (100%), 518 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.88 (d, <i>J</i> = 1.77 Hz, 1H), 7.57 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.40–7.49 (m, 3H), 7.31–7.40 (m, 2H), 7.00 (d, <i>J</i> = 1.77 Hz, 1H), 6.09–6.21 (m, 1H), 5.97 (s, 2H), 4.28–4.46 (m, 1H), 3.39–3.54 (m, 1H), 2.57–2.73 (m, 3H), 2.18–2.29 (m, 1H), 1.81 (d, <i>J</i> = 6.57 Hz, 3H), 0.78–1.05 (m, 6H). HPLC purity (method A): <i>t</i><sub>R</sub> = 7.661, 100%</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>44</b>)</h3><div id="secy" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 1</h4><div class="NLM_p last">To a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>39</b>, 1.00 g, 5.15 mmol) in DMF (25 mL, 0.2M) were added 2-iodopropane (0.55 mL, 5.15 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (2.50 g, 7.73 mmol). The mixture was stirred at 90 °C for 16 h, cooled, diluted with water, and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole as a white solid (1.20 g, 100% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.80 (s, 1H), 7.75 (s, 1H), 4.53 (dt, <i>J</i> = 13.39, 6.69 Hz, 1H), 1.51 (d, <i>J</i> = 6.57 Hz, 6H), 1.32 (s, 12H).</div></div><div id="secz" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 2</h4><div class="NLM_p last">In a microwave vessel were added 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (122 mg, 0.515 mmol), 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-iodopyridin-2-amine (200 mg, 0.468 mmol), DME (4 mL), and a freshly made solution of CsF (234 mg, 1.545 mmol) in water (1 mL). The reaction mixture was purged with N<sub>2</sub> for 5 min. Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (16.4 mg, 0.023 mmol) was added, and the system was purged with N<sub>2</sub> for 5 min. The mixture was heated in a microwave for 40 min at 120 °C. To the mixture were added EtOAc and water (10 mL each). The aqueous layer was extracted with EtOAc (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified with a reversed phase C-18 preparative HPLC column, eluting with acetonitrile/water with 0.1% acetic acid to afford <b>44</b> as a white amorphous solid (121 mg, 63% yield): LCMS <i>m</i>/<i>z</i> 409 (100%), 411 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.53–7.56 (m, 1H), 7.48 (s, 1H), 7.44 (d, <i>J</i> = 1.77 Hz, 1H), 7.37 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.10–7.17 (m, 1H), 7.00–7.06 (m, 1H), 6.17 (q, <i>J</i> = 6.82 Hz, 1H), 4.42–4.60 (m, 1H), 1.91–1.97 (m, 3H), 1.51–1.57 (m, 6H). HPLC purity (method A): <i>t</i><sub>R</sub> = 9.577, 100%.</div></div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2-(4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(2-(dimethylamino)ethyl)-2-methylpropanamide (<b>45</b>)</h3><div id="secd" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Step 1</h4><div class="NLM_p last">To a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (5 g, 25.77 mmol) and methyl 2-bromo-2-methylpropanoate (12.6 g, 27.06 mmol) in DMF (85 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (12.6 g, 38.65 mmol). The reaction mixture was heated in a 90 °C oil bath overnight. The reaction solution was cooled to room temperature and partitioned between water and ethyl acetate. The combined ethyl acetate solution was washed with water five times, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give methyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)propanoate (4.776 g, 63% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.89 (s, 1H), 7.84 (s, 1H), 3.71 (s, 3H), 1.85 (s, 6H), 1.32 (s, 12H).</div></div><div id="secc" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Step 2</h4><div class="NLM_p last">To a solution of <b>23</b> (6.363 g, 14.90 mmol) and methyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)propanoate (4.6 g, 15.64 mmol) in DME (27 mL) was added a solution of CsF (6.79 g, 44.7 mmol) in water (9.3 mL). The reaction mixture was degassed 3 times with N<sub>2</sub>. 1,1′-Bis(diphenylphosphino)ferrocene palladium dichloride (545 mg, 0.745 mmol) was added, and the reaction mixture was degassed 3 times with N<sub>2</sub> and then microwaved at 120 °C for 1 h. The reaction solution was diluted with water and extracted with EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, purified by a silica gel column chromatography with a gradient of 25–50% EtOAc/hexanes to provide methyl 2-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)-2-methylpropanoate (1.46 g, 21% yield): LCMS <i>m</i>/<i>z</i> 467 (100%), 469 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.79 (d, <i>J</i> = 1.77 Hz, 1H), 7.62–7.66 (m, 2H), 7.30 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.06 (t, <i>J</i> = 8.46 Hz, 1H), 6.89 (d, <i>J</i> = 1.52 Hz, 1H), 6.05–6.11 (m, 1H), 4.76–4.87 (m, 2H), 3.72–3.74 (m, 3H), 1.85–1.89 (m, 9H).</div></div><div id="secb" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Step 3</h4><div class="NLM_p last">To a solution of methyl 2-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)-2-methylpropanoate (2.92 g, 6.25 mmol) in MeOH (31 mL) was added a solution of LiOH (450 mg, 18.76 mmol) in water (6.25 mL). The mixture was heated at 60 °C for 45 min and cooled to ambient temperature. The pH of the reaction solution was adjusted to ∼5 with 1 N HCl, and the product was precipitated out. 2-(4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)-2-methylpropanoic acid was obtained after filtration (2.825 g, 100% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.09 (s, 1H), 7.82 (d, <i>J</i> = 1.52 Hz, 1H), 7.57–7.62 (m, 2H), 7.43–7.48 (m, 1H), 6.98 (s, 1H), 5.94–6.24 (m, 3H), 1.83 (d, <i>J</i> = 6.57 Hz, 3H), 1.75 (s, 6H).</div></div><div id="seca" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Step 4</h4><div class="NLM_p last">To a solution of 2-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)-2-methylpropanoic acid (1.00 g, 2.20 mmol) in DMF (5.5 mL) were added HOBT (300 mg, 2.20 mmol), EDC (633 mg, 3.30 mmol), and <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-dimethylethane-1,2-diamine (225 mg, 2.20 mmol). The mixture was stirred overnight and then purified by a reversed phase C-18 preparative HPLC column, eluting with acetonitrile/water with 0.1% acetic acid to afford <b>45</b> as a white solid (170 mg, 14% yield): LCMS <i>m</i>/<i>z</i> 523 (100%), 525 (64%) (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.65–7.72 (m, 2H), 7.64 (s, 1H), 7.32 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.07 (t, <i>J</i> = 8.34 Hz, 1H), 6.90–6.96 (m, 1H), 6.87 (d, <i>J</i> = 1.52 Hz, 1H), 6.04–6.11 (m, 1H), 5.25 (br s, 2H), 3.43–3.51 (m, 2H), 2.80 (t, <i>J</i> = 5.68 Hz, 2H), 2.51 (s, 6H), 2.06 (s, 3H), 1.81–1.92 (m, 9H). HPLC purity (method B): <i>t</i><sub>R</sub> = 3.156, 95.2%.</div></div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-(4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(3-(dimethylamino)propyl)acetamide (<b>46</b>)</h3><div class="NLM_p last">Compound <b>46</b> was prepared with similar procedures as compound <b>45</b>: LCMS (APCI) <i>m</i>/<i>z</i> 509 (100%), 511 (64%) (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.78 (d, <i>J</i> = 1.77 Hz, 1H), 7.70–7.77 (m, 1H), 7.67 (s, 1H), 7.50 (s, 1 H), 7.31 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.01–7.09 (m, 1H), 6.86 (d, <i>J</i> = 1.77 Hz, 1H), 6.07 (q, <i>J</i> = 6.65 Hz, 1H), 4.74–4.86 (m, 4H), 3.30–3.41 (m, 2H), 2.22–2.34 (m, 2H), 1.94 (s, 6H), 1.87 (d, <i>J</i> = 6.57 Hz, 3H), 1.57 (dt, <i>J</i> = 11.94, 6.03 Hz, 2H). Anal. Calcd for C<sub>23</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub>Cl<sub>2</sub>F·1.5H<sub>2</sub>O: C, 51.50; H, 5.64; N, 15.67. Found: C, 51.47; H, 5.39; N, 15.70.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 4-((4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)methyl)-tetrahydro-2<i>H</i>-pyran-4-ol (<b>47</b>)</h3><div id="sec5_2_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Step 1: <i>tert</i>-Butyl 1-Oxa-6-azaspiro[2.5]octane-6-carboxylate (<b>52</b>)</h4><div class="NLM_p last">To a solution of dimethylsulfoxonium methylide, which was prepared under N<sub>2</sub> from NaH of 60% dispersion in mineral oil (440 mg, 11.0 mmol) and trimethylsulfoxonium iodide (2.421 g, 11.0 mmol) in 5 mL of anhydrous DMSO, was added 1-Boc-4-oxo-1-piperidincarboxylate (<b>50</b>, 1.993 g, 10.0 mmol) in 5 mL of DMSO dropwise. The resulting mixture was stirred at 55 °C for 6 h. The cooled reaction mixture was poured into ice–water and extracted with EtOAc (2 × 200 mL). The combined organic layers were washed with H<sub>2</sub>O (50 mL), brine (50 mL) and then dried over Na<sub>2</sub>SO<sub>4</sub>. After concentration, <b>52</b> was obtained as a yellow oil (1.479 g, 69% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.62–3.78 (m, 2H), 3.35–3.49 (m, 2 H), 2.63–2.72 (m, 2 H), 1.71–1.84 (m, 2 H), 1.37–1.52 (m, 11 H).</div></div><div id="sec5_2_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Step 2: <i>tert</i>-Butyl 4-Hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)methyl)piperidine-1-carboxylate (<b>53</b>)</h4><div class="NLM_p last">A reaction mixture of <b>52</b> (214 mg, 1.0 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>39</b>, 194 mg, 1.0 mmol) with NaH of 60% dispersion in mineral oil (60 mg, 1.5 mmol) in DMF (3 mL) was stirred at 90 °C for 3 h. The reaction mixture was partitioned between EtOAc (200 mL) and saturated NaHCO<sub>3</sub> solution (50 mL) and washed with brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give <b>53</b> as a yellow grease (361 mg, 89% yield): LCMS <i>m</i>/<i>z</i> 408 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.00 (s, 1H), 7.80 (s, 1H), 7.65 (s, 1H), 4.05 (s, 2H), 3.72–3.91 (m, 2H), 3.13–3.15 (m, 2H), 1.56–1.78 (m, 4H), 1.45 (s, 9H), 1.30 (s, 12H).</div></div><div id="sec5_2_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Step 3: 4-((4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)methyl)tetrahydro-2<i>H</i>-pyran-4-ol (<b>47</b>)</h4><div class="NLM_p last">To a reaction mixture of <b>53</b> (361 mg, 0.89 mmol) and <b>23</b> (378 mg, 0.89 mmol) in ethylene glycol dimethyl ether (DME) (9 mL) were added Na<sub>2</sub>CO<sub>3</sub> solution (1.0 N, 3.9 mL, 3.9 mmol) and Pd(II)(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (32 mg, 0.05 mmol). The reaction mixture was purged with N<sub>2</sub> for 15 min and stirred at 85 °C under N<sub>2</sub> overnight. The mixture was partitioned between EtOAc (200 mL) and saturated NaHCO<sub>3</sub> solution (2 × 50 mL) and washed with brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by a reversed phase C-18 preparative HPLC column, eluting with 25–95% MeCN in H<sub>2</sub>O with 0.1% HOAc. <i>tert</i>-Butyl 4-((4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)methyl)-4-hydroxypiperidine-1-carboxylate was obtained as a white solid (147 mg, 28% yield), which was dissolved in 5 mL of CH<sub>2</sub>Cl<sub>2</sub>. To the solution was added 4.0 M HCl in dioxane (2.0 mL, 8.1 mmol). The reaction mixture was stirred at ambient temperature for 2.0 h, concentrated, and purified with reversed phase C-18 preparative HPLC column, eluting with 5–95% MeCN in H<sub>2</sub>O with 0.1% HOAc, and <b>47</b> was obtained as an off-white solid (76 mg, 63% yield): LCMS <i>m</i>/<i>z</i> 481 (100%), 483 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.65–7.69 (m, 1H), 7.57–7.62 (m, 1H), 7.44–7.49 (m, 1H), 7.32 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.08 (d, <i>J</i> = 8.08 Hz, 1H), 6.87 (d, <i>J</i> = 1.77 Hz, 1H), 6.04–6.14 (m, 1H), 5.44 (br s, 2H), 4.09 (s, 2H), 3.72–3.85 (m, 4H), 1.87 (d, <i>J</i> = 6.57 Hz, 3H), 1.59–1.69 (m, 2H), 1.32–1.40 (m, 2H). HPLC purity (method B): <i>t</i><sub>R</sub> = 0.765, 95.1%.</div></div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 5-(1-(Azetidin-3-yl)-1<i>H</i>-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine (<b>50</b>)</h3><div id="sec5_2_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Step 1. <i>tert</i>-Butyl 3-(Methylsulfonyloxy)azetidine-1-carboxylate</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-hydroxyazetidine-1-carboxylate (466 mg, 2.69 mmol), Et<sub>3</sub>N (0.75 mL, 5.38 mmol), and 4-(dimethylamino)pyridine (33 mg, 0.269 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C was added methanesulfonyl chloride (0.25 mL, 3.23 mmol). The resulting brown mixture was stirred at 0 °C to ambient temperature overnight. The reaction was quenched with NaHCO<sub>3</sub>, and then the mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and saturated NaHCO<sub>3</sub> solution (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through a silica gel pad, and eluted with hexane/EtOAc, 1:1. The filtrate was concentrated by vacuum to give <i>tert</i>-butyl 3-(methylsulfonyloxy)azetidine-1-carboxylate as a yellow oil (614 mg, 91% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 5.26–5.11 (m, 1H), 4.26 (dd, <i>J</i> = 10.36, 6.82 Hz, 2H), 4.08 (dd, <i>J</i> = 10.36, 4.29 Hz, 2H), 3.05 (s, 3H), 1.43 (s, 9H).</div></div><div id="sec5_2_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Step 2: <i>tert</i>-Butyl 3-(4-Bromo-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate</h4><div class="NLM_p last">A microwave tube (5 mL) was charged with <i>tert</i>-butyl 3-(methylsulfonyloxy)azetidine-1-carboxylate (304 mg, 1.21 mmol), 4-bromopyrazole (178 mg, 1.21 mmol), NaH 60% in mineral oil (73 mg, 1.82 mmol), and anhydrous DMF (2 mL). The resulting mixture was microwaved at 110 °C for 30 min and then partitioned between EtOAc (200 mL) and saturated NaHCO<sub>3</sub> solution (2 × 50 mL) and washed with brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated by vacuum to afford <i>tert</i>-butyl 3-(4-bromo-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate as a yellow oil (360 mg, 98%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.14 (s, 1H), 7.67 (s, 1H), 5.22–5.12 (m, 1H), 4.31–4.18 (m, 2H), 4.08 (s, 2H), 1.43–1.36 (m, 9H).</div></div><div id="sec5_2_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Step 3: <i>tert</i>-Butyl 3-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate</h4><div class="NLM_p last">A reaction mixture of <i>tert</i>-butyl 3-(4-bromo-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate (225 mg, 0.74 mmol) and bis(pinacolate)diboron (227 mg, 0.89 mmol) with KOAc (247 mg, 2.52 mmol) in DMSO (3 mL) was purged with N<sub>2</sub> for 15 min. Then PdCl<sub>2</sub>(dppf)<sub>2</sub>CH<sub>2</sub>Cl<sub>2</sub> (30 mg, 2.52 mmol) was added. The resulting mixture was stirred at 80 °C under N<sub>2</sub> overnight. After it cooled to room temperature, the mixture was filtered through a Celite pad and washed well with EtOAc. The filtrate was washed with H<sub>2</sub>O (2 × 50 mL) and brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated by vacuum. The residue was purified on a silica gel column, eluting with hexane/EtOAc (3:2) to provide <i>tert</i>-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate as a clear oil (250 mg, 97% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)) δ ppm 7.83 (s, 2H), 5.13–4.98 (m, 1H), 4.36 (t, <i>J</i> = 8.59 Hz, 2H), 4.33–4.22 (m, 2H), 1.49–1.41 (m, 6H), 1.34–1.28 (m, 6H), 1.27–1.18 (m, 9H).</div></div><div id="sec5_2_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Step 4: <i>tert</i>-Butyl 3-(4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate</h4><div class="NLM_p last">A reaction mixture of <i>tert</i>-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate (459 mg, 1.31 mmol) and 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-iodopyridin-2-amine (<b>27</b>, 374 mg, 0.88 mmol) in 13 mL of ethylene glycol dimethyl ether (13 mL) was purged with N<sub>2</sub> for 15 min. Then Pd(II)(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (46 mg, 0.07 mmol) was added and purging continued with N<sub>2</sub> for another 15 min. Another 1.0 N Na<sub>2</sub>CO<sub>3</sub> solution (3.9 mL, 3.9 mmol) was added after purging with N<sub>2</sub> for 15 min. The resulting mixture was stirred at 85 °C under N<sub>2</sub> overnight. The reaction mixture was filtered through a Celite pad and washed well with MeOH. The filtrate was concentrated by vacuum. The residue was partitioned between EtOAc (200 mL) and saturated NaHCO<sub>3</sub> solution (2 × 50 mL) and washed with brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by a flash chromatography, eluting with 0–10% methanol in CH<sub>2</sub>Cl<sub>2</sub> to afford <i>tert</i>-butyl 3-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate as a brown grease (421 mg, 92% yield): LCMS <i>m</i>/<i>z</i> 522 (100%), 524 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.78–7.72 (m, 1H), 7.65–7.59 (m, 1H), 7.58–7.53 (m, 1H), 7.52–7.44 (m, 1H), 7.41–7.33 (m, 1H), 7.04 (t, <i>J</i> = 8.46 Hz, 1H), 5.02 (d, <i>J</i> = 7.58 Hz, 1H), 4.79 (s, 2H), 4.41–4.34 (m, 1H), 4.33–4.20 (m, 2H), 4.18–4.04 (m, 2H), 1.87–1.80 (m, 3H), 1.26–1.17 (m, 9H).</div></div><div id="sec5_2_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Step 5. 5-(1-Azetidin-3-yl-1<i>H</i>-pyrazol-4-yl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine (<b>50</b>)</h4><div class="NLM_p">A reaction mixture of <i>tert</i>-butyl 3-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)azetidine-1-carboxylate (421 mg, 0.81 mmol) with dry HCl in dioxane (4.0 M, 2.0 mL, 8.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was stirred at ambient temperature for 2.0 h. The reaction mixture was concentrated by vacuum. The residue was treated with EtOAc. The precipitated solid was filtered off and washed well with EtOAc, hexane, then dried under vacuum to give <b>50</b> as a sand color solid of HCl salt (275 mg, 81% yield), which was further purified on a reversed phase HPLC column, eluting with acetonitrile in water with 0.1% acetic acid to provide <b>50</b> as a white amorphous solid after lyophilization: LCMS <i>m</i>/<i>z</i> 422 (100%), 424 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.20 (s, 1H), 8.12 (s, 1H), 7.86 (s, 1H), 7.73–7.83 (m, 1H), 7.59 (dd, <i>J</i> – 8.84, 5.05 Hz, 1H), 7.40–7.54 (m, 1H), 7.09 (s, 1H), 6.23 (d, <i>J</i> = 6.57 Hz, 2H), 5.40 (s, 1H), 4.35 (s, 4H), 3.56 (s, 1H), 1.79–1.89 (m, 3H). Anal. Calcd for C<sub>19</sub>H<sub>18</sub>N<sub>5</sub>OCl<sub>2</sub>F·2H<sub>2</sub>O·1CH<sub>3</sub>CO<sub>2</sub>H: C, 48.66; H, 5.06; N, 13.51. Found: C, 48.41; H, 4.89; N, 13.14.</div><div class="NLM_p last">Compounds <b>48</b> and <b>49</b> were prepared with similar procedures as compound <b>50.</b></div></div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 5-(1-(Azetidin-3-ylmethyl)-1<i>H</i>-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine (<b>48</b>)</h3><div class="NLM_p last">Yield: 78%. LCMS <i>m</i>/<i>z</i> 436 (100%), 438 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 7.69 (s, 1H), 7.57 (s, 1H), 7.48 (s, 1H), 7.35 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.14 (t, <i>J</i> = 8.59 Hz, 1H), 6.83 (s, 1H), 6.08 (d, <i>J</i> = 6.57 Hz, 1H), 4.29 (d, <i>J</i> = 6.82 Hz, 2H), 4.00 (t, <i>J</i> = 9.73 Hz, 2H), 3.84–3.95 (m, 2H), 3.32 (d, <i>J</i> = 8.08 Hz, 1H), 1.78 (d, <i>J</i> = 6.57 Hz, 3H). Anal. Calcd for C<sub>20</sub>H<sub>20</sub>N<sub>5</sub>OCl<sub>2</sub>F·2.5HCl·2H<sub>2</sub>O·2.5CH<sub>3</sub>CO<sub>2</sub>H: C, 42.08; H, 5.16; N, 9.81. Found: C, 42.34; H, 4.98; N, 9.41.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 1-(3-((4-(6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)methyl)azetidin-1-yl)-2-(dimethylamino)ethanone (<b>49</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 521 (100%), 523 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.91 (d, <i>J</i> = 1.52 Hz, 1H), 7.74 (d, <i>J</i> = 1.77 Hz, 1H), 7.52–7.61 (m, 2H), 7.40–7.47 (m, 1H), 6.88 (s, 1H), 6.08 (q, <i>J</i> = 6.57 Hz, 1H), 5.66 (s, 2H), 4.31 (d, <i>J</i> = 7.33 Hz, 2H), 4.21 (t, <i>J</i> = 8.59 Hz, 1H), 3.98 (dd, <i>J</i> = 8.97, 5.43 Hz, 1H), 3.90 (t, <i>J</i> = 9.09 Hz, 1H), 3.68 (dd, <i>J</i> = 9.98, 5.43 Hz, 1H), 2.84–2.92 (m, 2H), 2.15 (s, 6H), 1.80 (d, <i>J</i> = 6.57 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.731, 100%.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>61</b>)</h3><div id="secj" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Step 1</h4><div class="NLM_p last">To a solution of 5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-ylamine (<b>22</b>, 12.83 g, 33.76 mmol) in anhydrous DMF (100 mL) were added di-<i>tert</i>-butyl dicarbonate (21.25 g, 97.35 mmol) and 4-dimethylaminopyridine (0.793 g, 6.49 mmol). The mixture was stirred at ambient temperature for 18 h. Saturated NaHCO<sub>3</sub> solution (300 mL) was added to the mixture and extracted with EtOAc (3 × 250 mL). The combined extracts were washed with water (5 × 100 mL), saturated NaHCO<sub>3</sub>, and brine, then dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, evaporation, and high vacuum drying, <b>54</b> was obtained as an off-white foam solid (19.59 g, 100% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.18 (d, <i>J</i> = 1.77 Hz, 1H), 7.83 (d, <i>J</i> = 2.02 Hz, 1H), 7.52–7.61 (m, 1H), 7.43–7.52 (m, 1H), 6.21–6.33 (m, 1H), 1.75 (d, <i>J</i> = 6.57 Hz, 3H), 1.39 (s, 9H), 1.16–1.27 (m, 9H).</div></div><div id="seci" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Step 2</h4><div class="NLM_p last">To a solution of <b>54</b> (19.58 g, 33.76 mmol) in DMSO (68 mL) was added potassium acetate (11.26 g, 114.78 mmol) and bis(pinacolato)diboron (10.29 g, 40.51 mmol). The mixture was degassed and charged with nitrogen three times. Then Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (1.38 g, 1.69 mmol) was added. The reaction mixture was degassed and charged with nitrogen three times and then stirred in a 80 °C oil bath for 12 h. The reaction was cooled to ambient temperature, diluted with ethyl acetate (100 mL), and filtered through a Celite pad which was washed with ethyl acetate. The combined ethyl acetate solution (700 mL) was washed with water (5 × 100 mL), brine (100 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified on a silica gel column, eluting with EtOAc/hexane (0–50%) to provide <b>56</b> as a foam solid (20.59 g, 97% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.18 (d, <i>J</i> = 1.26 Hz, 1H), 7.51–7.61 (m, 2H), 7.42–7.50 (m, 1H), 6.12–6.21 (m, 1H), 1.74 (d, <i>J</i> = 6.57 Hz, 3H), 1.16–1.42 (m, 30H).</div></div><div id="secg" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Step 3</h4><div class="NLM_p last">To a solution of <b>56</b> (20.34 g, 32.42 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (80 mL) was added a solution of dry HCl in dioxane (4 N, 40.5 mL, 162 mmol). The reaction solution was stirred in a 40 °C oil bath for 12 h. The reaction mixture was cooled to ambient temperature, diluted with EtOAc (400 mL), then washed carefully but quickly with saturated NaHCO<sub>3</sub> until the water layer was basic (pH > 8). The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, evaporation, and high vacuum drying, <b>57</b> was obtained as an off-white foam solid (13.48 g, 97% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.71–7.78 (m, 1H), 7.54 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.36–7.49 (m, 1H), 6.87 (d, <i>J</i> = 1.01 Hz, 1H), 6.13 (br s, 2H), 5.99 (q, <i>J</i> = 6.65 Hz, 1H), 1.77 (d, <i>J</i> = 6.82 Hz, 3H), 1.22 (s, 6 H) 1.20 (s, 6 H).</div></div><div id="secf" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Step 4</h4><div class="NLM_p last">To a stirred solution of <b>57</b> (4.2711 g, 10.0 mmol) and <i>tert</i>-butyl 4-(4-bromo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (3.9628 g, 12.0 mmol) in DME (40 mL) was added a solution of Na<sub>2</sub>CO<sub>3</sub> (3.1787 g, 30.0 mmol) in water (10 mL). The solution was degassed and charged with nitrogen three times. To the solution was added Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (351 mg, 0.50 mmol). The reaction solution was degassed and charged with nitrogen again three times and then stirred in an 87 °C oil bath for 16 h. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc (200 mL), filtered through a pad of Celite, and washed with EtOAc. The combined EtOAc solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was purified on a silica gel column, eluting with EtOAc/hexane system (0–100% EtOAc) to afford <i>tert</i>-butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate as a foam solid (3.4167 g, 65% yield).</div></div><div id="sece" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Step 5</h4><div class="NLM_p">To a solution of <i>tert</i>-butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (566.7 mg, 1.03 mmol) in methanol (5 mL) was added 4 N HCl in dioxane (1 mL, 4 mmol). The solution was stirred for about 1 h or until the deprotection was complete. The solvents were evaporated and the residue was dissolved in methanol and purified on a reversed phase C-18 preparative HPLC column, eluting with acetonitrile/water with 0.1% acetic acid from 5% to 30% with a linear gradient. After lyophilization, <b>61</b> was obtained as a white solid (410 mg, 78% yield): LCMS <i>m</i>/<i>z</i> 450 (100%), 452 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.92 (s, 1H), 7.75 (d, <i>J</i> = 1.77 Hz, 1H), 7.58 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.52 (s, 1H), 7.42–7.48 (m, 1H), 6.89 (d, <i>J</i> = 1.77 Hz, 1H), 6.03–6.14 (m, 1H), 5.65 (s, 2H), 4.08–4.20 (m, 1H), 2.99–3.07 (m, 2H), 2.57 (td, <i>J</i> = 12.38, 2.27 Hz, 2H), 1.90–1.97 (m, 2H), 1.80 (d, <i>J</i> = 6.82 Hz, 3H), 1.74 (dd, <i>J</i> = 12.00, 3.92 Hz, 2H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.694, 100%.</div><div class="NLM_p last">Compounds <b>58</b>–<b>60</b> were prepared by using similar procedures described for the synthesis of compound <b>61</b>.</div></div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-((<i>S</i>)-pyrrolidin-3-yl)-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>58</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 436 (100%), 438 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.65 (s, 1H), 7.56 (s, 1H), 7.46 (s, 1H), 7.39 (dd, <i>J</i> = 8.59, 5.05 Hz, 1H), 7.15 (t, <i>J</i> = 8.08 Hz, 1H), 6.99–7.03 (m, 1H), 6.13–6.22 (m, 1H), 5.06–5.13 (m, 1H), 3.74–3.84 (m, 2H), 3.57–3.72 (m, 2H), 2.55–2.70 (m, 1H), 2.33–2.47 (m, 1H), 1.95 (d, <i>J</i> = 6.82 Hz, 3H). HPLC purity (method B): <i>t</i><sub>R</sub> = 2.872, 100%.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-3-yl)-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>59</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 450 (100%), 452 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.70 (d, <i>J</i> = 1.52 Hz, 1H), 7.56 (s, 1H), 7.53 (s, 1H), 7.32 (dd, <i>J</i> = 8.84, 4.80 Hz, 1H), 7.02–7.10 (m, 1H), 6.87 (d, <i>J</i> = 1.77 Hz, 1H), 6.03–6.13 (m, 1H), 5.22 (br s, 2H), 4.18–4.31 (m, 1H), 3.37–3.44 (m, 1H), 3.03–3.12 (m, 2H), 2.72–2.83 (m, 1H), 1.98–2.05 (m, 3H), 1.87 (d, <i>J</i> = 6.57 Hz, 3H), 1.60–1.72 (m, 1H). HPLC purity (method B): <i>t</i><sub>R</sub> = 2.892, 100%</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (<b>60</b>)</h3><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 451 (100%), 453 (64%) (M + H)<sup>+</sup>; 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.96 (s, 1H), 7.76 (d, <i>J</i> = 1.77 Hz, 1H), 7.54–7.63 (m, 2H), 7.41–7.48 (m, 1H), 6.90 (d, <i>J</i> = 1.52 Hz, 1H), 6.06–6.13 (m, 1H), 5.65 (s, 2H), 4.30–4.41 (m, 1H), 3.90–4.01 (m, 2H), 3.43–3.53 (m, 2H), 1.93–2.00 (m, 2H), 1.84–1.91 (m, 2H), 1.81 (d, <i>J</i> = 6.82 Hz, 3H). HPLC purity (method A): <i>t</i><sub>R</sub> = 8.712, 100%.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 3-((<i>R</i>)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (Crizotinib)</h3><div class="NLM_p">To a stirred solution of <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate (7.94 g, 39.45 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL), cooled to 0 °C, was slowly added Et<sub>3</sub>N (5.54 mL, 39.45 mmol) followed by methane sulfonyl chloride (3.06 mL, 39.45 mmol) and DMAP (48 mg, 0.39 mmol). The mixture was stirred at room temperature overnight. To the mixture was added water (30 mL). Extraction with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL) followed by drying (Na<sub>2</sub>SO<sub>4</sub>) and removal of the solvent in vacuo afforded <i>tert</i>-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate <b>65</b> as a white solid (11.00 g, >99% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.89 (m, 1H), 3.69 (m, 2H), 3.31 (m, 2H), 3.04 (s, 3H), 1.95 (m, 2H), 1.83 (m, 2H), 1.46 (s, 9H).</div><div class="NLM_p">NaH (16.32 g, 0.68 mol) was added portionwise to a stirred solution of 4-iodopyrazole (<b>66</b>, 110.57 g, 0.57 mol) in DMF (2 L) at 4 °C. The resulting mixture was stirred for 1 h at 4 °C, and <b>65</b> (176.00 g., 0.63 mol) was then added. The resulting mixture was heated to 100 °C for 12 h. The reaction was quenched with H<sub>2</sub>O, and the aqueous portion was extracted with EtOAc several times. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford an orange oil. The residue was purified by a silica gel column, eluting with 5% EtOAc in pentane to give <i>tert</i>-butyl 4-(4-iodo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate <b>67</b> as a white solid (140 g, 66%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.98 (s, 1H), 7.52 (s, 1H), 4.30–4.43 (m, 1H), 3.93–4.07 (m, 2H), 2.77–2.97 (m, 2H), 1.90–2.00 (m, 2H), 1.66–1.83 (m, 2H), 1.40 (s, 9H).</div><div class="NLM_p">Bis(pinacilato)diboron (<b>55</b>, 134 g, 0.52 mol) and potassium acetate (145 g, 1.48 mol) were added sequentially to a solution of <b>67</b> (140 g, 0.37 mol) in DMSO (1.5 L). The mixture was purged with nitrogen several times, and dichlorobis(triphenylphosphino)palladium(II) (12.9 g, 0.018 mol) was then added. The resulting mixture was heated at 80 °C for 2 h. The reaction mixture was cooled to ambient temperature and filtered through a bed of Celite and washed with EtOAc. The filtrate was washed with brine (2 × 500 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by a silica gel column, eluting with 5% EtOAc in hexanes to give <b>68</b> as a white solid (55 g, 40%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.97 (s, 1H), 7.59 (s, 1H), 4.29–4.44 (m, 1H), 4.01 (d, <i>J</i> = 13.14 Hz, 2H), 2.77–3.01 (m, 2H), 1.92–1.99 (m, 2H), 1.78 (dd, <i>J</i> = 12.00, 4.17 Hz, 2H), 1.41 (s, 9H), 1.24 (s, 12H).</div><div class="NLM_p">A reaction solution of (<i>R</i>)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine (<b>69</b>, 14.4 g, 37.9 mmol) and <b>68</b> (17.2 g, 45.5 mmol) in DME (114 mL) was purged with nitrogen. Then Pd(dppf)Cl<sub>2</sub> (1.24 g, 1.52 mmol) and Cs<sub>2</sub>CO<sub>3</sub> aqueous solution (2.0 N, 57 mL, 114 mmol) were added. The resulting mixture was purged with nitrogen and stirred at 90 °C for 3 h. The reaction mixture was cooled to ambient temperature and filtered through a Celite pad and washed well with MeOH. The filtrate was concentrated by vacuum. The residue was partitioned between EtOAc (800 mL) and saturated NaHCO<sub>3</sub> solution (2 × 150 mL) and brine (150 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then filtered through a silica gel pad and washed well with EtOAc to remove black solid. The filtrate was concentrated by vacuum. The residue was purified by a silica gel column, eluting with EtOAc/hexane system to collect desired fraction and then concentrated by vacuum. The residue of off-white foam was treated with ether (100 mL) and hexane (500 mL). The precipitated solid was filtered off and washed well with hexane, then dried under vacuum to afford <i>tert</i>-butyl 4-(4-(6-amino-5-((<i>R</i>)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate as an off-white solid (19.55 g, 94% yield).</div><div class="NLM_p last">To a solution of 4-(4-(6-amino-5-((<i>R</i>)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (19.54 g, 35.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) at 0 °C was added 4.0 N HCl in dioxane (133 mL, 532 mmol) dropwise. The resulting mixture was stirred at 0 °C to room temperature for 4 h. The white suspension was filtered off, and the yellowish crude product was dissolved in H<sub>2</sub>O (500 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (500 mL). The pH of the aqueous layer was adjusted to ∼10 by adding Na<sub>2</sub>CO<sub>3</sub>, and then the aqueous portion was extracted with EtOAc (1000 mL). The organic layer was washed with saturated aqueous NaHCO<sub>3</sub> (400 mL) and brine (150 mL), then dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated by vacuum. The precipitated solid was treated with ether and hexane and filtered off, washed well with ether and hexane, then dried under vacuum to afford crizotinib (<b>63</b>) as a white powder (15.34 g, 96% yield): mp 196–199 °C; LCMS <i>m</i>/<i>z</i> 450 (100%), 452 (64%) (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.92 (s, 1H), 7.75 (d, <i>J</i> = 1.77 Hz, 1H), 7.58 (dd, <i>J</i> = 8.97, 4.93 Hz, 1H), 7.52 (s, 1H), 7.42–7.48 (m, 1H), 6.89 (d, <i>J</i> = 1.77 Hz, 1H), 6.03–6.14 (m, 1H), 5.65 (s, 2H), 4.08–4.20 (m, 1H), 2.99–3.07 (m, 2H), 2.57 (td, <i>J</i> = 12.38, 2.27 Hz, 2H), 1.90–1.97 (m, 2H), 1.80 (d, <i>J</i> = 6.82 Hz, 3H), 1.74 (dd, <i>J</i> = 12.00, 3.92 Hz, 2H). HPLC purity (method A): <i>t</i><sub>R</sub> = 6.694, 100%. Anal. Calcd for C<sub>21</sub>H<sub>22</sub>N<sub>5</sub>OCl<sub>2</sub>F<b>·</b>0.5H<sub>2</sub>O: C, 54.91; H, 5.05; N, 15.25. Found: C, 55.20; H, 4.91; N, 15.13.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Biochemical Kinase Assays</h3><div class="NLM_p last">c-MET enzyme inhibition was meaured by Omnia (Invitrogen Inc.) continuous fluorometric assay as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The reactions were conducted in 50 μL volumes in 96-well plates at 30 °C. Mixtures contained 1 nM human recombinant c-MET kinase domain (aa 1051–1348), 2 μM phosphoacceptor peptide Ac-EEEEYI(cSx)-IV-NH2 (Invitrogen Inc.), test compound (11-dose 3-fold serial dilutions, 2% DMSO final) or DMSO only, 0.2 mM DTT, and 10 mM MgCl<sub>2</sub> in 20 mM Hepes, pH 7.5, and the reactions were initiated by addition of ATP (100 μM final concentration) following a 20 min preincubation. The initial rates of phosphopeptide formation were measured over 20 min using a Tecan Safire microplate reader with wavelength settings of 360 nm for excitation and 485 nm for emission. The inhibitors were shown to be ATP-competitive from kinetic and crystallographic studies. The <i>K</i><sub>i</sub> values were calculated by fitting the data to the equation for competitive inhibition using nonlinear regression method (GraphPad Prism, GraphPad Software, San Diego, CA) and experimentally measured ATP <i>K</i><sub>m</sub> = 56 μM.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Cellular Kinase Phosphorylation ELISA Assays<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a></h3><div class="NLM_p last">All experiments were done under standard conditions (37 °C and 5% CO<sub>2</sub>). IC<sub>50</sub> values were calculated by concentration–response curve fitting using a Microsoft Excel based four-parameter method. Cells were seeded in 96-well plates in medium supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free medium [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors were added for up to 20 min. After incubation of cells with an inhibitor for 1 h and/or appropriate ligands for the designated times, cells were washed once with HBSS supplemented with 1 mmol/L Na<sub>3</sub>VO<sub>4</sub>, and protein lysates were generated from cells. Subsequently, phosphorylation of selected protein kinases was assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates were (a) incubated in the presence of protein lysates at 4 °C overnight, (b) washed seven times in 1% Tween 20 in PBS, (c) incubated in a horseradish peroxidase conjugated anti-total-phosphotyrosine (PY-20) antibody (1:500) for 30 min, (d) washed seven times again, (e) incubated in 3,3,5,5-tetramethylbenzidine peroxidase substrate (Bio-Rad) to initiate a colorimetric reaction that was stopped by adding 0.09 N H<sub>2</sub>SO<sub>4</sub>, and (f) measured for absorbance in 450 nm using a spectrophotometer. Cell lines used for individual kinases include A549 for c-MET, Karpas 299 for ALK, 3T3-RON for RON, 293-AXL for AXL, 3T3-E/TIE2 for TIE2, PAE-TRKA for TRKA, PAE-TRKB for TRKB, BaF3-BCL-ABL for ABL, 293-hIR for IR, and Jurkat for LCK.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Human Microsomal Stability Studies</h3><div class="NLM_p last">Compounds (1 μM) were incubated at 37 °C for 30 min in a final volume of 200 μL of 100 mM potassium phosphate buffer (pH 7.4) containing pooled human liver microsomes (0.8 mg/mL protein) and 2 mM NADPH. Reactions were initiated with the addition of NADPH following a 10 min preincubation. Aliquots of incubation samples were protein precipitated with cold methanol containing 0.1 μM buspirone (internal standard) and centrifuged, and supernatants were analyzed by LCMS/MS. All incubations were performed in triplicate, and the percent remaining of parent drug at the end of incubation was determined by LCMS/MS peak area ratio.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Cocrystal Structures</h3><div class="NLM_p last">c-MET cocrystals were obtained at 13 °C by the hanging drop vapor diffusion method by mixing 1.2 μL of protein solution (containing 7–13 mg/mL c-MET KD (residues 1051–1348) with a 5-fold molar excess of either crizotinib or <b>3</b>) with 1.2 μL of solution containing 0.05 M citrate–phosphate, pH 4.6, 0–0.275 M NaCl, and 21% polyethylene glycol (MW = 3350). Details of the crystal structure determinations can be accessed from the PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj">2wgj</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm">2wkm</a>. The crizotinib and compound <b>3</b> cocrystal structures were refined to resolution limits of 2.0 and 2.2 Å, respectively.</div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Jean Cui</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b8d2ddd9d696dbcdd1f8c8ded1c2ddca96dbd7d5"><span class="__cf_email__" data-cfemail="89e3ece8e7a7eafce0c9f9efe0f3ecfba7eae6e4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Tran-Dubé</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitchell Nambu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pei-Pei Kung</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mason Pairish</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Jia</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerry Meng</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lee Funk</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iriny Botrous</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele McTigue</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Grodsky</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Ryan</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ellen Padrique</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gordon Alton</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sergei Timofeevski</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shinji Yamazaki</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuhua Li</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Zou</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Christensen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Mroczkowski</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Bender</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert S. Kania</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin P. Edwards</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm2007613" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Dr. Nikolaus Schiering for generating the first cocrystal structure of PHA-665752 bound to c-MET, to Muhammad Alimuddin for analytical support, to the Pfizer PDM group for metabolic stability studies, to Dr. Klaus Dress for discussions and making Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, and to Dr. Beth Lunney for c-MET/ALK sequence identity analyses.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i95" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i95"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i96" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i96"> Abbreviations Used</h2><tr><td class="NLM_term">c-MET</td><td class="NLM_def"><p class="first last">mesenchymal–epithelial transition factor</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">c-KIT</td><td class="NLM_def"><p class="first last">proto-oncogene tyrosine-protein kinase kit</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">breakpoint-cluster region</p></td></tr><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson leukemia</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">Von Hippel–Lindau</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">LTK</td><td class="NLM_def"><p class="first last">leukocyte tyrosine kinase</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule associated protein-like 4</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure based drug design</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">A-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">FGFR1K</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1 kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte specific kinase</p></td></tr><tr><td class="NLM_term">AXL</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase receptor UFO (AXL gene)</p></td></tr><tr><td class="NLM_term">TIE2</td><td class="NLM_def"><p class="first last">tyrosine kinase with Ig</p></td></tr><tr><td class="NLM_term">TRKA</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase A</p></td></tr><tr><td class="NLM_term">TRKB</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase B</p></td></tr><tr><td class="NLM_term">RON</td><td class="NLM_def"><p class="first last">receptor d'origine nantais</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large cell lymphoma</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lgevoBynNj6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_contrib-group">Krause, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as targets for cancer therapy</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMra044389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=16014887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=172-187&author=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Tyrosine+kinases+as+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets for cancer therapy</span></div><div class="casAuthors">Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the mechanisms of aberrant tyrosine kinase signaling and strategies to inhibit TKs in cancer.  It also summarizes the status of TK-directed cancer therapies, and discusses challenges and prospects for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89QOl9E0UMLVg90H21EOLACvtfcHk0liNbjY7eESwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D&md5=0a98c8840a983300f6b0743673cf480c</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra044389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra044389%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D172%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kijima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-MET%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0liNbjY7eESwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520c-MET%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET: structure, functions and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1023%2FA%3A1023768811842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=12884908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=309-325&author=P.+C.+Maauthor=G.+Maulikauthor=J.+Christensenauthor=R.+Salgia&title=c-MET%3A+structure%2C+functions+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met: Structure, functions and potential for therapeutic inhibition</span></div><div class="casAuthors">Ma, Patrick C.; Maulik, Gautam; Christensen, James; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Studies on signal transduction pathways have generated various promising mol. targets for therapeutic inhibition in cancer therapy.  Receptor tyrosine kinases represent an important class of such therapeutic targets.  C-Met is a receptor tyrosine kinase that has been shown to be overexpressed and/or mutated in a variety of malignancies.  A no. of c-Met activating mutations, many of which are located in the tyrosine kinase domain, have been detected in various solid tumors and have been implicated in invasion and metastasis of tumor cells.  It is known that stimulation of c-Met via its natural ligand, hepatocyte growth factor (also known as scatter factor, HGF/SF) results in a plethora of biol. and biochem. effects in the cell.  Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.  Moreover, we summarize current knowledge on various pathways of c-Met signal transduction, highlighting the central role in the cytoskeletal functions.  In this summary is included recent data in our lab. indicating that phosphorylation of focal adhesion proteins, such as paxillin, p125FAK, and PYK2, occurs in response to c-Met stimulation in lung cancer cells.  Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rIdb5Ao4a7Vg90H21EOLACvtfcHk0liNbjY7eESwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D&md5=7b7bf60da872071a39ce313efd32fd1f</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023768811842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023768811842%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%253A%2520structure%252C%2520functions%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D309%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET as a target in human cancer and characterization of inhibitors for therapeutic intervention</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">225</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2Fj.canlet.2004.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15922853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2005&pages=1-26&author=J.+Christensenauthor=J.+Burrowsauthor=R.+Salgia&title=c-MET+as+a+target+in+human+cancer+and+characterization+of+inhibitors+for+therapeutic+intervention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention</span></div><div class="casAuthors">Christensen, James G.; Burrows, Jon; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-26</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, Imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers.  A unique member of the RTK family, c-Met, also represents an intriguing target for cancer therapy that is yet to be explored in a clin. setting.  The proto-oncogene, c-Met, encodes the high-affinity receptor for hepatocyte growth factor (HGF) or scatter factor (SF).  C-Met and HGF are each required for normal mammalian development and have been shown to be particularly important in cell migration, morphogenic differentiation, and organization of three-dimensional tubular structures (e.g. renal tubular cells, gland formation, etc.) as well as cell growth and angiogenesis.  Both c-Met and HGF have been shown to be deregulated in and to correlate with poor prognosis in a no. of major human cancers.  New data describing the constitutive phosphorylation of c-Met in a no. of human tumors is presented here along with a variety of mechanisms by which c-Met can become activated, including mutation and gene amplification.  In support of the clin. data implicating c-Met activation in the pathogenesis of human cancers, introduction of c-Met and HGF (or mutant c-Met) into cells conferred the properties of motility, invasiveness, and tumorigenicity to the transformed cells.  Conversely, the inhibition of c-Met with a variety of receptor antagonists inhibited the motility, invasiveness, and tumorigenicity of human tumor cell lines.  Consistent with this observation, small-mol. inhibitors of c-Met were developed that antagonized c-Met/HGF-dependent phenotypes and tumor growth in mouse models.  This review will address the potential for development of c-Met inhibitors for treatment of human cancers with particular emphasis on recent findings with small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojTbSn0ouMILVg90H21EOLACvtfcHk0liwc6HwRn8FIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D&md5=106b145cbf442e9fec9667817697658d</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%2520as%2520a%2520target%2520in%2520human%2520cancer%2520and%2520characterization%2520of%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D225%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_contrib-group">Benvenuti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">The met receptor tyrosine kinase in invasion and metastasis</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fjcp.21183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=17607709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=316-325&author=S.+Benvenutiauthor=P.+M.+Comoglio&title=The+met+receptor+tyrosine+kinase+in+invasion+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The MET receptor tyrosine kinase in invasion and metastasis</span></div><div class="casAuthors">Benvenuti, Silvia; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Various cytokines and sol. growth factors upon interaction with their membrane receptors are responsible for inducing cellular proliferation, differentiation, movement, and protection from anoikis (a planned suicide activated by normal cells in absence of attachment to neighboring cells or extracellular matrix (EMC)).  Among those sol. factors a major position is exerted by hepatocyte growth factor (HGF) together with its receptor MET and macrophage-stimulating protein (MSP) in cooperation with its receptor RON.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1QrqNHPoSM7Vg90H21EOLACvtfcHk0liwc6HwRn8FIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM&md5=8994572071201c78fd2df1b504ab1a4e</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21183%26sid%3Dliteratum%253Aachs%26aulast%3DBenvenuti%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DThe%2520met%2520receptor%2520tyrosine%2520kinase%2520in%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2e"><span><span class="NLM_contrib-group">Knudsen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Showering c-MET-dependent cancers with drugs</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0liwc6HwRn8FIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_contrib-group">Cheng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1200%2FJCO.20.6.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=11896103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1544-1550&author=H.-L.+Chengauthor=B.+Trinkauthor=T.-S.+Tzaiauthor=H.-S.+Liuauthor=S.-H.+Chanauthor=C.-L.+Hoauthor=D.+Sidranskyauthor=N.-H.+Chow&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+transitional+cell+carcinoma+of+the+urinary+bladder%3A+a+comparison+with+p53+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation</span></div><div class="casAuthors">Cheng, Hong-Lin; Trink, Barry; Tzai, Tzong-Shin; Liu, Hsiao-Sheng; Chan, Shih-Huang; Ho, Chung-Liang; Sidransky, David; Chow, Nan-Haw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1550</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis.  Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clin. significance of Met in human bladder cancer.  Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines.  Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients).  Results: Expression of c-met mRNA tended to pos. correlate with differentiation of cancer cell lines in the absence of point mutation.  High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and neg. expression in 103 cases (72.5%).  Expression of Met was pos. assocd. with histol. grade, stage classification, tumor size, and nodular tumor growth (P < .05, resp.); however, it was not related to TP53 status.  Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P < .05, resp.).  Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, resp.).  Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53.  Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfd5r45qOJLVg90H21EOLACvtfcHk0liwc6HwRn8FIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D&md5=2b9b03134c74318b533f82908304a28e</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.6.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.6.1544%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DTrink%26aufirst%3DB.%26aulast%3DTzai%26aufirst%3DT.-S.%26aulast%3DLiu%26aufirst%3DH.-S.%26aulast%3DChan%26aufirst%3DS.-H.%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DN.-H.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520urinary%2520bladder%253A%2520a%2520comparison%2520with%2520p53%2520nuclear%2520accumulation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1544%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_contrib-group">Lengyel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resau, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harneck, N.</span><span> </span><span class="NLM_article-title">c-MET overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fijc.20598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15455388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1Km" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2005&pages=678-682&author=E.+Lengyelauthor=D.+Prechtelauthor=J.+H.+Resauauthor=K.+Gaugerauthor=A.+Welkauthor=K.+Lindemannauthor=G.+Salantiauthor=T.+Richterauthor=B.+Knudsenauthor=G.+F.+Vande+Woudeauthor=N.+Harneck&title=c-MET+overexpression+in+node-positive+breast+cancer+identifies+patients+with+poor+clinical+outcome+independent+of+Her2%2Fneu"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span></div><div class="casAuthors">Lengyel, Ernst; Prechtel, Dieter; Resau, James H.; Gauger, Katja; Welk, Anita; Lindemann, Kristina; Salanti, Georgia; Richter, Thomas; Knudsen, Beatrice; Vande Woude, George F.; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-682</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis.  In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochem. and confocal immunofluorescence.  Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade.  Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression.  Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addn. to Her2/neu.  Median disease-free survival in patients with c-Met overexpressing tumors was 8 mo compared to 53 mo when c-Met expression was low (p = 0.037; RR = 3.0).  This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate anal.  In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further anal. in a larger cohort of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx-vk_XMTZ6LVg90H21EOLACvtfcHk0lgpLSTVbHpe_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1Km&md5=d1d709a602edbff17ee9240e05cb8412</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1002%2Fijc.20598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20598%26sid%3Dliteratum%253Aachs%26aulast%3DLengyel%26aufirst%3DE.%26aulast%3DPrechtel%26aufirst%3DD.%26aulast%3DResau%26aufirst%3DJ.%2BH.%26aulast%3DGauger%26aufirst%3DK.%26aulast%3DWelk%26aufirst%3DA.%26aulast%3DLindemann%26aufirst%3DK.%26aulast%3DSalanti%26aufirst%3DG.%26aulast%3DRichter%26aufirst%3DT.%26aulast%3DKnudsen%26aufirst%3DB.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DHarneck%26aufirst%3DN.%26atitle%3Dc-MET%2520overexpression%2520in%2520node-positive%2520breast%2520cancer%2520identifies%2520patients%2520with%2520poor%2520clinical%2520outcome%2520independent%2520of%2520Her2%252Fneu%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D113%26spage%3D678%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_contrib-group">Lo Muzio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coccia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capogreco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campisi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carinci, F.</span><span> </span><span class="NLM_article-title">Effect of c-MET expression on survival in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1159%2F000092716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=116-121&author=L.+Lo+Muzioauthor=A.+Farinaauthor=C.+Rubiniauthor=E.+Cocciaauthor=M.+Capogrecoauthor=G.+Colellaauthor=R.+Leonardiauthor=G.+Campisiauthor=F.+Carinci&title=Effect+of+c-MET+expression+on+survival+in+head+and+neck+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1159%2F000092716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000092716%26sid%3Dliteratum%253Aachs%26aulast%3DLo%2BMuzio%26aufirst%3DL.%26aulast%3DFarina%26aufirst%3DA.%26aulast%3DRubini%26aufirst%3DC.%26aulast%3DCoccia%26aufirst%3DE.%26aulast%3DCapogreco%26aufirst%3DM.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DLeonardi%26aufirst%3DR.%26aulast%3DCampisi%26aufirst%3DG.%26aulast%3DCarinci%26aufirst%3DF.%26atitle%3DEffect%2520of%2520c-MET%2520expression%2520on%2520survival%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2006%26volume%3D27%26spage%3D116%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3d"><span><span class="NLM_contrib-group">Sawada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radjabi, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kistner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkyilmaz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, E.</span><span> </span><span class="NLM_article-title">c-MET overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1670</span><span class="NLM_x">–</span> <span class="NLM_lpage">1679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1670-1679&author=K.+Sawadaauthor=A.+E.+Radjabiauthor=N.+Shinomiyaauthor=E.+Kistnerauthor=H.+Kennyauthor=A.+R.+Beckerauthor=M.+A.+Turkyilmazauthor=R.+Salgiaauthor=S.+D.+Yamadaauthor=G.+F.+Vande+Woudeauthor=M.+S.+Tretiakovaauthor=E.+Lengyel&title=c-MET+overexpression+is+a+prognostic+factor+in+ovarian+cancer+and+an+effective+target+for+inhibition+of+peritoneal+dissemination+and+invasion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DRadjabi%26aufirst%3DA.%2BE.%26aulast%3DShinomiya%26aufirst%3DN.%26aulast%3DKistner%26aufirst%3DE.%26aulast%3DKenny%26aufirst%3DH.%26aulast%3DBecker%26aufirst%3DA.%2BR.%26aulast%3DTurkyilmaz%26aufirst%3DM.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DYamada%26aufirst%3DS.%2BD.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DLengyel%26aufirst%3DE.%26atitle%3Dc-MET%2520overexpression%2520is%2520a%2520prognostic%2520factor%2520in%2520ovarian%2520cancer%2520and%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520peritoneal%2520dissemination%2520and%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1670%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3e"><span><span class="NLM_contrib-group">Drebber, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldus, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollschweiler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienes, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hölscher, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mönig, S. P.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18497953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1477-1483&author=U.+Drebberauthor=S.+E.+Baldusauthor=B.+Noldenauthor=G.+Grassauthor=E.+Bollschweilerauthor=H.+P.+Dienesauthor=A.+H.+H%C3%B6lscherauthor=S.+P.+M%C3%B6nig&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+gastric+carcinoma+compared+to+p53+and+p21+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3eR"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span></div><div class="casAuthors">Drebber Uta; Baldus Stephan E; Nolden Britt; Grass Guido; Bollschweiler Elfriede; Dienes Hans P; Holscher Arnulf H; Monig Stefan P</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1477-83</span>
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    </div><div class="casAbstract">The purpose of this study was to clarify the relationship of the immunohistochemical expression of c-met, p53 and p21 with clinicopathological parameters and prognosis in gastric carcinomas.  We analyzed specimens from 114 gastric cancer patients (median age 64 years, range: 33-86) who underwent gastrectomy with lymphadenectomy.  Specimens were categorized according to the tumor differentiation, based on UICC, WHO, Lauren, Ming and Goseki classifications.  Specimens were examined immunohistochemically with antibodies against c-met, p53 and p21.  The expression was evaluated semiquantitatively and correlated with the clinicopathological parameters.  The c-met staining pattern was positive in 73.7%.  P53 and p21 were positive in 86.8 and 67.5%, respectively.  No significant correlation between c-met or p21 expression and the clinicopathological parameters was seen.  A significant increase of p53 expression was observed in stage pT3 and -4.  The overexpression of c-met and p53 was significantly associated with a poor prognosis in the univariate survival analysis.  In the multivariate analysis this impact was maintained for c-met.  P21 proved to be a significant prognostic factor in the multivariate analysis.  Our data suggest that the overexpression of c-met and p21 may represent independent prognostic factors in gastric carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcwNSw0zEj49-cVm4E2RlLfW6udTcc2ebjS9auuzxBRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D&md5=5f503921226de1902468d1526a7322e7</span></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrebber%26aufirst%3DU.%26aulast%3DBaldus%26aufirst%3DS.%2BE.%26aulast%3DNolden%26aufirst%3DB.%26aulast%3DGrass%26aufirst%3DG.%26aulast%3DBollschweiler%26aufirst%3DE.%26aulast%3DDienes%26aufirst%3DH.%2BP.%26aulast%3DH%25C3%25B6lscher%26aufirst%3DA.%2BH.%26aulast%3DM%25C3%25B6nig%26aufirst%3DS.%2BP.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520gastric%2520carcinoma%2520compared%2520to%2520p53%2520and%2520p21%2520nuclear%2520accumulation%26jtitle%3DOncol.%2520Rep.%26date%3D2008%26volume%3D19%26spage%3D1477%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bischof, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2312</span><span class="NLM_x">–</span> <span class="NLM_lpage">2325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1128%2FMCB.17.4.2312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=9121481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADyaK2sXhvFOhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=2312-2325&author=D.+Bischofauthor=K.+Pulfordauthor=D.+Y.+Masonauthor=S.+W.+Morris&title=Role+of+the+nucleophosmin+%28NPM%29+portion+of+the+non-Hodgkin%E2%80%99s+lymphoma-associated+NPM-anaplastic+lymphoma+kinase+fusion+protein+in+oncogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis</span></div><div class="casAuthors">Bischof, Daniela; Pulford, Karen; Mason, David Y.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2312-2325</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NPM-ALK fusion gene, formed by the t(2;5)(p23;q35) translocation in non-Hodgkin's lymphoma, encodes a 75-kDa hybrid protein that contains the amino-terminal 117 amino acid residues of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase).  Here, the authors demonstrate the transforming ability of NPM-ALK and show that oncogenesis by the chimeric protein requires the activation of its kinase function as a result of oligomerization mediated by the NPM segment.  Sedimentation gradient expts. revealed that NPM-ALK forms in vivo multimeric complexes of approx. 200 kDa or greater that also contain normal NPM.  Cell fractionation studies of the t(2;5) translocation-contg. lymphoma cell line SUP-M2 showed NPM-ALK to be localized within both the cytoplasmic and nuclear compartments.  Immunostaining performed with both polyclonal and monoclonal anti-ALK antibodies confirmed the dual location of the oncoprotein and also indicated that NPM-ALK is abundant within both the nucleoplasm and the nucleolus.  An intact NPM segment is absolutely required for NPM-ALK-mediated oncogenesis, as indicated by the authors' observation that three different NPM-ALK mutant proteins lacking nonoverlapping portions of the NPM segment were each unable to form complexes, lacked kinase activity in vivo, and failed to transform cells.  However, NPM could be functionally replaced in the fusion protein with the portion of the unrelated translocated promoter region (TPR) protein that activates the TPR-MET fusion kinase by mediating dimerization through its leucine zipper motif.  This engineered TPR-ALK hybrid protein, which transformed cells almost as efficiently as NPM-ALK, was localized solely within the cytoplasm of cells.  These data indicate that the nuclear and nucleolar localization of NPM-ALK, which probably occur because of transport via the shuttling activity of NPM, is not required for oncogenesis.  Further, the activation of the truncated ALK protein by a completely heterologous oligomerization domain suggests that the functionally important role of the NPM segment of NPM-ALK in transformation is restricted to the formation of kinase-active oligomers and does not involve the alteration of normal NPM functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzwe8k7qW59rVg90H21EOLACvtfcHk0lhz5Brqrf6cwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhvFOhsLo%253D&md5=5530ead614a941232bcff372ee7fae4b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2FMCB.17.4.2312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.17.4.2312%26sid%3Dliteratum%253Aachs%26aulast%3DBischof%26aufirst%3DD.%26aulast%3DPulford%26aufirst%3DK.%26aulast%3DMason%26aufirst%3DD.%2BY.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DRole%2520of%2520the%2520nucleophosmin%2520%2528NPM%2529%2520portion%2520of%2520the%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma-associated%2520NPM-anaplastic%2520lymphoma%2520kinase%2520fusion%2520protein%2520in%2520oncogenesis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D2312%26epage%3D2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Palmer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernersson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, B.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: signalling in development and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">420</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+lymphoma+kinase%3A+signalling+in+development+and+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520signalling%2520in%2520development%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=Q.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+MacNeillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.-L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signaling+identifies+oncogenic+kinases+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacNeill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signaling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">A mouse model for EML4-ALK-positive lung cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">19893</span><span class="NLM_x">–</span> <span class="NLM_lpage">19897</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=19893-19897&author=M.+Sodaauthor=S.+Takadaauthor=K.+Takeuchiauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=T.+Uenoauthor=H.+Harutaauthor=T.+Hamadaauthor=Y.+Yamashitaauthor=Y.+Ishikawaauthor=Y.+Sugiyamaauthor=H.+Mano&title=A+mouse+model+for+EML4-ALK-positive+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DA%2520mouse%2520model%2520for%2520EML4-ALK-positive%2520lung%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D19893%26epage%3D19897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Caren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinsson, I.</span><span> </span><span class="NLM_article-title">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">416</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Carenauthor=F.+Abelauthor=P.+Kognerauthor=I.+Martinsson&title=High+incidence+of+DNA+mutations+and+gene+amplifications+of+the+ALK+gene+in+advanced+sporadic+neuroblastoma+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaren%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DI.%26atitle%3DHigh%2520incidence%2520of%2520DNA%2520mutations%2520and%2520gene%2520amplifications%2520of%2520the%2520ALK%2520gene%2520in%2520advanced%2520sporadic%2520neuroblastoma%2520tumors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of <i>ALK</i> as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alain Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Alain+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lj202lc_p1H9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DAlain%2BPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=Li.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DLi.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9e"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanael S. Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan W. Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provides a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Nathanael+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Stephan+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provides+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DNathanael%2BS.%2BGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DStephan%2BW.%2BMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provides%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=B.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-MET%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ljj4gm2jDeEew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DB.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-MET%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+Altonauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-MET%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lgYa2YQyufHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-MET%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Classon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3389</span><span class="NLM_x">–</span> <span class="NLM_lpage">3395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F0008-5472.CAN-07-6186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18451166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3389-3395&author=U.+McDermottauthor=A.+J.+Iafrateauthor=N.+S.+Grayauthor=T.+Shiodaauthor=M.+Classonauthor=S.+Maheswaranauthor=W.+Zhouauthor=H.+G.+Choiauthor=S.+L.+Smithauthor=L.+Dowellauthor=L.+E.+Ulkusauthor=G.+Kuhlmannauthor=P.+Greningerauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=J.+Settleman&title=Genomic+alterations+of+anaplastic+lymphoma+kinase+may+sensitize+tumors+to+anaplastic+lymphoma+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3389-3395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective kinase inhibitors have had a substantial impact on the field of medical oncol.  Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.  We have established an automated platform for examg. the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant.  Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.  This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.  ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.  Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.  Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.  These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtwwG7vhYTbVg90H21EOLACvtfcHk0lgYa2YQyufHEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D&md5=5168e6ce3ea650df3722dbd4f1aa53ea</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6186%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DClasson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DS.%2BL.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DKuhlmann%26aufirst%3DG.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGenomic%2520alterations%2520of%2520anaplastic%2520lymphoma%2520kinase%2520may%2520sensitize%2520tumors%2520to%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3389%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=S.+Sistlaauthor=T.+L.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lhjel_pplyJnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DS.%26aulast%3DLuu%26aufirst%3DT.%2BL.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_contrib-group">Cui, J. J.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cui%2C+J.+J.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_contrib-group">Cui, J.; Zhang, R.; Shen, H.; Chu, J. Y.; Zhang, F.-J.; Koenig, M.; Do, S. H.; Li, X.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Preparation of 4-Aryl Substituted Indolinones as Protein Kinase Signal Transduction Modulators for Inhibiting Abnormal Cell Proliferation</span>. PCT Int. Appl. WO2002055517,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=R.+Zhang&author=H.+Shen&author=J.+Y.+Chu&author=F.-J.+Zhang&author=M.+Koenig&author=S.+H.+Do&author=X.+Li&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+4-Aryl+Substituted+Indolinones+as+Protein+Kinase+Signal+Transduction+Modulators+for+Inhibiting+Abnormal+Cell+Proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25204-Aryl%2520Substituted%2520Indolinones%2520as%2520Protein%2520Kinase%2520Signal%2520Transduction%2520Modulators%2520for%2520Inhibiting%2520Abnormal%2520Cell%2520Proliferation%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_contrib-group">Cui, J.; Ramphal, Y.; Liang, C.; Sun, L.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Preparation of 5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone Derivatives as Kinase Inhibitors</span>. PCT Int. Appl. WO2002096361,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=Y.+Ramphal&author=C.+Liang&author=L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+5-Aralkylsulfonyl-3-%28pyrrol-2-ylmethylidene%29-2-indolinone+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25205-Aralkylsulfonyl-3-%2528pyrrol-2-ylmethylidene%2529-2-indolinone%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornea, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correiac, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owena, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompsona, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trana, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttc, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngc, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneaauthor=A.+M.+Correiacauthor=D.+R.+Owenaauthor=L.+R.+Thompsonaauthor=I.+Tranaauthor=M.+F.+Tuttcauthor=T.+Youngc&title=Rapid+assessment+of+a+novel+series+of+selective+CB2+agonists+using+parallel+synthesis+protocols%3A+a+lipophilic+efficiency+%28LipE%29+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lhjel_pplyJnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHornea%26aufirst%3DV.%2BA.%26aulast%3DCorreiac%26aufirst%3DA.%2BM.%26aulast%3DOwena%26aufirst%3DD.%2BR.%26aulast%3DThompsona%26aufirst%3DL.%2BR.%26aulast%3DTrana%26aufirst%3DI.%26aulast%3DTuttc%26aufirst%3DM.%2BF.%26aulast%3DYoungc%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB2%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520a%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and lipophilic ligand efficiency (LipE or LLE) in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+lipophilic+ligand+efficiency+%28LipE+or+LLE%29+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520lipophilic%2520ligand%2520efficiency%2520%2528LipE%2520or%2520LLE%2529%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiewlich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Li</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=14617781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=1085-1092&author=X.+Wangauthor=P.+Leauthor=C.+Liangauthor=J.+Chanauthor=D.+Kiewlichauthor=T.+Millerauthor=D.+Harrisauthor=Li+Sunauthor=A.+Riceauthor=S.+Vasileauthor=R.+A.+Blakeauthor=A.+R.+Howlettauthor=N.+Patelauthor=G.+McMahonauthor=K.+E.+Lipson&title=Potent+and+selective+inhibitors+of+the+Met+%5Bhepatocyte+growth+factor%2Fscatter+factor+%28HGF%2FSF%29+receptor%5D+tyrosine+kinase+block+HGF%2FSF-induced+tumor+cell+growth+and+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span></div><div class="casAuthors">Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; Blake, Robert A.; Howlett, Anthony R.; Patel, Neela; McMahon, Gerald; Lipson, Kenneth E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met, mediates various cellular responses on activation with its ligand, including proliferation, survival, motility, invasion, and tubular morphogenesis.  Met expression is frequently up-regulated in sarcomas and carcinomas.  Exptl. evidence suggests that Met activation correlates with poor clin. outcome and the likelihood of metastasis.  Therefore, inhibitors of Met tyrosine kinase may be useful for the treatment of a wide variety of cancers that have spread from the primary site.  We have discovered potent and selective pyrrole-indolinone Met kinase inhibitors and characterized them for their ability to inhibit HGF/SF-induced cellular responses in vitro.  These compds. inhibit HGF/SF-induced receptor phosphorylation in a dose-dependent manner.  They also inhibit the HGF/SF-induced motility and invasion of epithelial and carcinoma cells.  Therefore, these compds. represent a class of prototype small mols. that selectively inhibit the Met kinase and could lead to identification of compds. with potential therapeutic utility in treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVAQRRxT_J1rVg90H21EOLACvtfcHk0lhsGEXlny_G2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D&md5=3b3141600b15ed4f9c97d86fb7ade81d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DKiewlich%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DLi%26aulast%3DRice%26aufirst%3DA.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DHowlett%26aufirst%3DA.%2BR.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520Met%2520%255Bhepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520%2528HGF%252FSF%2529%2520receptor%255D%2520tyrosine%2520kinase%2520block%2520HGF%252FSF-induced%2520tumor%2520cell%2520growth%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D1085%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruganti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruslim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramphal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET kinase inhibits c-MET-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7345</span><span class="NLM_x">–</span> <span class="NLM_lpage">7355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7345-7355&author=J.+G.+Christensenauthor=R.+Schreckauthor=J.+Burrowsauthor=P.+Kurugantiauthor=E.+Chanauthor=P.+Leauthor=J.+Chenauthor=X.+Wangauthor=L.+Ruslimauthor=R.+Blakeauthor=K.+E.+Lipsonauthor=J.+Ramphalauthor=S.+Doauthor=J.+J.+Cuiauthor=J.+M.+Cherringtonauthor=D.+B.+Mendel&title=A+selective+small+molecule+inhibitor+of+c-MET+kinase+inhibits+c-MET-dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antimutor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DKuruganti%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRuslim%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%2520kinase%2520inhibits%2520c-MET-dependent%2520phenotypes%2520in%2520vitro%2520and%2520exhibits%2520cytoreductive%2520antimutor%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7345%26epage%3D7355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_contrib-group">Hov, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utne Holt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baade Rø, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerli, U.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjorth-Hansen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baykov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waage, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Børset, M.</span><span> </span><span class="NLM_article-title">A selective c-MET inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">6686</span><span class="NLM_x">–</span> <span class="NLM_lpage">6694</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1078-0432.CCR-04-0874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15475459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Ohsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=6686-6694&author=H.+Hovauthor=R.+Utne+Holtauthor=T.+Baade+R%C3%B8author=U.-M.+Fagerliauthor=H.+Hjorth-Hansenauthor=V.+Baykovauthor=J.+G.+Christensenauthor=A.+Waageauthor=A.+Sundanauthor=M.+B%C3%B8rset&title=A+selective+c-MET+inhibitor+blocks+an+autocrine+hepatocyte+growth+factor+growth+loop+in+ANBL-6+cells+and+prevents+migration+and+adhesion+of+myeloma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells</span></div><div class="casAuthors">Hov, Hakon; Holt, Randi Utne; Ro, Torstein Baade; Fagerli, Unn-Merete; Hjorth-Hansen, Henrik; Baykov, Vadim; Christensen, James G.; Waage, Anders; Sundan, Anders; Borset, Magne</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6686-6694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors wanted to examine the role of the hepatocyte growth factor (HGF) receptor c-Met in multiple myeloma by applying a novel selective small mol. tyrosine kinase inhibitor, PHA-665752, directed against the receptor.  Four biol. sequels of HGF related to multiple myeloma were studied: (1) proliferation of myeloma cells, (2) secretion of interleukin-11 from osteogenic cells, (3) migration of myeloma cells, and (4) adhesion of myeloma cells to fibronectin.  The authors also examd. effects of the c-Met inhibitor on intracellular signaling pathways in myeloma cells.  PHA-665752 effectively blocked the biol. responses to HGF in all assays, with 50% inhibition at 5 to 15 nmol/L concn. and complete inhibition at around 100 nmol/L.  PHA-665752 inhibited phosphorylation of several tyrosine residues in c-Met (Tyr1003, Tyr1230/1234/1235, and Tyr1349), blocked HGF-mediated activation of Akt and p44/42 mitogen-activated protein kinase, and prevented the adaptor mol. Gab1 from complexing with c-Met.  In the HGF-producing myeloma cell line ANBL-6, PHA-665752 revealed an autocrine HGF-c-Met-mediated growth loop.  The inhibitor also blocked proliferation of purified primary myeloma cells, suggesting that autocrine HGF-c-Met-driven growth loops are important for progression of multiple myeloma.  Collectively, these findings support the role of c-Met and HGF in the proliferation, migration, and adhesion of myeloma cells and identify c-Met kinase as a therapeutic target for treatment of patients with multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhIE0e1cVIbVg90H21EOLACvtfcHk0lhsGEXlny_G2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Ohsr8%253D&md5=f92327485713764358a8cfe9607a61ec</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0874%26sid%3Dliteratum%253Aachs%26aulast%3DHov%26aufirst%3DH.%26aulast%3DUtne%2BHolt%26aufirst%3DR.%26aulast%3DBaade%2BR%25C3%25B8%26aufirst%3DT.%26aulast%3DFagerli%26aufirst%3DU.-M.%26aulast%3DHjorth-Hansen%26aufirst%3DH.%26aulast%3DBaykov%26aufirst%3DV.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWaage%26aufirst%3DA.%26aulast%3DSundan%26aufirst%3DA.%26aulast%3DB%25C3%25B8rset%26aufirst%3DM.%26atitle%3DA%2520selective%2520c-MET%2520inhibitor%2520blocks%2520an%2520autocrine%2520hepatocyte%2520growth%2520factor%2520growth%2520loop%2520in%2520ANBL-6%2520cells%2520and%2520prevents%2520migration%2520and%2520adhesion%2520of%2520myeloma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D6686%26epage%3D6694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngchul Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce E. Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Youngchul+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.-M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Bruce+E.+Johnsonauthor=L.+C.+Cantleyauthor=A.+Pasiauthor=P.+A.+J%C3%A4nne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0ljt7jUTYpSeGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYoungchul%2BSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBruce%2BE.%2BJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DPasi%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_contrib-group">Smolen, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohapatra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barmettler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sgroi, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Amplification of Met may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">2316</span><span class="NLM_x">–</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=2316-2321&author=G.+A.+Smolenauthor=R.+Sordellaauthor=B.+Muirauthor=G.+Mohapatraauthor=A.+Barmettlerauthor=H.+Archibaldauthor=W.+J.+Kimauthor=R.+A.+Okimotoauthor=D.+W.+Bellauthor=D.+C.+Sgroiauthor=J.+G.+Christensenauthor=J.+Settlemanauthor=D.+A.+Haber&title=Amplification+of+Met+may+identify+a+subset+of+cancers+with+extreme+sensitivity+to+the+selective+tyrosine+kinase+inhibitor+PHA-665752"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DG.%2BA.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DMuir%26aufirst%3DB.%26aulast%3DMohapatra%26aufirst%3DG.%26aulast%3DBarmettler%26aufirst%3DA.%26aulast%3DArchibald%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.%2BJ.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSgroi%26aufirst%3DD.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DAmplification%2520of%2520Met%2520may%2520identify%2520a%2520subset%2520of%2520cancers%2520with%2520extreme%2520sensitivity%2520to%2520the%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520PHA-665752%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D2316%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2312</span><span class="NLM_x">–</span> <span class="NLM_lpage">2319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1078-0432.CCR-04-1708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15788682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2312-2319&author=P.+C.+Maauthor=E.+Schaeferauthor=J.+G.+Christensenauthor=R.+Salgia&title=A+selective+small+molecule+c-MET+inhibitor%2C+PHA665752%2C+cooperates+with+rapamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin</span></div><div class="casAuthors">Ma, Patrick C.; Schaefer, Erik; Christensen, James G.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2319</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">c-MET is believed to be an attractive receptor target for mol. therapeutic inhibition.  TPR-MET, a constitutively active oncogenic variant of MET, serves as excellent model for testing c-MET inhibitors.  Here, we characterized a small mol. c-MET inhibitor, PHA665752, and tested its cooperation with the mammalian target of rapamycin inhibitor as potential targeted therapy.  The effect of PHA665752 treatment was detd. on cell growth, motility and migration, apoptosis, and cell-cycle arrest of TPR-MET-transformed cells.  Moreover, the effect of PHA665752 on the phosphorylation on MET, as well as its downstream effectors, p-AKT and p-S6K, was also detd.  Finally, growth of TPR-MET-transformed cells was tested in the presence of PHA665752 and rapamycin.  H441 non-small cell lung cancer (NSCLC) cells (with activated c-Met) were also tested against both PHA665752 and rapamycin.  PHA665752 specifically inhibited cell growth in BaF3.  TPR-MET cells (IC50 < 0.06 μmol/L), induced apoptosis and cell cycle arrest.  Constitutive cell motility and migration of the BaF3.  TPR-MET cells was also inhibited.  PHA665752 inhibited specific phosphorylation of TPR-MET as well as phosphorylation of downstream targets of the mammalian target of rapamycin pathway.  When combined with PHA665752, rapamycin showed cooperative inhibition to reduce growth of BaF3.  TPR-MET- and c-MET-expressing H441 NSCLC cells.  PHA665752 is a potent small mol.-selective c-MET inhibitor and is highly active against TPR-MET-transformed cells both biol. and biochem.  PHA665752 is also active against H441 NSCLC cells.  The c-MET inhibitor can cooperate with rapamycin in therapeutic inhibition of NSCLC, and in vivo studies of this combination against c-MET expressing cancers would be merited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ6fVYSbU8ibVg90H21EOLACvtfcHk0ljt7jUTYpSeGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFaju7c%253D&md5=9e69f0253f675f4a1aeb96c115e2e420</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1708%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DA%2520selective%2520small%2520molecule%2520c-MET%2520inhibitor%252C%2520PHA665752%252C%2520cooperates%2520with%2520rapamycin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2312%26epage%3D2319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18d"><span><span class="NLM_contrib-group">Puri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khramtsov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetzel, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karczmar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">3529</span><span class="NLM_x">–</span> <span class="NLM_lpage">3534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=3529-3534&author=N.+Puriauthor=A.+Khramtsovauthor=S.+Ahmedauthor=V.+Nallasuraauthor=J.+T.+Hetzelauthor=R.+Jagadeeswaranauthor=G.+Karczmarauthor=R.+Salgia&title=A+selective+small+molecule+inhibitor+of+c-MET%2C+PHA665752%2C+inhibits+tumorigenicity+and+angiogenesis+in+mouse+lung+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DN.%26aulast%3DKhramtsov%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DHetzel%26aufirst%3DJ.%2BT.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKarczmar%26aufirst%3DG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%252C%2520PHA665752%252C%2520inhibits%2520tumorigenicity%2520and%2520angiogenesis%2520in%2520mouse%2520lung%2520cancer%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D3529%26epage%3D3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18e"><span><span class="NLM_contrib-group">Chattopadhyay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Naggar, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayman, G. L.</span><span> </span><span class="NLM_article-title">Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma</span> <span class="citation_source-journal">Head Neck</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fhed.20816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=991-1000&author=C.+Chattopadhyayauthor=A.+K.+El-Naggarauthor=M.+D.+Williamsauthor=G.+L.+Clayman&title=Small+molecule+c-MET+inhibitor+PHA665752%3A+effect+on+cell+growth+and+motility+in+papillary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1002%2Fhed.20816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhed.20816%26sid%3Dliteratum%253Aachs%26aulast%3DChattopadhyay%26aufirst%3DC.%26aulast%3DEl-Naggar%26aufirst%3DA.%2BK.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DClayman%26aufirst%3DG.%2BL.%26atitle%3DSmall%2520molecule%2520c-MET%2520inhibitor%2520PHA665752%253A%2520effect%2520on%2520cell%2520growth%2520and%2520motility%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DHead%2520Neck%26date%3D2007%26volume%3D30%26spage%3D991%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18f"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wislez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izzo, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurie, J. M.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET, PHA-665752, reverses lung premalignancy induced by mutant <i>K-ras</i></span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18f&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1535-7163.MCT-07-2045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18f&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18413809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18f&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=952-960&author=Y.+Yangauthor=M.+Wislezauthor=N.+Fujimotoauthor=L.+Prudkinauthor=J.+G.+Izzoauthor=F.+Unoauthor=L.+Jiauthor=E.+Amyauthor=A.+E.+Hannaauthor=R.+R.+Langleyauthor=D.+Liuauthor=F.+M.+Johnsonauthor=I.+Wistubaauthor=J.+M.+Kurie&title=A+selective+small+molecule+inhibitor+of+c-MET%2C+PHA-665752%2C+reverses+lung+premalignancy+induced+by+mutant+K-ras"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18fR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras</span></div><div class="casAuthors">Yang, Yanan; Wislez, Marie; Fujimoto, Nobukazu; Prudkin, Ludmila; Izzo, Julie G.; Uno, Futoshi; Ji, Lin; Hanna, Amy E.; Langley, Robert R.; Liu, Diane; Johnson, Faye M.; Wistuba, Ignacio; Kurie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-960</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase has been implicated in cellular transformation induced by mutant Ras, a commonly activated proto-oncogene in non-small cell lung cancer (NSCLC).  However, the role of c-Met has not been defined in K-ras-mutant NSCLC, a disease for which no effective targeted therapeutic options currently exist.  To acquire a greater understanding of its role, we used genetic and pharmacol. approaches to inhibit c-Met in mice and cultured cells.  In KrasLA1 mice, which develop premalignant lung lesions that progress to multifocal lung adenocarcinomas owing to somatic mutations in K-ras, c-Met was expressed in multiple cell types within premalignant lung lesions, and high concns. of HGF were detected in bronchoalveolar lavage samples.  Short-term treatment with PHA-665752, a c-Met inhibitor, decreased the nos. of premalignant lung lesions and induced apoptosis in tumor cells and vascular endothelial cells within lesions.  In cell culture, PHA-665752 induced apoptosis of a lung adenocarcinoma cell line derived from KrasLA1 mice (LKR-13) and a murine lung endothelial cell line (MEC).  C-Met depletion by siRNA transfection induced apoptosis of MECs but not LKR-13 cells.  Collectively, these findings suggest that apoptosis was an on-target effect of PHA-665752 in MECs but not in LKR-13 cells.  We conclude that PHA-665752 inhibited lung tumorigenesis in KrasLA1 mice and may provide a novel therapeutic approach to the prevention of K-ras-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lgtND1nnfbVg90H21EOLACvtfcHk0lhEY1IiI6fRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gmsb0%253D&md5=0d2ee01079be38dc194598c659bde3b5</span></div><a href="/servlet/linkout?suffix=cit18f&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2045%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWislez%26aufirst%3DM.%26aulast%3DFujimoto%26aufirst%3DN.%26aulast%3DPrudkin%26aufirst%3DL.%26aulast%3DIzzo%26aufirst%3DJ.%2BG.%26aulast%3DUno%26aufirst%3DF.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DAmy%26aufirst%3DE.%26aulast%3DHanna%26aufirst%3DA.%2BE.%26aulast%3DLangley%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DF.%2BM.%26aulast%3DWistuba%26aufirst%3DI.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%252C%2520PHA-665752%252C%2520reverses%2520lung%2520premalignancy%2520induced%2520by%2520mutant%2520K-ras%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D952%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cui, J. J.</span> Unpublished results. PHA-665752 was discovered as a potent and selective c-MET kinase inhibitor. Because of the high lipophilicity and large molecular weight, PHA-665752 demonstrated high metabolic clearance (CL = 77 (mL/min)/kg in rat in vivo PK study), low permeability, and a pH dependent solubility. PHA-665752 was originally positioned as a preclinic candidate with an intravenous drug profile. However, the low solubility at pH 7.4 (0.9 μg/mL) prevented PHA-665752 as a potential intravenous drug candidate for clinical applications.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cui%2C+J.+J.+Unpublished+results.+PHA-665752+was+discovered+as+a+potent+and+selective+c-MET+kinase+inhibitor.+Because+of+the+high+lipophilicity+and+large+molecular+weight%2C+PHA-665752+demonstrated+high+metabolic+clearance+%28CL+%3D+77+%28mL%2Fmin%29%2Fkg+in+rat+in+vivo+PK+study%29%2C+low+permeability%2C+and+a+pH+dependent+solubility.+PHA-665752+was+originally+positioned+as+a+preclinic+candidate+with+an+intravenous+drug+profile.+However%2C+the+low+solubility+at+pH+7.4+%280.9+%CE%BCg%2FmL%29+prevented+PHA-665752+as+a+potential+intravenous+drug+candidate+for+clinical+applications."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">–</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0lhEY1IiI6fRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1126%2Fscience.276.5314.955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=9139660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=955-960&author=M.+Mohammadiauthor=G.+McMahonauthor=Li.+Sunauthor=C.+Tangauthor=P.+Hirthauthor=B.+K.+Yehauthor=S.+R.+Hubbardauthor=J.+Schlessinger&title=Structures+of+the+tyrosine+kinase+domain+of+fibroblast+growth+factor+receptor+in+complex+with+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span></div><div class="casAuthors">Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5314</span>),
    <span class="NLM_cas:pages">955-960</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones).  Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases.  Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were detd.  The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes.  The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop.  This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwP7A-FMgDLVg90H21EOLACvtfcHk0lhEY1IiI6fRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D&md5=fdbedba79850d11771677e6d25f3842f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5314.955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5314.955%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DLi.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DYeh%26aufirst%3DB.%2BK.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520in%2520complex%2520with%2520inhibitors%26jtitle%3DScience%26date%3D1997%26volume%3D276%26spage%3D955%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">LE = [–<i>RT</i> log(<i>K</i><sub>i</sub> or IC<sub>50</sub>)]/number of heavy atoms.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cui, J. J.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cui%2C+J.+J.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">–</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+c-MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520c-MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Structure-Based Design and Characterization of Axitinib</span>. In  <span class="citation_source-book">Kinase Inhibitor Drugs</span>; <span class="NLM_contrib-group">Li, R.; Stafford, J. A.</span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2F9780470524961.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=167-200&author=R.+S.+Kaniaauthor=R.+Li&author=J.+A.+Stafford&title=Kinase+Inhibitor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F9780470524961.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470524961.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DStructure-Based%2520Design%2520and%2520Characterization%2520of%2520Axitinib%26btitle%3DKinase%2520Inhibitor%2520Drugs%26aulast%3DLi%26aufirst%3DR.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2009%26spage%3D167%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wagh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peace, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, S. E.</span><span> </span><span class="NLM_article-title">Met-related receptor tyrosine kinase Ron in tumor growth and metastasis</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=1-33&author=P.+K.+Waghauthor=B.+E.+Peaceauthor=S.+E.+Waltz&title=Met-related+receptor+tyrosine+kinase+Ron+in+tumor+growth+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWagh%26aufirst%3DP.%2BK.%26aulast%3DPeace%26aufirst%3DB.%2BE.%26aulast%3DWaltz%26aufirst%3DS.%2BE.%26atitle%3DMet-related%2520receptor%2520tyrosine%2520kinase%2520Ron%2520in%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2008%26volume%3D100%26spage%3D1%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Accornero, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, M.</span><span> </span><span class="NLM_article-title">The scatter factor signaling pathways as therapeutic associated target in cancer treatment</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2692</span><span class="NLM_x">–</span> <span class="NLM_lpage">2712</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.2174%2F092986710791859261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2692-2712&author=P.+Accorneroauthor=L.+M.+Pavoneauthor=M.+Baratta&title=The+scatter+factor+signaling+pathways+as+therapeutic+associated+target+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F092986710791859261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791859261%26sid%3Dliteratum%253Aachs%26aulast%3DAccornero%26aufirst%3DP.%26aulast%3DPavone%26aufirst%3DL.%2BM.%26aulast%3DBaratta%26aufirst%3DM.%26atitle%3DThe%2520scatter%2520factor%2520signaling%2520pathways%2520as%2520therapeutic%2520associated%2520target%2520in%2520cancer%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2692%26epage%3D2712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_contrib-group">Cheng, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N. H.</span><span> </span><span class="NLM_article-title">Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1906</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1038%2Fsj.bjc.6602593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15870710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=1906-1914&author=H.+L.+Chengauthor=H.+S.+Liuauthor=Y.+J.+Linauthor=H.+H.+Chenauthor=P.+Y.+Hsuauthor=T.+Y.+Changauthor=C.+L.+Hoauthor=T.+S.+Tzaiauthor=N.+H.+Chow&title=Co-expression+of+RON+and+MET+is+a+prognostic+indicator+for+patients+with+transitional-cell+carcinoma+of+the+bladder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder</span></div><div class="casAuthors">Cheng, H-L.; Liu, H-S.; Lin, Y-J.; Chen, H. H-W.; Hsu, P-Y.; Chang, T-Y.; Ho, C-L.; Tzai, T-S.; Chow, N-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1906-1914</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recepteur d'Origine Nantais (RON) is a distinct receptor tyrosine kinase in the c-met proto-oncogene family.  We examd. the mutational and expression patterns of RON in eight human uroepithelial cell lines.  Biol. effects of RON overexpression on cancer cells were investigated in vitro, and the prognostic significance of RON and/or c-met protein (MET) expression was analyzed in a bladder cancer cohort (n=183).  There was no evidence of mutation in the kinase domain of RON.  Overexpression of RON using an inducible Tet-off system induced increased cell proliferation, motility, and antiapoptosis.  Immunohistochem. anal. showed that RON was overexpressed in 60 cases (32.8%) of primary tumors, with 14 (23.3%) showing a high level of expression.  Recepteur d'Origine Nantais expression was pos. assocd. with histol. grading, larger size, nonpapillary contour, and tumor stage (all P<0.01).  In addn., MET was overexpressed in 82 cases (44.8%).  Co-expressed RON and MET was significantly assocd. with decreased overall survival (P=0.005) or metastasis-free survival (P=0.01) in 35 cases (19.1%).  Recepteur d'Origine Nantais-assocd. signalling may play an important role in the progression of human bladder cancer.  Evaluation of RON and MET expression status may identify a subset of bladder-cancer patients who require more intensive treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy3Jc9r7lea7Vg90H21EOLACvtfcHk0lgOj2iP7fY1sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D&md5=2da682ab6fe899da8b0b959e6c86d0e4</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602593%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BL.%26aulast%3DLiu%26aufirst%3DH.%2BS.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DH.%2BH.%26aulast%3DHsu%26aufirst%3DP.%2BY.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DHo%26aufirst%3DC.%2BL.%26aulast%3DTzai%26aufirst%3DT.%2BS.%26aulast%3DChow%26aufirst%3DN.%2BH.%26atitle%3DCo-expression%2520of%2520RON%2520and%2520MET%2520is%2520a%2520prognostic%2520indicator%2520for%2520patients%2520with%2520transitional-cell%2520carcinoma%2520of%2520the%2520bladder%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D1906%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_contrib-group">Catenacci, D. V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hashani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanteti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Dinali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasina, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brägelmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanicola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grushko, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olopade, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgi, R.</span><span> </span><span class="NLM_article-title">RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.4161%2Fcbt.12.1.15747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=21543897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2hsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=9-46&author=D.+V.+T.+Catenacciauthor=G.+Cervantesauthor=S.+Yalaauthor=E.+A.+Nelsonauthor=E.+El-Hashaniauthor=R.+Kantetiauthor=M.+El+Dinaliauthor=R.+Hasinaauthor=J.+Br%C3%A4gelmannauthor=T.+Seiwertauthor=M.+Sanicolaauthor=L.+Hendersonauthor=T.+A.+Grushkoauthor=O.+Olopadeauthor=T.+Karrisonauthor=Y.-J.+Bangauthor=W.+H.+Kimauthor=M.+Tretiakovaauthor=E.+Vokesauthor=D.+A.+Frankauthor=H.+L.+Kindlerauthor=H.+Huetauthor=R.+Salgi&title=RON+%28MST1R%29+is+a+novel+prognostic+marker+and+therapeutic+target+for+gastroesophageal+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma</span></div><div class="casAuthors">Catenacci, Daniel V. T.; Cervantes, Gustavo; Yala, Soheil; Nelson, Erik A.; El-Hashani, Essam; Kanteti, Rajani; El Dinali, Mohamed; Hasina, Rifat; Bragelmann, Johannes; Seiwert, Tanguy; Sanicola, Michele; Henderson, Les; Grushko, Tatyana A.; Olopade, Olufunmilayo; Karrison, Theodore; Bang, Yung-Jue; Kim, Woo Ho; Tretiakova, Maria; Vokes, Everett; Frank, David A.; Kindler, Hedy L.; Huet, Heather; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-46</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">RON (MST1R) is one of two members of the MET receptor tyrosine kinase family, along with parent receptor MET.  RON has a putative role in several cancers, but its expression and function is poorly characterized in gastroesophageal adenocarcinoma.  A recognized functional role of MET tyrosine kinase in gastroesophageal cancer has led to early phase clin. trials using MET inhibitors, with unimpressive results.  Therefore, the role of RON in gastroesophageal cancer, as well as its role in cooperative signaling with MET and as a mechanism of resistance to MET inhibition, was studied in gastroesophageal tissues and cell lines.  By IHC, RON was highly overexpressed in 74% of gastroesophageal samples (n = 94) and overexpression was prognostic of poor survival (p = 0.008); RON and MET co-expression occurred in 43% of samples and was prognostic of worst survival (p = 0.03).  High MST1R gene copy no. by quant. polymerase chain reaction and confirmed by fluorescence in situ hybridization and/or array comparative genomic hybridization, was seen in 35.5% (16/45) of cases.  High MST1R gene copy no. correlated with poor survival (p = 0.01), and was assocd. with high MET and ERBB2 gene copy no.  A novel somatic MST1R juxtamembrane mutation R1018G was found in 11% of samples.  RON signaling was functional in cell lines, activating downstream effector STAT3, and resulted in increased viability over controls.  RON and MET co-stimulation assays led to enhanced malignant phenotypes over stimulation of either receptor alone.  Growth inhibition as evidenced by viability and apoptosis assays was optimal using novel blocking monoclonal antibodies to both RON and MET, vs. either alone.  SU11274, a classic MET small mol. tyrosine kinase inhibitor, blocked signaling of both receptors and proved synergistic when combined with STAT3 inhibition (combination index <1).  These preclin. studies define RON as an important novel prognostic marker and therapeutic target for gastroesophageal cancer warranting further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIwsWP_-5oL7Vg90H21EOLACvtfcHk0lh5lFen3OB91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2hsL4%253D&md5=3a5218b61d602dfddab721e62ec43353</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.4161%2Fcbt.12.1.15747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.12.1.15747%26sid%3Dliteratum%253Aachs%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%2BT.%26aulast%3DCervantes%26aufirst%3DG.%26aulast%3DYala%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DEl-Hashani%26aufirst%3DE.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DEl%2BDinali%26aufirst%3DM.%26aulast%3DHasina%26aufirst%3DR.%26aulast%3DBr%25C3%25A4gelmann%26aufirst%3DJ.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DSanicola%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DGrushko%26aufirst%3DT.%2BA.%26aulast%3DOlopade%26aufirst%3DO.%26aulast%3DKarrison%26aufirst%3DT.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DTretiakova%26aufirst%3DM.%26aulast%3DVokes%26aufirst%3DE.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26aulast%3DHuet%26aufirst%3DH.%26aulast%3DSalgi%26aufirst%3DR.%26atitle%3DRON%2520%2528MST1R%2529%2520is%2520a%2520novel%2520prognostic%2520marker%2520and%2520therapeutic%2520target%2520for%2520gastroesophageal%2520adenocarcinoma%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2011%26volume%3D12%26spage%3D9%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_contrib-group">Drexler, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gignac, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Wasielewski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirks, W. G.</span><span> </span><span class="NLM_article-title">Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1533</span><span class="NLM_x">–</span> <span class="NLM_lpage">1559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=1533-1559&author=H.+G.+Drexlerauthor=S.+M.+Gignacauthor=R.+von+Wasielewskiauthor=M.+Wernerauthor=W.+G.+Dirks&title=Pathobiology+of+NPM-ALK+and+variant+fusion+genes+in+anaplastic+large+cell+lymphoma+and+other+lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26aulast%3DGignac%26aufirst%3DS.%2BM.%26aulast%3Dvon%2BWasielewski%26aufirst%3DR.%26aulast%3DWerner%26aufirst%3DM.%26aulast%3DDirks%26aufirst%3DW.%2BG.%26atitle%3DPathobiology%2520of%2520NPM-ALK%2520and%2520variant%2520fusion%2520genes%2520in%2520anaplastic%2520large%2520cell%2520lymphoma%2520and%2520other%2520lymphomas%26jtitle%3DLeukemia%26date%3D2000%26volume%3D14%26spage%3D1533%26epage%3D1559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedeutour, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Wolf-Peeters, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span> </span><span class="NLM_article-title">Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fgcc.10033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=12112524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2002&pages=354-362&author=J.+Coolsauthor=I.+Wlodarskaauthor=R.+Somersauthor=N.+Mentensauthor=F.+Pedeutourauthor=B.+Maesauthor=C.+De+Wolf-Peetersauthor=P.+Pauwelsauthor=A.+Hagemeijerauthor=P.+Marynen&title=Identification+of+novel+fusion+partners+of+ALK%2C+the+anaplastic+lymphoma+kinase%2C+in+anaplastic+large-cell+lymphoma+and+inflammatory+myofibroblastic+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Cools, Jan; Wlodarska, Iwona; Somers, Riet; Mentens, Nicole; Pedeutour, Florence; Maes, Brigitte; De Wolf-Peeters, Christiane; Pauwels, Patrick; Hagemeijer, Anne; Marynen, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">ALK-pos. anaplastic large-cell lymphoma (ALCL) has been recognized as a distinct type of lymphoma in the heterogeneous group of T/Null-ALCL.  While most of the ALK-pos. ALCL (ALKomas) are characterized by the presence of the NPM-ALK fusion protein, the product of the t(2;5)(p23;q35), 10-20% of ALKomas contain variant ALK fusions, including ATIC-ALK, TFG-ALK, CLTC-ALK (previously designated CLTCL-ALK), TMP3-ALK, and MSN-ALK.  TMP3-ALK and TMP4-ALK fusions also have been detected in inflammatory myofibroblastic tumors (IMTs), making clear that aberrations of the ALK gene are not assocd. exclusively with the pathogenesis of ALK-pos. ALCL.  Here the authors report results of mol. studies on two lymphoma cases and one IMT case with variant rearrangements of ALK.  The authors' study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA 1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).  These results confirm the recurrent involvement of ALK in IMT and further demonstrate the diversity of ALK fusion partners, with the ability to homodimerize as a common characteristic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXRK_iZnUkNrVg90H21EOLACvtfcHk0lh5lFen3OB91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D&md5=5e15ec7d207444665354c7f08d2620fc</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1002%2Fgcc.10033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.10033%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DSomers%26aufirst%3DR.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DPedeutour%26aufirst%3DF.%26aulast%3DMaes%26aufirst%3DB.%26aulast%3DDe%2BWolf-Peeters%26aufirst%3DC.%26aulast%3DPauwels%26aufirst%3DP.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520fusion%2520partners%2520of%2520ALK%252C%2520the%2520anaplastic%2520lymphoma%2520kinase%252C%2520in%2520anaplastic%2520large-cell%2520lymphoma%2520and%2520inflammatory%2520myofibroblastic%2520tumor%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2002%26volume%3D34%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Viaud, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamoneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savelon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillaumet, G.</span><span> </span><span class="NLM_article-title">Synthesis of 6-substituted 2-phenyloxazolo[4,5-<i>b</i>]pyridines</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2799</span><span class="NLM_x">–</span> <span class="NLM_lpage">2809</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1995&pages=2799-2809&author=M.-C.+Viaudauthor=P.+Jamoneauauthor=L.+Savelonauthor=G.+Guillaumet&title=Synthesis+of+6-substituted+2-phenyloxazolo%5B4%2C5-b%5Dpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DViaud%26aufirst%3DM.-C.%26aulast%3DJamoneau%26aufirst%3DP.%26aulast%3DSavelon%26aufirst%3DL.%26aulast%3DGuillaumet%26aufirst%3DG.%26atitle%3DSynthesis%2520of%25206-substituted%25202-phenyloxazolo%255B4%252C5-b%255Dpyridines%26jtitle%3DHeterocycles%26date%3D1995%26volume%3D41%26spage%3D2799%26epage%3D2809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Suh, Y.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J.-S.</span><span> </span><span class="NLM_article-title">Concise and versatile syntheses of <i>N</i>-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1998&pages=239-242&author=Y.-G.+Suhauthor=D.-Y.+Shinauthor=K.-H.+Choauthor=J.-S.+Ryu&title=Concise+and+versatile+syntheses+of+N-arylalkylpiperidines+as+potential+intermediates+for+4-anilidopiperidine+analgesics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuh%26aufirst%3DY.-G.%26aulast%3DShin%26aufirst%3DD.-Y.%26aulast%3DCho%26aufirst%3DK.-H.%26aulast%3DRyu%26aufirst%3DJ.-S.%26atitle%3DConcise%2520and%2520versatile%2520syntheses%2520of%2520N-arylalkylpiperidines%2520as%2520potential%2520intermediates%2520for%25204-anilidopiperidine%2520analgesics%26jtitle%3DHeterocycles%26date%3D1998%26volume%3D48%26spage%3D239%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Carlos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metselaar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruithof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span> </span><span class="NLM_article-title">Biotransformation-mediated synthesis of (1<i>S</i>)-1-(2,6-dichloro-3-fluorophenyl)ethanol in enantiomerically pure form</span> <span class="citation_source-journal">Tetrahedron: Asymmetry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=2408-2412&author=A.+Carlosauthor=C.+A.+Martinezauthor=E.+Kellerauthor=R.+Meijerauthor=G.+Metselaarauthor=G.+Kruithofauthor=C.+Mooreauthor=P.-P.+Kung&title=Biotransformation-mediated+synthesis+of+%281S%29-1-%282%2C6-dichloro-3-fluorophenyl%29ethanol+in+enantiomerically+pure+form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlos%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DC.%2BA.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DMeijer%26aufirst%3DR.%26aulast%3DMetselaar%26aufirst%3DG.%26aulast%3DKruithof%26aufirst%3DG.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DKung%26aufirst%3DP.-P.%26atitle%3DBiotransformation-mediated%2520synthesis%2520of%2520%25281S%2529-1-%25282%252C6-dichloro-3-fluorophenyl%2529ethanol%2520in%2520enantiomerically%2520pure%2520form%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D2010%26volume%3D21%26spage%3D2408%26epage%3D2412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaptason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span> </span><span class="NLM_article-title">Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically-based pharmacokinetic modeling versus traditional one-compartment model</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=383-393&author=S.+Yamazakiauthor=J.+Skaptasonauthor=D.+Romeroauthor=S.+Vekichauthor=H.+M.+Jonesauthor=W.+Tanauthor=K.+Wilnerauthor=T.+Koudriakova&title=Prediction+of+oral+pharmacokinetics+of+cMet+kinase+inhibitors+in+humans%3A+physiologically-based+pharmacokinetic+modeling+versus+traditional+one-compartment+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DVekich%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DPrediction%2520of%2520oral%2520pharmacokinetics%2520of%2520cMet%2520kinase%2520inhibitors%2520in%2520humans%253A%2520physiologically-based%2520pharmacokinetic%2520modeling%2520versus%2520traditional%2520one-compartment%2520model%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D383%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaptason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetic–pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available c-MET kinase inhibitor in human tumor xenograft mouse models</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1267-1274&author=S.+Yamazakiauthor=J.+Skaptasonauthor=D.+Romeroauthor=J.+H.+Leeauthor=H.+Y.+Zouauthor=J.+G.+Christensenauthor=J.+R.+Koupauthor=B.+J.+Smithauthor=T.+Koudriakova&title=Pharmacokinetic%E2%80%93pharmacodynamic+modeling+of+biomarker+response+and+tumor+growth+inhibition+to+an+orally+available+c-MET+kinase+inhibitor+in+human+tumor+xenograft+mouse+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DKoup%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DPharmacokinetic%25E2%2580%2593pharmacodynamic%2520modeling%2520of%2520biomarker%2520response%2520and%2520tumor%2520growth%2520inhibition%2520to%2520an%2520orally%2520available%2520c-MET%2520kinase%2520inhibitor%2520in%2520human%2520tumor%2520xenograft%2520mouse%2520models%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1267%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35a"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell-lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&author=E.+L.+Kwakauthor=Y.-J.+Bangauthor=R.+Camidgeauthor=A.+T.+Shawauthor=B+Solomonauthor=R.+G.+Makiauthor=S.-H.+I.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.-H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell-lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0lhIvILYVpT5iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DCamidge%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.-H.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell-lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35b"><span><span class="NLM_contrib-group">Butrynski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornick, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Cin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhanwar, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMoa1007056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=20979472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1727-1733&author=J.+E.+Butrynskiauthor=D.+R.+D%E2%80%99Adamoauthor=J.+L.+Hornickauthor=P.+Dal+Cinauthor=C.+R.+Antonescuauthor=S.+C.+Jhanwarauthor=M.+Ladanyiauthor=M.+Capellettiauthor=S.+J.+Rodigauthor=N.+Ramaiyaauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=K.+D.+Wilnerauthor=J.+G.+Christensenauthor=P.+A.+J%C3%A4nneauthor=R.+G.+Makiauthor=G.+D.+Demetriauthor=G.+I.+Shapiro&title=Crizotinib+in+ALK-rearranged+inflammatory+myofibroblastic+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Butrynski, James E.; D'Adamo, David R.; Hornick, Jason L.; Dal Cin, Paola; Antonescu, Cristina R.; Jhanwar, Suresh C.; Ladanyi, Marc; Capelletti, Marzia; Rodig, Scott J.; Ramaiya, Nikhil; Kwak, Eunice L.; Clark, Jeffrey W.; Wilner, Keith D.; Christensen, James G.; Janne, Pasi A.; Maki, Robert G.; Demetri, George D.; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1727-1733</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate.  Approx. half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression.  We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no obsd. activity in another patient without the ALK translocation.  These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeQPUocISij7Vg90H21EOLACvtfcHk0lhZXSkYhkl_bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FI&md5=757a1bfa766ea47507542afb93387895</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007056%26sid%3Dliteratum%253Aachs%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%2BR.%26aulast%3DHornick%26aufirst%3DJ.%2BL.%26aulast%3DDal%2BCin%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DJhanwar%26aufirst%3DS.%2BC.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DRamaiya%26aufirst%3DN.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCrizotinib%2520in%2520ALK-rearranged%2520inflammatory%2520myofibroblastic%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1727%26epage%3D1733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35c"><span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogliani, E. M.</span><span> </span><span class="NLM_article-title">Crizotinib in large cell anaplastic lymphoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">776</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMc1013224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=21345110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A280%3ADC%252BC3M3hsVOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=775-776&author=C.+Gambacorti-Passeriniauthor=C.+Messaauthor=E.+M.+Pogliani&title=Crizotinib+in+large+cell+anaplastic+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in anaplastic large-cell lymphoma</span></div><div class="casAuthors">Gambacorti-Passerini Carlo; Messa Cristina; Pogliani Enrico M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">775-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS57pbSZcjKy5I8NvIb08rbfW6udTcc2eZftUMGSggtjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3hsVOntg%253D%253D&md5=34f64413ae3c80d4faac17d07c05284e</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1013224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1013224%26sid%3Dliteratum%253Aachs%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMessa%26aufirst%3DC.%26aulast%3DPogliani%26aufirst%3DE.%2BM.%26atitle%3DCrizotinib%2520in%2520large%2520cell%2520anaplastic%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D775%26epage%3D776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_contrib-group">Ou, S. -H. I.; Kwak, E. L.; Siwak-Tapp, C.; Dy, J.; Bergethon, K.; Clark, J. W.; Camidge, D. R.; Solomon, B. J.; Maki, R. G.; Bang, Y. -J.; Kim, D. -W; Christensen, J.; Tan, W.; Wilner, K. D.; Salgia, R.; Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-Small Cell Lung Cancer Patient with de novo <i>MET</i> Amplification</span>. J. Thorac. Oncol.<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+-H.+I.+Ou&author=E.+L.+Kwak&author=C.+Siwak-Tapp&author=J.+Dy&author=K.+Bergethon&author=J.+W.+Clark&author=D.+R.+Camidge&author=B.+J.+Solomon&author=R.+G.+Maki&author=Y.+-J.+Bang&author=D.+-W+Kim&author=J.+Christensen&author=W.+Tan&author=K.+D.+Wilner&author=R.+Salgia&author=A.+J.+Iafrate&title=Activity+of+Crizotinib+%28PF02341066%29%2C+a+Dual+Mesenchymal-Epithelial+Transition+%28MET%29+and+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor%2C+in+a+Non-Small+Cell+Lung+Cancer+Patient+with+de+novo+MET+Amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2eZftUMGSggtjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2B-H.%2BI.%26atitle%3DActivity%2520of%2520Crizotinib%2520%2528PF02341066%2529%252C%2520a%2520Dual%2520Mesenchymal-Epithelial%2520Transition%2520%2528MET%2529%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%252C%2520in%2520a%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Patient%2520with%2520de%2520novo%2520MET%2520Amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_contrib-group">Chi, A. S.; Kwak, E. L.; Clark, J. W.; Wang, D. L.; Louis, D. N.; Iafrate, A. J.; Batchelor, T.</span><span> </span><span class="NLM_article-title">Clinical Improvement and Rapid Radiographic Regression Induced by a MET Inhibitor in a Patient with MET-Amplified Glioblastoma</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 2072.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+S.+Chi&author=E.+L.+Kwak&author=J.+W.+Clark&author=D.+L.+Wang&author=D.+N.+Louis&author=A.+J.+Iafrate&author=T.+Batchelor&title=Clinical+Improvement+and+Rapid+Radiographic+Regression+Induced+by+a+MET+Inhibitor+in+a+Patient+with+MET-Amplified+Glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%2BS.%26atitle%3DClinical%2520Improvement%2520and%2520Rapid%2520Radiographic%2520Regression%2520Induced%2520by%2520a%2520MET%2520Inhibitor%2520in%2520a%2520Patient%2520with%2520MET-Amplified%2520Glioblastoma%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36c"><span><span class="NLM_contrib-group">Lennerz, J. K.; Kwak, E. L.; Michael, M.; Fox, S. B.; Ackerman, A.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y.; Clark, J. W.; Solomon, B. J.; Iafrate, A., J.</span><span> </span><span class="NLM_article-title">Identification of a Small and Lethal Subgroup of Esophagogastric Adenocarcinoma with Evidence of Responsiveness to Crizotinib by MET Amplification</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 4130.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+K.+Lennerz&author=E.+L.+Kwak&author=M.+Michael&author=S.+B.+Fox&author=A.+Ackerman&author=K.+Bergethon&author=G.+Y.+Lauwers&author=J.+G.+Christensen&author=K.+D.+Wilner&author=D.+A.+Haber&author=R.+Salgia&author=Y.+Bang&author=J.+W.+Clark&author=B.+J.+Solomon&author=A.%2C+J.+Iafrate&title=Identification+of+a+Small+and+Lethal+Subgroup+of+Esophagogastric+Adenocarcinoma+with+Evidence+of+Responsiveness+to+Crizotinib+by+MET+Amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26atitle%3DIdentification%2520of%2520a%2520Small%2520and%2520Lethal%2520Subgroup%2520of%2520Esophagogastric%2520Adenocarcinoma%2520with%2520Evidence%2520of%2520Responsiveness%2520to%2520Crizotinib%2520by%2520MET%2520Amplification%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e'],'ref3':['cit3a','cit3b','cit3c','cit3d','cit3e'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d','cit9e'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b','cit18c','cit18d','cit18e','cit18f'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35a','cit35b','cit35c'],'ref36':['cit36a','cit36b','cit36c']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 539 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu, <span class="NLM_string-name hlFld-ContribAuthor">Shengtao Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9120-9140. <a href="https://doi.org/10.1021/acs.jmedchem.1c00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00270%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BAlectinib-Based%252BPROTACs%252Bas%252BNovel%252BPotent%252BDegraders%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DXie%26aufirst%3DShaowen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11022021%26date%3D28062021%26volume%3D64%26issue%3D13%26spage%3D9120%26epage%3D9140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lixian Wang, Jin Lin, Qiangsheng Sun, Chungu Xia, <span class="NLM_string-name hlFld-ContribAuthor">Wei Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Amino Acid Derived Chiral Aminobenzimidazole Manganese Catalysts for Asymmetric Transfer Hydrogenation of Ketones. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (13)
                                     , 8033-8041. <a href="https://doi.org/10.1021/acscatal.1c00616" title="DOI URL">https://doi.org/10.1021/acscatal.1c00616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.1c00616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.1c00616%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DAmino%252BAcid%252BDerived%252BChiral%252BAminobenzimidazole%252BManganese%252BCatalysts%252Bfor%252BAsymmetric%252BTransfer%252BHydrogenation%252Bof%252BKetones%26aulast%3DWang%26aufirst%3DLixian%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08022021%26date%3D03062021%26date%3D17062021%26volume%3D11%26issue%3D13%26spage%3D8033%26epage%3D8041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qing Tang, Alex M. Aronov, David D. Deininger, Simon Giroux, David J. Lauffer, Pan Li, Jianglin Liang, Kira McGinty, Steven Ronkin, Rebecca Swett, Nathan Waal, Diane Boucher, Pamella J. Ford, <span class="NLM_string-name hlFld-ContribAuthor">Cameron S. Moody</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 955-960. <a href="https://doi.org/10.1021/acsmedchemlett.1c00094" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00094%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%25252C%252BSelective%252BTriazolothiadiazole-Containing%252Bc-Met%252BInhibitors%26aulast%3DTang%26aufirst%3DQing%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18022021%26date%3D11052021%26date%3D24052021%26volume%3D12%26issue%3D6%26spage%3D955%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gavin W. Collie, Iacovos N. Michaelides, Kevin Embrey, Christopher J. Stubbs, Ulf Börjesson, Ian L. Dale, Arjan Snijder, Louise Barlind, Kun Song, Puneet Khurana, Christopher Phillips, <span class="NLM_string-name hlFld-ContribAuthor">R. Ian Storer</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Targeting the Folded P-Loop Conformation of c-MET. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 162-167. <a href="https://doi.org/10.1021/acsmedchemlett.0c00392" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00392%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructural%252BBasis%252Bfor%252BTargeting%252Bthe%252BFolded%252BP-Loop%252BConformation%252Bof%252Bc-MET%26aulast%3DCollie%26aufirst%3DGavin%2BW.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13072020%26date%3D30112020%26date%3D08122020%26volume%3D12%26issue%3D1%26spage%3D162%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ikuo Fujimori, Takeshi Wakabayashi, Morio Murakami, Atsutoshi Okabe, Tsuyoshi Ishii, Aaron McGrath, Hua Zou, Kumar Singh Saikatendu, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (49)
                                     , 31984-32001. <a href="https://doi.org/10.1021/acsomega.0c04900" title="DOI URL">https://doi.org/10.1021/acsomega.0c04900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04900%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDiscovery%252Bof%252BNovel%252Band%252BHighly%252BSelective%252BCyclopropane%252BALK%252BInhibitors%252Bthrough%252Ba%252BFragment-Assisted%25252C%252BStructure-Based%252BDrug%252BDesign%26aulast%3DFujimori%26aufirst%3DIkuo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07102020%26date%3D13112020%26date%3D30112020%26volume%3D5%26issue%3D49%26spage%3D31984%26epage%3D32001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jianyong Chen, Yunlong Zhou, Xuyuan Dong, Liu Liu, Longchuan Bai, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne Stuckey, Xiaoqin Li, Bo Wen, Ting Zhao, Siwei Sun, Duxin Sun, Lingling Jiao, Yu Jing, Ming Guo, Dajun Yang, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13994-14016. <a href="https://doi.org/10.1021/acs.jmedchem.0c01550" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01550</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01550%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BCJ-2360%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252BCapable%252Bof%252BAchieving%252BComplete%252BTumor%252BRegression%26aulast%3DChen%26aufirst%3DJianyong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04092020%26date%3D13112020%26volume%3D63%26issue%3D22%26spage%3D13994%26epage%3D14016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, Graham F. Smith, <span class="NLM_string-name hlFld-ContribAuthor">Heike J. Wobst</span>. </span><span class="cited-content_cbyCitation_article-title">Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6251-6275. <a href="https://doi.org/10.1021/acs.jmedchem.9b01625" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01625</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01625%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPromiscuity%252Bof%252Bin%252BVitro%252BSecondary%252BPharmacology%252BAssays%252Band%252BImplications%252Bfor%252BLead%252BOptimization%252BStrategies%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D30092019%26date%3D26112019%26date%3D12112019%26volume%3D63%26issue%3D12%26spage%3D6251%26epage%3D6275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marina Y. Raynbird, Joanne B. Sampson, Dan A. Smith, Siân M. Forsyth, Jonathan D. Moseley, <span class="NLM_string-name hlFld-ContribAuthor">Andrew S. Wells</span>. </span><span class="cited-content_cbyCitation_article-title">Ketone Reductase Biocatalysis in the Synthesis of Chiral Intermediates Toward Generic Active Pharmaceutical Ingredients. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (6)
                                     , 1131-1140. <a href="https://doi.org/10.1021/acs.oprd.0c00120" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00120%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DKetone%252BReductase%252BBiocatalysis%252Bin%252Bthe%252BSynthesis%252Bof%252BChiral%252BIntermediates%252BToward%252BGeneric%252BActive%252BPharmaceutical%252BIngredients%26aulast%3DRaynbird%26aufirst%3DMarina%2BY.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24032020%26date%3D02062020%26volume%3D24%26issue%3D6%26spage%3D1131%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zheng Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Philip E. Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2020,</strong> <em>16 </em>
                                    (5)
                                     , 3152-3161. <a href="https://doi.org/10.1021/acs.jctc.9b01134" title="DOI URL">https://doi.org/10.1021/acs.jctc.9b01134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.9b01134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.9b01134%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DRevealing%252BAcquired%252BResistance%252BMechanisms%252Bof%252BKinase-Targeted%252BDrugs%252BUsing%252Ban%252Bon-the-Fly%25252C%252BFunction-Site%252BInteraction%252BFingerprint%252BApproach%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D13112019%26date%3D24042020%26date%3D13042020%26volume%3D16%26issue%3D5%26spage%3D3152%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chia-Yi Lin, Hsin-Yi Wu, Yuan-Ling Hsu, Ting-Jen Rachel Cheng, Jyung-Hurng Liu, Rou-Jie Huang, Tzu-Hung Hsiao, Chia-Jen Wang, Pei-Fang Hung, Albert Lan, Szu-Hua Pan, Rong-Jie Chein, Chi-Huey Wong, <span class="NLM_string-name hlFld-ContribAuthor">Pan-Chyr Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Suppression of Drug-Resistant Non-Small-Cell Lung Cancer with Inhibitors Targeting Minichromosomal Maintenance Protein. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3172-3187. <a href="https://doi.org/10.1021/acs.jmedchem.9b01783" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01783</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01783%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSuppression%252Bof%252BDrug-Resistant%252BNon-Small-Cell%252BLung%252BCancer%252Bwith%252BInhibitors%252BTargeting%252BMinichromosomal%252BMaintenance%252BProtein%26aulast%3DLin%26aufirst%3DChia-Yi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D26112019%26date%3D17032020%26date%3D03032020%26volume%3D63%26issue%3D6%26spage%3D3172%26epage%3D3187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie E. Garces, Mohammed Al-Hayali, Jong Bong Lee, Jiaxin Li, Pavel Gershkovich, Tracey D. Bradshaw, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 316-321. <a href="https://doi.org/10.1021/acsmedchemlett.9b00378" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00378</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00378%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCodrug%252BApproach%252Bfor%252Bthe%252BPotential%252BTreatment%252Bof%252BEML4-ALK%252BPositive%252BLung%252BCancer%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D27092019%26date%3D01102019%26date%3D27092019%26volume%3D11%26issue%3D3%26spage%3D316%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tigran M. Abramyan, Yi An, <span class="NLM_string-name hlFld-ContribAuthor">Dmitri Kireev</span>. </span><span class="cited-content_cbyCitation_article-title">Off-Pocket Activity Cliffs: A Puzzling Facet of Molecular Recognition. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 152-161. <a href="https://doi.org/10.1021/acs.jcim.9b00731" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00731%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DOff-Pocket%252BActivity%252BCliffs%25253A%252BA%252BPuzzling%252BFacet%252Bof%252BMolecular%252BRecognition%26aulast%3DAbramyan%26aufirst%3DTigran%2BM.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D31082019%26date%3D16122019%26date%3D02122019%26volume%3D60%26issue%3D1%26spage%3D152%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin Wang, Wei-Gang Liu, Chen-Ho Tung, Li-Zhu Wu, <span class="NLM_string-name hlFld-ContribAuthor">Huan Cong</span>. </span><span class="cited-content_cbyCitation_article-title">A Monophosphine Ligand Derived from Anthracene Photodimer: Synthetic Applications for Palladium-Catalyzed Coupling Reactions. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (20)
                                     , 8158-8163. <a href="https://doi.org/10.1021/acs.orglett.9b02414" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02414%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BMonophosphine%252BLigand%252BDerived%252Bfrom%252BAnthracene%252BPhotodimer%25253A%252BSynthetic%252BApplications%252Bfor%252BPalladium-Catalyzed%252BCoupling%252BReactions%26aulast%3DWang%26aufirst%3DXin%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12072019%26date%3D12082019%26volume%3D21%26issue%3D20%26spage%3D8158%26epage%3D8163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fangzhao Li, Guomin Zhao, Zhenmei Deng, Yonghong Hu, <span class="NLM_string-name hlFld-ContribAuthor">Wenge Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Solubility Measurement and Modeling of 3-Hydroxy-2-nitropyridine in Ten Pure Solvents and Two Binary Mixed Solvents for T = (278.15–318.15) K. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical & Engineering Data</span><span> <strong>2019,</strong> <em>64 </em>
                                    (10)
                                     , 4518-4524. <a href="https://doi.org/10.1021/acs.jced.9b00564" title="DOI URL">https://doi.org/10.1021/acs.jced.9b00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jced.9b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jced.9b00564%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520%2526%2520Engineering%2520Data%26atitle%3DSolubility%252BMeasurement%252Band%252BModeling%252Bof%252B3-Hydroxy-2-nitropyridine%252Bin%252BTen%252BPure%252BSolvents%252Band%252BTwo%252BBinary%252BMixed%252BSolvents%252Bfor%252BT%252B%25253D%252B%252528278.15%2525E2%252580%252593318.15%252529%252BK%26aulast%3DLi%26aufirst%3DFangzhao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D18092019%26date%3D30092019%26volume%3D64%26issue%3D10%26spage%3D4518%26epage%3D4524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gavin W. Collie, Cheryl M. Koh, Daniel J. O’Neill, Christopher J. Stubbs, Puneet Khurana, Alice Eddershaw, Arjan Snijder, Fredrik Mauritzson, Louise Barlind, Ian L. Dale, Joseph Shaw, Christopher Phillips, Edward J. Hennessy, Tony Cheung, <span class="NLM_string-name hlFld-ContribAuthor">Ana J. Narvaez</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (9)
                                     , 1322-1327. <a href="https://doi.org/10.1021/acsmedchemlett.9b00276" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00276%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructural%252Band%252BMolecular%252BInsight%252Binto%252BResistance%252BMechanisms%252Bof%252BFirst%252BGeneration%252BcMET%252BInhibitors%26aulast%3DCollie%26aufirst%3DGavin%2BW.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21062019%26date%3D02082019%26date%3D17082019%26date%3D02082019%26volume%3D10%26issue%3D9%26spage%3D1322%26epage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Makoto Fushimi, Ikuo Fujimori, Takeshi Wakabayashi, Tomoaki Hasui, Youichi Kawakita, Keisuke Imamura, Tomoko Kato, Morio Murakami, Tsuyoshi Ishii, Yorifumi Kikko, Maki Kasahara, Atsushi Nakatani, Yuto Hiura, Maki Miyamoto, Kumar Saikatendu, Hua Zou, Scott Weston Lane, J. David Lawson, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4915-4935. <a href="https://doi.org/10.1021/acs.jmedchem.8b01630" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01630%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%25252C%252BSelective%25252C%252Band%252BBrain-Penetrant%252B1H-Pyrazol-5-yl-1H-pyrrolo%25255B2%25252C3-b%25255Dpyridines%252Bas%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BInhibitors%26aulast%3DFushimi%26aufirst%3DMakoto%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21102018%26date%3D03052019%26date%3D22042019%26volume%3D62%26issue%3D10%26spage%3D4915%26epage%3D4935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Seb Caille, Sheng Cui, Margaret M. Faul, Steven M. Mennen, Jason S. Tedrow, <span class="NLM_string-name hlFld-ContribAuthor">Shawn D. Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4583-4603. <a href="https://doi.org/10.1021/acs.joc.9b00735" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00735</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00735%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMolecular%252BComplexity%252Bas%252Ba%252BDriver%252Bfor%252BChemical%252BProcess%252BInnovation%252Bin%252Bthe%252BPharmaceutical%252BIndustry%26aulast%3DCaille%26aufirst%3DSeb%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15032019%26date%3D10042019%26date%3D27032019%26volume%3D84%26issue%3D8%26spage%3D4583%26epage%3D4603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shangwen Fang, Yanwei Zhao, Haiyan Li, Yonggao Zheng, Pengcheng Lian, <span class="NLM_string-name hlFld-ContribAuthor">Xiaobing Wan</span>. </span><span class="cited-content_cbyCitation_article-title">[3 + 3]-Cycloaddition of α-Diazocarbonyl Compounds and N-Tosylaziridines: Synthesis of Polysubstituted 2H-1,4-Oxazines through Synergetic Catalysis of AgOTf/Cu(OAc)2. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (7)
                                     , 2356-2359. <a href="https://doi.org/10.1021/acs.orglett.9b00632" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00632</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00632%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3D%25255B3%252B%25252B%252B3%25255D-Cycloaddition%252Bof%252B%2525CE%2525B1-Diazocarbonyl%252BCompounds%252Band%252BN-Tosylaziridines%25253A%252BSynthesis%252Bof%252BPolysubstituted%252B2H-1%25252C4-Oxazines%252Bthrough%252BSynergetic%252BCatalysis%252Bof%252BAgOTf%25252FCu%252528OAc%2525292%26aulast%3DFang%26aufirst%3DShangwen%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19022019%26date%3D20032019%26volume%3D21%26issue%3D7%26spage%3D2356%26epage%3D2359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Quan-Xing Zi, Sheng-Jiao Yan, Chang-Long Yang, Kun Li, <span class="NLM_string-name hlFld-ContribAuthor">Jun Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Three-Component Cascade Reaction of 1,1-Enediamines, N,N-Dimethylformamide Dimethyl Acetal, and 1,3-Dicarbonyl Compounds: Selective Synthesis of Diverse 2-Aminopyridine Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 2863-2873. <a href="https://doi.org/10.1021/acsomega.8b03284" title="DOI URL">https://doi.org/10.1021/acsomega.8b03284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b03284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b03284%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DThree-Component%252BCascade%252BReaction%252Bof%252B1%25252C1-Enediamines%25252C%252BN%25252CN-Dimethylformamide%252BDimethyl%252BAcetal%25252C%252Band%252B1%25252C3-Dicarbonyl%252BCompounds%25253A%252BSelective%252BSynthesis%252Bof%252BDiverse%252B2-Aminopyridine%252BDerivatives%26aulast%3DZi%26aufirst%3DQuan-Xing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D25112018%26date%3D25012019%26volume%3D4%26issue%3D2%26spage%3D2863%26epage%3D2873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Helen L. Lightfoot, Frederick W. Goldberg, <span class="NLM_string-name hlFld-ContribAuthor">Joerg Sedelmeier</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of Small Molecule Kinase Drugs. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (2)
                                     , 153-160. <a href="https://doi.org/10.1021/acsmedchemlett.8b00445" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00445%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEvolution%252Bof%252BSmall%252BMolecule%252BKinase%252BDrugs%26aulast%3DLightfoot%26aufirst%3DHelen%2BL.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27092018%26date%3D17122018%26date%3D10012019%26date%3D18122018%26volume%3D10%26issue%3D2%26spage%3D153%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tim Markovic, Philip R. D. Murray, Benjamin N. Rocke, Andre Shavnya, David C. Blakemore, <span class="NLM_string-name hlFld-ContribAuthor">Michael C. Willis</span>. </span><span class="cited-content_cbyCitation_article-title">Heterocyclic Allylsulfones as Latent Heteroaryl Nucleophiles in Palladium-Catalyzed Cross-Coupling Reactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (46)
                                     , 15916-15923. <a href="https://doi.org/10.1021/jacs.8b09595" title="DOI URL">https://doi.org/10.1021/jacs.8b09595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b09595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b09595%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DHeterocyclic%252BAllylsulfones%252Bas%252BLatent%252BHeteroaryl%252BNucleophiles%252Bin%252BPalladium-Catalyzed%252BCross-Coupling%252BReactions%26aulast%3DMarkovic%26aufirst%3DTim%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05092018%26date%3D09112018%26volume%3D140%26issue%3D46%26spage%3D15916%26epage%3D15923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fei Ling, Sanfei Nian, Jiachen Chen, Wenjun Luo, Ze Wang, Yaping Lv, <span class="NLM_string-name hlFld-ContribAuthor">Weihui Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Ferrocene-Based Diamine-Phosphine-Sulfonamide Ligands for Iridium-Catalyzed Asymmetric Hydrogenation of Ketones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (18)
                                     , 10749-10761. <a href="https://doi.org/10.1021/acs.joc.8b01276" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01276%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDevelopment%252Bof%252BFerrocene-Based%252BDiamine-Phosphine-Sulfonamide%252BLigands%252Bfor%252BIridium-Catalyzed%252BAsymmetric%252BHydrogenation%252Bof%252BKetones%26aulast%3DLing%26aufirst%3DFei%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17052018%26date%3D13082018%26date%3D31072018%26volume%3D83%26issue%3D18%26spage%3D10749%26epage%3D10761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, Alexei Brooun, Dan Gehlhaar, <span class="NLM_string-name hlFld-ContribAuthor">Michele McTigue</span>. </span><span class="cited-content_cbyCitation_article-title">Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 878-883. <a href="https://doi.org/10.1021/acsmedchemlett.8b00147" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00147%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReviving%252BB-Factors%25253A%252BRetrospective%252BNormalized%252BB-Factor%252BAnalysis%252Bof%252Bc-ros%252BOncogene%252B1%252BReceptor%252BTyrosine%252BKinase%252Band%252BAnaplastic%252BLymphoma%252BKinase%252BL1196M%252Bwith%252BCrizotinib%252Band%252BLorlatinib%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28032018%26date%3D18062018%26date%3D28082018%26date%3D18062018%26volume%3D9%26issue%3D9%26spage%3D878%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Ben Bolanos, Alexei Brooun, Rebecca A. Gallego, Dan Gehlhaar, Mehran Jalaie, Michele McTigue, <span class="NLM_string-name hlFld-ContribAuthor">Sergei Timofeevski</span>. </span><span class="cited-content_cbyCitation_article-title">Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 872-877. <a href="https://doi.org/10.1021/acsmedchemlett.8b00348" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00348%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReviving%252BB-Factors%25253A%252BActivating%252BALK%252BMutations%252BIncrease%252BProtein%252BDynamics%252Bof%252Bthe%252BUnphosphorylated%252BKinase%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D31072018%26date%3D24082018%26date%3D28082018%26date%3D24082018%26volume%3D9%26issue%3D9%26spage%3D872%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, <span class="NLM_string-name hlFld-ContribAuthor">Martin P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Lipophilic Efficiency as an Important Metric in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6401-6420. <a href="https://doi.org/10.1021/acs.jmedchem.8b00077" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLipophilic%252BEfficiency%252Bas%252Ban%252BImportant%252BMetric%252Bin%252BDrug%252BDesign%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D17042018%26date%3D28032018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria
J. Matos, Bruno L. Oliveira, Nuria Martínez-Sáez, Ana Guerreiro, Pedro M. S. D. Cal, Jean Bertoldo, María Maneiro, Elizabeth Perkins, Julie Howard, Michael J. Deery, Justin M. Chalker, Francisco Corzana, Gonzalo Jiménez-Osés, <span class="NLM_string-name hlFld-ContribAuthor">Gonçalo J. L. Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Chemo- and Regioselective Lysine Modification on Native Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (11)
                                     , 4004-4017. <a href="https://doi.org/10.1021/jacs.7b12874" title="DOI URL">https://doi.org/10.1021/jacs.7b12874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b12874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b12874%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DChemo-%252Band%252BRegioselective%252BLysine%252BModification%252Bon%252BNative%252BProteins%26aulast%3DMatos%26aufirst%3DMaria%2BJ.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D05122017%26date%3D08032018%26date%3D23022018%26volume%3D140%26issue%3D11%26spage%3D4004%26epage%3D4017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mette Ishoey, Someth Chorn, Natesh Singh, Martin G. Jaeger, Matthias Brand, Joshiawa Paulk, Sophie Bauer, Michael A. Erb, Katja Parapatics, André C. Müller, Keiryn L. Bennett, Gerhard F. Ecker, James E. Bradner, <span class="NLM_string-name hlFld-ContribAuthor">Georg E. Winter</span>. </span><span class="cited-content_cbyCitation_article-title">Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (3)
                                     , 553-560. <a href="https://doi.org/10.1021/acschembio.7b00969" title="DOI URL">https://doi.org/10.1021/acschembio.7b00969</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.7b00969%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DTranslation%252BTermination%252BFactor%252BGSPT1%252BIs%252Ba%252BPhenotypically%252BRelevant%252BOff-Target%252Bof%252BHeterobifunctional%252BPhthalimide%252BDegraders%26aulast%3DIshoey%26aufirst%3DMette%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D11112017%26date%3D22012018%26date%3D29012018%26date%3D22012018%26volume%3D13%26issue%3D3%26spage%3D553%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicia J.  Angelbello</span>, <span class="hlFld-ContribAuthor ">Jonathan L.  Chen</span>, <span class="hlFld-ContribAuthor ">Jessica L.  Childs-Disney</span>, <span class="hlFld-ContribAuthor ">Peiyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi-Fu  Wang</span>, and <span class="hlFld-ContribAuthor ">Matthew D.  Disney</span>  . </span><span class="cited-content_cbyCitation_article-title">Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2018,</strong> <em>118 </em>
                                    (4)
                                     , 1599-1663. <a href="https://doi.org/10.1021/acs.chemrev.7b00504" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00504%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DUsing%252BGenome%252BSequence%252Bto%252BEnable%252Bthe%252BDesign%252Bof%252BMedicines%252Band%252BChemical%252BProbes%26aulast%3DAngelbello%26aufirst%3DAlicia%2BJ.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D19082017%26date%3D11012018%26date%3D28022018%26volume%3D118%26issue%3D4%26spage%3D1599%26epage%3D1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allyson M.  Freedy</span>, <span class="hlFld-ContribAuthor ">Maria J.  Matos</span>, <span class="hlFld-ContribAuthor ">Omar  Boutureira</span>, <span class="hlFld-ContribAuthor ">Francisco  Corzana</span>, <span class="hlFld-ContribAuthor ">Ana  Guerreiro</span>, <span class="hlFld-ContribAuthor ">Padma  Akkapeddi</span>, <span class="hlFld-ContribAuthor ">Víctor J.  Somovilla</span>, <span class="hlFld-ContribAuthor ">Tiago  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Karl  Nicholls</span>, <span class="hlFld-ContribAuthor ">Bangwen  Xie</span>, <span class="hlFld-ContribAuthor ">Gonzalo  Jiménez-Osés</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Brindle</span>, <span class="hlFld-ContribAuthor ">André A.  Neves</span>, and <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemoselective Installation of Amine Bonds on Proteins through Aza-Michael Ligation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (50)
                                     , 18365-18375. <a href="https://doi.org/10.1021/jacs.7b10702" title="DOI URL">https://doi.org/10.1021/jacs.7b10702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b10702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b10702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DChemoselective%252BInstallation%252Bof%252BAmine%252BBonds%252Bon%252BProteins%252Bthrough%252BAza-Michael%252BLigation%26aulast%3DFreedy%26aufirst%3DAllyson%2BM.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11102017%26date%3D05122017%26date%3D20122017%26volume%3D139%26issue%3D50%26spage%3D18365%26epage%3D18375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nanyi  Wang</span>, <span class="hlFld-ContribAuthor ">Lirong  Wang</span>, and <span class="hlFld-ContribAuthor ">Xiang-Qun  Xie</span>  . </span><span class="cited-content_cbyCitation_article-title">ProSelection: A Novel Algorithm to Select Proper Protein Structure Subsets for in Silico Target Identification and Drug Discovery Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (11)
                                     , 2686-2698. <a href="https://doi.org/10.1021/acs.jcim.7b00277" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00277</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00277%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DProSelection%25253A%252BA%252BNovel%252BAlgorithm%252Bto%252BSelect%252BProper%252BProtein%252BStructure%252BSubsets%252Bfor%252Bin%252BSilico%252BTarget%252BIdentification%252Band%252BDrug%252BDiscovery%252BResearch%26aulast%3DWang%26aufirst%3DNanyi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17052017%26date%3D26102017%26date%3D27112017%26date%3D10102017%26volume%3D57%26issue%3D11%26spage%3D2686%26epage%3D2698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Jung Hee  Park</span>, <span class="hlFld-ContribAuthor ">Hoi-Yun  Jung</span>, <span class="hlFld-ContribAuthor ">Kukcheol  Ahn</span>, <span class="hlFld-ContribAuthor ">Soyeon  Choi</span>, <span class="hlFld-ContribAuthor ">Hyun Seop  Tae</span>, <span class="hlFld-ContribAuthor ">Kyung Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Jin Kyung  Rho</span>, <span class="hlFld-ContribAuthor ">Jae Cheol  Lee</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (22)
                                     , 9205-9221. <a href="https://doi.org/10.1021/acs.jmedchem.7b01039" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B4-Phenoxyquinoline%252BBased%252BInhibitors%252Bfor%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bby%252BStructure-Based%252BDesign%26aulast%3DMah%26aufirst%3DShinmee%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17072017%26date%3D09112017%26date%3D22112017%26date%3D01112017%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lukasz  Skora</span> and <span class="hlFld-ContribAuthor ">Wolfgang  Jahnke</span>  . </span><span class="cited-content_cbyCitation_article-title">19F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 632-635. <a href="https://doi.org/10.1021/acsmedchemlett.7b00084" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00084%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D19F-NMR-Based%252BDual-Site%252BReporter%252BAssay%252Bfor%252Bthe%252BDiscovery%252Band%252BDistinction%252Bof%252BCatalytic%252Band%252BAllosteric%252BKinase%252BInhibitors%26aulast%3DSkora%26aufirst%3DLukasz%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D26022017%26date%3D27032017%26date%3D06042017%26date%3D08062017%26volume%3D8%26issue%3D6%26spage%3D632%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilva  Kayastha</span>, <span class="hlFld-ContribAuthor ">Dragos  Horvath</span>, <span class="hlFld-ContribAuthor ">Erik  Gilberg</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>, and <span class="hlFld-ContribAuthor ">Alexandre  Varnek</span>  . </span><span class="cited-content_cbyCitation_article-title">Privileged Structural Motif Detection and Analysis Using Generative Topographic Maps. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (5)
                                     , 1218-1232. <a href="https://doi.org/10.1021/acs.jcim.7b00128" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00128%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPrivileged%252BStructural%252BMotif%252BDetection%252Band%252BAnalysis%252BUsing%252BGenerative%252BTopographic%252BMaps%26aulast%3DKayastha%26aufirst%3DShilva%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D02032017%26date%3D21042017%26date%3D22052017%26date%3D14042017%26volume%3D57%26issue%3D5%26spage%3D1218%26epage%3D1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Ye</span>, <span class="hlFld-ContribAuthor ">Mansour  Haddad</span>, <span class="hlFld-ContribAuthor ">Virginie  Ratovelomanana-Vidal</span>, and <span class="hlFld-ContribAuthor ">Véronique  Michelet</span>  . </span><span class="cited-content_cbyCitation_article-title">Ruthenium-Catalyzed [2 + 2 + 2] Cycloaddition Reaction Forming 2-Aminopyridine Derivatives from α,ω-Diynes and Cyanamides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (5)
                                     , 1104-1107. <a href="https://doi.org/10.1021/acs.orglett.7b00130" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b00130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b00130%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRuthenium-Catalyzed%252B%25255B2%252B%25252B%252B2%252B%25252B%252B2%25255D%252BCycloaddition%252BReaction%252BForming%252B2-Aminopyridine%252BDerivatives%252Bfrom%252B%2525CE%2525B1%25252C%2525CF%252589-Diynes%252Band%252BCyanamides%26aulast%3DYe%26aufirst%3DFei%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D13012017%26date%3D22022017%26date%3D03032017%26volume%3D19%26issue%3D5%26spage%3D1104%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianfei  Yu</span>, <span class="hlFld-ContribAuthor ">Jiao  Long</span>, <span class="hlFld-ContribAuthor ">Yuhong  Yang</span>, <span class="hlFld-ContribAuthor ">Weilong  Wu</span>, <span class="hlFld-ContribAuthor ">Peng  Xue</span>, <span class="hlFld-ContribAuthor ">Lung Wa  Chung</span>, <span class="hlFld-ContribAuthor ">Xiu-Qin  Dong</span>, and <span class="hlFld-ContribAuthor ">Xumu  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Iridium-Catalyzed Asymmetric Hydrogenation of Ketones with Accessible and Modular Ferrocene-Based Amino-phosphine Acid (f-Ampha) Ligands. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (3)
                                     , 690-693. <a href="https://doi.org/10.1021/acs.orglett.6b03862" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b03862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b03862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b03862%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIridium-Catalyzed%252BAsymmetric%252BHydrogenation%252Bof%252BKetones%252Bwith%252BAccessible%252Band%252BModular%252BFerrocene-Based%252BAmino-phosphine%252BAcid%252B%252528f-Ampha%252529%252BLigands%26aulast%3DYu%26aufirst%3DJianfei%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D27122016%26date%3D17012017%26date%3D03022017%26volume%3D19%26issue%3D3%26spage%3D690%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Yu</span> and <span class="hlFld-ContribAuthor ">JinJia  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Modified Process for the Kilogram-Scale Synthesis of c-Met/ALK Inhibitor HS-10168. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (1)
                                     , 133-137. <a href="https://doi.org/10.1021/acs.oprd.6b00402" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00402%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BModified%252BProcess%252Bfor%252Bthe%252BKilogram-Scale%252BSynthesis%252Bof%252Bc-Met%25252FALK%252BInhibitor%252BHS-10168%26aulast%3DYu%26aufirst%3DJun%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D30112016%26date%3D10012017%26date%3D20012017%26date%3D06012017%26volume%3D21%26issue%3D1%26spage%3D133%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianming  Yang</span>, <span class="hlFld-ContribAuthor ">Wai Har  Ng</span>, <span class="hlFld-ContribAuthor ">Huan  Chen</span>, <span class="hlFld-ContribAuthor ">Kamon  Chomchopbun</span>, <span class="hlFld-ContribAuthor ">The Hung  Huynh</span>, <span class="hlFld-ContribAuthor ">Mei Lin  Go</span>, and <span class="hlFld-ContribAuthor ">Oi Lian  Kon</span>  . </span><span class="cited-content_cbyCitation_article-title">Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (8)
                                     , 807-812. <a href="https://doi.org/10.1021/acsmedchemlett.6b00223" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00223%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMitochondrial-Targeting%252BMET%252BKinase%252BInhibitor%252BKills%252BErlotinib-Resistant%252BLung%252BCancer%252BCells%26aulast%3DYang%26aufirst%3DTianming%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26052016%26date%3D23062016%26date%3D28062016%26date%3D11082016%26date%3D23062016%26volume%3D7%26issue%3D8%26spage%3D807%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander J.  Wagner</span>, <span class="hlFld-ContribAuthor ">Shawn M.  Miller</span>, <span class="hlFld-ContribAuthor ">Ryan P.  King</span>, and <span class="hlFld-ContribAuthor ">Scott D.  Rychnovsky</span>  . </span><span class="cited-content_cbyCitation_article-title">Nanomole-Scale Assignment and One-Use Kits for Determining the Absolute Configuration of Secondary Alcohols. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (15)
                                     , 6253-6265. <a href="https://doi.org/10.1021/acs.joc.6b00816" title="DOI URL">https://doi.org/10.1021/acs.joc.6b00816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b00816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b00816%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DNanomole-Scale%252BAssignment%252Band%252BOne-Use%252BKits%252Bfor%252BDetermining%252Bthe%252BAbsolute%252BConfiguration%252Bof%252BSecondary%252BAlcohols%26aulast%3DWagner%26aufirst%3DAlexander%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D12042016%26date%3D14072016%26date%3D05082016%26volume%3D81%26issue%3D15%26spage%3D6253%26epage%3D6265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Xinyi  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Bin  Zhao</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Jun  Fan</span>, <span class="hlFld-ContribAuthor ">Yinglei  Gao</span>, <span class="hlFld-ContribAuthor ">Fanwang  Meng</span>, <span class="hlFld-ContribAuthor ">Yuming  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6690-6708. <a href="https://doi.org/10.1021/acs.jmedchem.6b00056" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00056%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%2525285%2525E2%252580%2525B2-Substituted%252529-Benzimidazole-5-%2525281-%2525283%25252C5-dichloropyridin-4-yl%252529ethoxy%252529-1H-indazoles%252Bas%252BPotent%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252BInhibitors%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D13012016%26date%3D06072016%26date%3D28072016%26date%3D27062016%26volume%3D59%26issue%3D14%26spage%3D6690%26epage%3D6708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>, <span class="hlFld-ContribAuthor ">Lijie  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6807-6825. <a href="https://doi.org/10.1021/acs.jmedchem.6b00608" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Oxo-1%25252C4-dihydroquinoline-3-carboxamide%252BDerivatives%252Bas%252BNew%252BAxl%252BKinase%252BInhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20042016%26date%3D19072016%26date%3D28072016%26date%3D05072016%26volume%3D59%26issue%3D14%26spage%3D6807%26epage%3D6825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Shuangying  Liu</span>, <span class="hlFld-ContribAuthor ">Dong  Zou</span>, <span class="hlFld-ContribAuthor ">Mathew  Thomas</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Jan  Romero</span>, <span class="hlFld-ContribAuthor ">Anna  Kohlmann</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Jiwei  Qi</span>, <span class="hlFld-ContribAuthor ">Lisi  Cai</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Dwight</span>, <span class="hlFld-ContribAuthor ">Yongjin  Xu</span>, <span class="hlFld-ContribAuthor ">Rongsong  Xu</span>, <span class="hlFld-ContribAuthor ">Rory  Dodd</span>, <span class="hlFld-ContribAuthor ">Angela  Toms</span>, <span class="hlFld-ContribAuthor ">Lois  Parillon</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Lu</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Sen  Zhang</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Keats</span>, <span class="hlFld-ContribAuthor ">Scott D.  Wardwell</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Qihong  Xu</span>, <span class="hlFld-ContribAuthor ">Lauren E.  Moran</span>, <span class="hlFld-ContribAuthor ">Qurish K.  Mohemmad</span>, <span class="hlFld-ContribAuthor ">Hyun Gyung  Jang</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">Narayana I.  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">David  Dalgarno</span>, and <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4948-4964. <a href="https://doi.org/10.1021/acs.jmedchem.6b00306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBrigatinib%252B%252528AP26113%252529%25252C%252Ba%252BPhosphine%252BOxide-Containing%25252C%252BPotent%25252C%252BOrally%252BActive%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%26aulast%3DHuang%26aufirst%3DWei-Sheng%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26022016%26date%3D12052016%26date%3D26052016%26date%3D04052016%26volume%3D59%26issue%3D10%26spage%3D4948%26epage%3D4964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Xie</span>, <span class="hlFld-ContribAuthor ">Lei  Xie</span>, and <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>  . </span><span class="cited-content_cbyCitation_article-title">Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (9)
                                     , 4326-4341. <a href="https://doi.org/10.1021/acs.jmedchem.5b02041" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b02041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b02041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b02041%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDelineation%252Bof%252BPolypharmacology%252Bacross%252Bthe%252BHuman%252BStructural%252BKinome%252BUsing%252Ba%252BFunctional%252BSite%252BInteraction%252BFingerprint%252BApproach%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D31122015%26date%3D17032016%26date%3D12052016%26date%3D01032016%26volume%3D59%26issue%3D9%26spage%3D4326%26epage%3D4341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel H.  Myers</span>, <span class="hlFld-ContribAuthor ">Valerie G.  Brunton</span>, and <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>  . </span><span class="cited-content_cbyCitation_article-title">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (8)
                                     , 3593-3608. <a href="https://doi.org/10.1021/acs.jmedchem.5b01273" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAXL%252BInhibitors%252Bin%252BCancer%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DMyers%26aufirst%3DSamuel%2BH.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D14082015%26date%3D20112015%26date%3D28042016%26date%3D10112015%26volume%3D59%26issue%3D8%26spage%3D3593%26epage%3D3608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chih-Hsiang  Tu</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Yi-Hui  Peng</span>, <span class="hlFld-ContribAuthor ">Tsu  Hsu</span>, <span class="hlFld-ContribAuthor ">Jian-Sung  Wu</span>, <span class="hlFld-ContribAuthor ">Chun-Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Cheng-Tai  Lu</span>, <span class="hlFld-ContribAuthor ">Ping-Chiang  Lyu</span>, <span class="hlFld-ContribAuthor ">Chuan  Shih</span>, <span class="hlFld-ContribAuthor ">Weir-Torn  Jiaang</span>, and <span class="hlFld-ContribAuthor ">Su-Ying  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (8)
                                     , 3906-3919. <a href="https://doi.org/10.1021/acs.jmedchem.6b00106" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00106%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrazolylamine%252BDerivatives%252BReveal%252Bthe%252BConformational%252BSwitching%252Bbetween%252BType%252BI%252Band%252BType%252BII%252BBinding%252BModes%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DTu%26aufirst%3DChih-Hsiang%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D22012016%26date%3D12042016%26date%3D28042016%26date%3D31032016%26volume%3D59%26issue%3D8%26spage%3D3906%26epage%3D3919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saemina  Shin</span>, <span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>, and <span class="hlFld-ContribAuthor ">Hwangseo  Park</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (4)
                                     , 802-810. <a href="https://doi.org/10.1021/acs.jcim.6b00026" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BLow%252BMicromolar%252BDual%252BInhibitors%252Bfor%252BWild%252BType%252Band%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bthrough%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DShin%26aufirst%3DSaemina%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20012016%26date%3D04042016%26date%3D25042016%26date%3D25032016%26volume%3D56%26issue%3D4%26spage%3D802%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Menichincheri</span>, <span class="hlFld-ContribAuthor ">Elena  Ardini</span>, <span class="hlFld-ContribAuthor ">Paola  Magnaghi</span>, <span class="hlFld-ContribAuthor ">Nilla  Avanzi</span>, <span class="hlFld-ContribAuthor ">Patrizia  Banfi</span>, <span class="hlFld-ContribAuthor ">Roberto  Bossi</span>, <span class="hlFld-ContribAuthor ">Laura  Buffa</span>, <span class="hlFld-ContribAuthor ">Giulia  Canevari</span>, <span class="hlFld-ContribAuthor ">Lucio  Ceriani</span>, <span class="hlFld-ContribAuthor ">Maristella  Colombo</span>, <span class="hlFld-ContribAuthor ">Luca  Corti</span>, <span class="hlFld-ContribAuthor ">Daniele  Donati</span>, <span class="hlFld-ContribAuthor ">Marina  Fasolini</span>, <span class="hlFld-ContribAuthor ">Eduard  Felder</span>, <span class="hlFld-ContribAuthor ">Claudio  Fiorelli</span>, <span class="hlFld-ContribAuthor ">Francesco  Fiorentini</span>, <span class="hlFld-ContribAuthor ">Arturo  Galvani</span>, <span class="hlFld-ContribAuthor ">Antonella  Isacchi</span>, <span class="hlFld-ContribAuthor ">Andrea Lombardi  Borgia</span>, <span class="hlFld-ContribAuthor ">Chiara  Marchionni</span>, <span class="hlFld-ContribAuthor ">Marcella  Nesi</span>, <span class="hlFld-ContribAuthor ">Christian  Orrenius</span>, <span class="hlFld-ContribAuthor ">Achille  Panzeri</span>, <span class="hlFld-ContribAuthor ">Enrico  Pesenti</span>, <span class="hlFld-ContribAuthor ">Luisa  Rusconi</span>, <span class="hlFld-ContribAuthor ">Maria Beatrice  Saccardo</span>, <span class="hlFld-ContribAuthor ">Ermes  Vanotti</span>, <span class="hlFld-ContribAuthor ">Ettore  Perrone</span>, and <span class="hlFld-ContribAuthor ">Paolo  Orsini</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (7)
                                     , 3392-3408. <a href="https://doi.org/10.1021/acs.jmedchem.6b00064" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BEntrectinib%25253A%252BA%252BNew%252B3-Aminoindazole%252BAs%252Ba%252BPotent%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%25252C%252Bc-ros%252BOncogene%252B1%252BKinase%252B%252528ROS1%252529%25252C%252Band%252BPan-Tropomyosin%252BReceptor%252BKinases%252B%252528Pan-TRKs%252529%252Binhibitor%26aulast%3DMenichincheri%26aufirst%3DMaria%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14012016%26date%3D30032016%26date%3D14042016%26date%3D22032016%26volume%3D59%26issue%3D7%26spage%3D3392%26epage%3D3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Pengcheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Directly Binding Rather than Induced-Fit Dominated Binding Affinity Difference in (S)- and (R)-Crizotinib Bound MTH1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2016,</strong> <em>12 </em>
                                    (2)
                                     , 851-860. <a href="https://doi.org/10.1021/acs.jctc.5b00973" title="DOI URL">https://doi.org/10.1021/acs.jctc.5b00973</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.5b00973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.5b00973%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D222%26epage%3D227%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D882%26epage%3D886%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DDirectly%252BBinding%252BRather%252Bthan%252BInduced-Fit%252BDominated%252BBinding%252BAffinity%252BDifference%252Bin%252B%252528S%252529-%252Band%252B%252528R%252529-Crizotinib%252BBound%252BMTH1%26aulast%3DSun%26aufirst%3DHuiyong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D13102015%26date%3D25012016%26date%3D09022016%26date%3D14012016%26volume%3D12%26issue%3D2%26spage%3D851%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">Patrick M.  Giguere</span>, <span class="hlFld-ContribAuthor ">Claire M.  Schmerberg</span>, <span class="hlFld-ContribAuthor ">Vladimir M.  Pogorelov</span>, <span class="hlFld-ContribAuthor ">Ramona M.  Rodriguiz</span>, <span class="hlFld-ContribAuthor ">Xi-Ping  Huang</span>, <span class="hlFld-ContribAuthor ">Hu  Zhu</span>, <span class="hlFld-ContribAuthor ">John D.  McCorvy</span>, <span class="hlFld-ContribAuthor ">William C.  Wetsel</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, and <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (2)
                                     , 578-591. <a href="https://doi.org/10.1021/acs.jmedchem.5b01153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01153%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFurther%252BAdvances%252Bin%252BOptimizing%252B%2525282-Phenylcyclopropyl%252529methylamines%252Bas%252BNovel%252BSerotonin%252B2C%252BAgonists%25253A%252BEffects%252Bon%252BHyperlocomotion%25252C%252BPrepulse%252BInhibition%25252C%252Band%252BCognition%252BModels%26aulast%3DCheng%26aufirst%3DJianjun%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D22072015%26date%3D13012016%26date%3D28012016%26date%3D24122015%26volume%3D59%26issue%3D2%26spage%3D578%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harikrishna  Batchu</span>, <span class="hlFld-ContribAuthor ">Soumya  Bhattacharyya</span>, <span class="hlFld-ContribAuthor ">Ruchir  Kant</span>, and <span class="hlFld-ContribAuthor ">Sanjay  Batra</span>  . </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Chelation-Assisted Regioselective Oxidative Dehydrogenative Homocoupling/Ortho-Hydroxylation in N-Phenylpyrazoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (15)
                                     , 7360-7374. <a href="https://doi.org/10.1021/acs.joc.5b00733" title="DOI URL">https://doi.org/10.1021/acs.joc.5b00733</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b00733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b00733%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPalladium-Catalyzed%252BChelation-Assisted%252BRegioselective%252BOxidative%252BDehydrogenative%252BHomocoupling%25252FOrtho-Hydroxylation%252Bin%252BN-Phenylpyrazoles%26aulast%3DBatchu%26aufirst%3DHarikrishna%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D02042015%26date%3D16072015%26date%3D07082015%26date%3D07072015%26volume%3D80%26issue%3D15%26spage%3D7360%26epage%3D7374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Jinkun  Huang</span>, <span class="hlFld-ContribAuthor ">Tsang-Lin  Hwang</span>, <span class="hlFld-ContribAuthor ">Maosheng J.  Chen</span>, <span class="hlFld-ContribAuthor ">Jason S.  Tedrow</span>, <span class="hlFld-ContribAuthor ">Robert P.  Farrell</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Bio</span>, and <span class="hlFld-ContribAuthor ">Sheng  Cui</span>  . </span><span class="cited-content_cbyCitation_article-title">Highly Regioselective Halogenation of Pyridine N-Oxide: Practical Access to 2-Halo-Substituted Pyridines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (12)
                                     , 2948-2951. <a href="https://doi.org/10.1021/acs.orglett.5b01057" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b01057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b01057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b01057%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DHighly%252BRegioselective%252BHalogenation%252Bof%252BPyridine%252BN-Oxide%25253A%252BPractical%252BAccess%252Bto%252B2-Halo-Substituted%252BPyridines%26aulast%3DChen%26aufirst%3DYing%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27042015%26date%3D03062015%26date%3D19062015%26volume%3D17%26issue%3D12%26spage%3D2948%26epage%3D2951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunpu  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Dengyou  Zhang</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Xi  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Chen</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (5)
                                     , 507-512. <a href="https://doi.org/10.1021/ml5004876" title="DOI URL">https://doi.org/10.1021/ml5004876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml5004876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml5004876%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BImidazo%25255B1%25252C2-a%25255Dpyridine%252BDerivatives%252Bas%252BPotent%252Bc-Met%252BInhibitors%26aulast%3DLi%26aufirst%3DChunpu%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D25112014%26date%3D01032015%26date%3D03042015%26date%3D14052015%26date%3D02032015%26volume%3D6%26issue%3D5%26spage%3D507%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel C.  Schmitt</span>, <span class="hlFld-ContribAuthor ">Alexandria P.  Taylor</span>, <span class="hlFld-ContribAuthor ">Andrew C.  Flick</span>, and <span class="hlFld-ContribAuthor ">Robert E.  Kyne, Jr.</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Pyrazoles from 1,3-Diols via Hydrogen Transfer Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (6)
                                     , 1405-1408. <a href="https://doi.org/10.1021/acs.orglett.5b00266" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b00266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b00266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b00266%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BPyrazoles%252Bfrom%252B1%25252C3-Diols%252Bvia%252BHydrogen%252BTransfer%252BCatalysis%26aulast%3DSchmitt%26aufirst%3DDaniel%2BC.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27012015%26date%3D26022015%26date%3D20032015%26volume%3D17%26issue%3D6%26spage%3D1405%26epage%3D1408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuchi  Ma</span>, <span class="hlFld-ContribAuthor ">Guangqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Danqi  Chen</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Yue-Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Jin  Liang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2513-2529. <a href="https://doi.org/10.1021/jm502018y" title="DOI URL">https://doi.org/10.1021/jm502018y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm502018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm502018y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BOptimization%252Bof%252Ba%252BSeries%252Bof%252B1-Sulfonylpyrazolo%25255B4%25252C3-b%25255Dpyridines%252Bas%252BSelective%252Bc-Met%252BInhibitors%26aulast%3DMa%26aufirst%3DYuchi%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D30122014%26date%3D25022015%26date%3D12032015%26date%3D10022015%26volume%3D58%26issue%3D5%26spage%3D2513%26epage%3D2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillaume  Médard</span>, <span class="hlFld-ContribAuthor ">Fiona  Pachl</span>, <span class="hlFld-ContribAuthor ">Benjamin  Ruprecht</span>, <span class="hlFld-ContribAuthor ">Susan  Klaeger</span>, <span class="hlFld-ContribAuthor ">Stephanie  Heinzlmeir</span>, <span class="hlFld-ContribAuthor ">Dominic  Helm</span>, <span class="hlFld-ContribAuthor ">Huichao  Qiao</span>, <span class="hlFld-ContribAuthor ">Xin  Ku</span>, <span class="hlFld-ContribAuthor ">Mathias  Wilhelm</span>, <span class="hlFld-ContribAuthor ">Thomas  Kuehne</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Wu</span>, <span class="hlFld-ContribAuthor ">Antje  Dittmann</span>, <span class="hlFld-ContribAuthor ">Carsten  Hopf</span>, <span class="hlFld-ContribAuthor ">Karl  Kramer</span>, and <span class="hlFld-ContribAuthor ">Bernhard  Kuster</span>  . </span><span class="cited-content_cbyCitation_article-title">Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2015,</strong> <em>14 </em>
                                    (3)
                                     , 1574-1586. <a href="https://doi.org/10.1021/pr5012608" title="DOI URL">https://doi.org/10.1021/pr5012608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/pr5012608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fpr5012608%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DOptimized%252BChemical%252BProteomics%252BAssay%252Bfor%252BKinase%252BInhibitor%252BProfiling%26aulast%3DM%25C3%25A9dard%26aufirst%3DGuillaume%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D05122014%26date%3D20022015%26date%3D06032015%26date%3D08022015%26volume%3D14%26issue%3D3%26spage%3D1574%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Yanhong  Yang</span>, <span class="hlFld-ContribAuthor ">Zhiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Junfeng  Guo</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Kui  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Ao  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 197-211. <a href="https://doi.org/10.1021/jm5005144" title="DOI URL">https://doi.org/10.1021/jm5005144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5005144%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252B2%25252C4-Diarylaminopyrimidine%252BAnalogues%252B%252528DAAPalogues%252529%252BShowing%252BPotent%252BInhibitory%252BActivities%252Bagainst%252BBoth%252BWild-type%252Band%252BMutant%252BALK%252BKinases%26aulast%3DSong%26aufirst%3DZilan%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D01042014%26date%3D08052014%26date%3D08012015%26date%3D30042014%26volume%3D58%26issue%3D1%26spage%3D197%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Agustin H.  Mohedas</span>, <span class="hlFld-ContribAuthor ">You  Wang</span>, <span class="hlFld-ContribAuthor ">Caroline E.  Sanvitale</span>, <span class="hlFld-ContribAuthor ">Peter  Canning</span>, <span class="hlFld-ContribAuthor ">Sungwoon  Choi</span>, <span class="hlFld-ContribAuthor ">Xuechao  Xing</span>, <span class="hlFld-ContribAuthor ">Alex N.  Bullock</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Cuny</span>, and <span class="hlFld-ContribAuthor ">Paul B.  Yu</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (19)
                                     , 7900-7915. <a href="https://doi.org/10.1021/jm501177w" title="DOI URL">https://doi.org/10.1021/jm501177w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501177w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501177w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252Bof%252B3%25252C5-Diaryl-2-aminopyridine%252BALK2%252BInhibitors%252BReveals%252BUnaltered%252BBinding%252BAffinity%252Bfor%252BFibrodysplasia%252BOssificans%252BProgressiva%252BCausing%252BMutants%26aulast%3DMohedas%26aufirst%3DAgustin%2BH.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D24112013%26date%3D04092014%26date%3D09102014%26date%3D07082014%26volume%3D57%26issue%3D19%26spage%3D7900%26epage%3D7915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Jin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Shihe  Hu</span>, <span class="hlFld-ContribAuthor ">Huifang  Li</span>, <span class="hlFld-ContribAuthor ">Jinxing  Xu</span>, <span class="hlFld-ContribAuthor ">Yaning  Hu</span>, <span class="hlFld-ContribAuthor ">Xiao  Xiong</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, and <span class="hlFld-ContribAuthor ">Tao  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (9)
                                     , 2544-2554. <a href="https://doi.org/10.1021/ci500268s" title="DOI URL">https://doi.org/10.1021/ci500268s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500268s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500268s%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMolecular%252BModeling%252Bof%252BExquisitely%252BSelective%252Bc-Met%252BInhibitors%252Bthrough%252B3D-QSAR%252Band%252BMolecular%252BDynamics%252BSimulations%26aulast%3DYuan%26aufirst%3DHaoliang%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D05052014%26date%3D09092014%26date%3D22092014%26date%3D02092014%26volume%3D54%26issue%3D9%26spage%3D2544%26epage%3D2554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Jean  Cui</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 4427-4453. <a href="https://doi.org/10.1021/jm401427c" title="DOI URL">https://doi.org/10.1021/jm401427c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401427c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401427c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BReceptor%252BTyrosine%252BKinase%252BMET%252Bin%252BCancer%25253A%252BSmall%252BMolecule%252BInhibitors%252Band%252BClinical%252BProgress%26aulast%3DCui%26aufirst%3DJ.%2BJean%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D16092013%26date%3D18122013%26date%3D12062014%26date%3D09122013%26volume%3D57%26issue%3D11%26spage%3D4427%26epage%3D4453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Paul F.  Richardson</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Alexei  Brooun</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Burke</span>, <span class="hlFld-ContribAuthor ">Michael R.  Collins</span>, <span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Ya-Li  Deng</span>, <span class="hlFld-ContribAuthor ">Dac  Dinh</span>, <span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Mingying  He</span>, <span class="hlFld-ContribAuthor ">Jacqui  Hoffman</span>, <span class="hlFld-ContribAuthor ">Robert L.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Qinhua  Huang</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Hieu  Lam</span>, <span class="hlFld-ContribAuthor ">Justine L.  Lam</span>, <span class="hlFld-ContribAuthor ">Phuong T.  Le</span>, <span class="hlFld-ContribAuthor ">Laura  Lingardo</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Cynthia L.  Palmer</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Graham L.  Smith</span>, <span class="hlFld-ContribAuthor ">Albert E.  Stewart</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Huichun  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinjiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Helen Y.  Zou</span>, and <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 4720-4744. <a href="https://doi.org/10.1021/jm500261q" title="DOI URL">https://doi.org/10.1021/jm500261q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500261q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%25252810R%252529-7-Amino-12-fluoro-2%25252C10%25252C16-trimethyl-15-oxo-10%25252C15%25252C16%25252C17-tetrahydro-2H-8%25252C4-%252528metheno%252529pyrazolo%25255B4%25252C3-h%25255D%25255B2%25252C5%25252C11%25255D-benzoxadiazacyclotetradecine-3-carbonitrile%252B%252528PF-06463922%252529%25252C%252Ba%252BMacrocyclic%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252Band%252Bc-ros%252BOncogene%252B1%252B%252528ROS1%252529%252Bwith%252BPreclinical%252BBrain%252BExposure%252Band%252BBroad-Spectrum%252BPotency%252Bagainst%252BALK-Resistant%252BMutations%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17022014%26date%3D03062014%26date%3D12062014%26date%3D13052014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengsheng  Zhan</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Tiantian  Chen</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (6)
                                     , 673-678. <a href="https://doi.org/10.1021/ml500066m" title="DOI URL">https://doi.org/10.1021/ml500066m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500066m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500066m%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BAnilinopyrimidines%252Bas%252BDual%252BInhibitors%252Bof%252Bc-Met%252Band%252BVEGFR-2%25253A%252BSynthesis%25252C%252BSAR%25252C%252Band%252BCellular%252BActivity%26aulast%3DZhan%26aufirst%3DZhengsheng%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D10022014%26date%3D26032014%26date%3D27032014%26date%3D12062014%26date%3D26032014%26volume%3D5%26issue%3D6%26spage%3D673%26epage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinhua  Huang</span>, <span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Alexei  Brooun</span>, <span class="hlFld-ContribAuthor ">Kevin D.  Bunker</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Burke</span>, <span class="hlFld-ContribAuthor ">Michael R.  Collins</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Cook</span>, <span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Kevin N.  Dack</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Ya-Li  Deng</span>, <span class="hlFld-ContribAuthor ">Dac  Dinh</span>, <span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Mingying  He</span>, <span class="hlFld-ContribAuthor ">Jacqui  Hoffman</span>, <span class="hlFld-ContribAuthor ">Robert L.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Patrick S.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Hieu  Lam</span>, <span class="hlFld-ContribAuthor ">Justine L.  Lam</span>, <span class="hlFld-ContribAuthor ">Phuong T.  Le</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Li</span>, <span class="hlFld-ContribAuthor ">Laura  Lingardo</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Melissa West  Lu</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Cynthia L.  Palmer</span>, <span class="hlFld-ContribAuthor ">Paul F.  Richardson</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Graham L.  Smith</span>, <span class="hlFld-ContribAuthor ">Albert E.  Stewart</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Konstantinos  Tsaparikos</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Huichun  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinjiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Helen Y.  Zou</span>, and <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (4)
                                     , 1170-1187. <a href="https://doi.org/10.1021/jm401805h" title="DOI URL">https://doi.org/10.1021/jm401805h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401805h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252BPotent%252Band%252BSelective%252BInhibitors%252Bto%252BOvercome%252BClinical%252BAnaplastic%252BLymphoma%252BKinase%252BMutations%252BResistant%252Bto%252BCrizotinib%26aulast%3DHuang%26aufirst%3DQinhua%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D22112013%26date%3D06022014%26date%3D27022014%26date%3D16012014%26volume%3D57%26issue%3D4%26spage%3D1170%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang  Wang</span>, <span class="hlFld-ContribAuthor ">María  Sánchez-Roselló</span>, <span class="hlFld-ContribAuthor ">José Luis  Aceña</span>, <span class="hlFld-ContribAuthor ">Carlos  del Pozo</span>, <span class="hlFld-ContribAuthor ">Alexander E.  Sorochinsky</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2014,</strong> <em>114 </em>
                                    (4)
                                     , 2432-2506. <a href="https://doi.org/10.1021/cr4002879" title="DOI URL">https://doi.org/10.1021/cr4002879</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cr4002879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcr4002879%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DFluorine%252Bin%252BPharmaceutical%252BIndustry%25253A%252BFluorine-Containing%252BDrugs%252BIntroduced%252Bto%252Bthe%252BMarket%252Bin%252Bthe%252BLast%252BDecade%252B%2525282001%2525E2%252580%2525932011%252529%26aulast%3DWang%26aufirst%3DJiang%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D27052013%26date%3D03122013%26date%3D26022014%26volume%3D114%26issue%3D4%26spage%3D2432%26epage%3D2506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar P. J.  van Linden</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Iwan J. P.  de Esch</span>, and <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>  . </span><span class="cited-content_cbyCitation_article-title">KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (2)
                                     , 249-277. <a href="https://doi.org/10.1021/jm400378w" title="DOI URL">https://doi.org/10.1021/jm400378w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400378w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400378w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKLIFS%25253A%252BA%252BKnowledge-Based%252BStructural%252BDatabase%252BTo%252BNavigate%252BKinase%2525E2%252580%252593Ligand%252BInteraction%252BSpace%26aulast%3Dvan%2BLinden%26aufirst%3DOscar%2BP.%2BJ.%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D14032013%26date%3D20092013%26date%3D23012014%26date%3D13082013%26volume%3D57%26issue%3D2%26spage%3D249%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongbing  Huang</span>, <span class="hlFld-ContribAuthor ">Angel  Guzman-Perez</span>, <span class="hlFld-ContribAuthor ">Lisa  Acquaviva</span>, <span class="hlFld-ContribAuthor ">Virginia  Berry</span>, <span class="hlFld-ContribAuthor ">Howard  Bregman</span>, <span class="hlFld-ContribAuthor ">Jennifer  Dovey</span>, <span class="hlFld-ContribAuthor ">Hakan  Gunaydin</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Liyue  Huang</span>, <span class="hlFld-ContribAuthor ">Doug  Saffran</span>, <span class="hlFld-ContribAuthor ">Randy  Serafino</span>, <span class="hlFld-ContribAuthor ">Steve  Schneider</span>, <span class="hlFld-ContribAuthor ">Cindy  Wilson</span>, and <span class="hlFld-ContribAuthor ">Erin F.  DiMauro</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of 2-Aminopyridine Oxazolidinones as Potent and Selective Tankyrase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (12)
                                     , 1218-1223. <a href="https://doi.org/10.1021/ml4003315" title="DOI URL">https://doi.org/10.1021/ml4003315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml4003315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml4003315%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-Based%252BDesign%252Bof%252B2-Aminopyridine%252BOxazolidinones%252Bas%252BPotent%252Band%252BSelective%252BTankyrase%252BInhibitors%26aulast%3DHuang%26aufirst%3DHongbing%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D27082013%26date%3D21102013%26date%3D23102013%26date%3D12122013%26date%3D21102013%26volume%3D4%26issue%3D12%26spage%3D1218%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2013,</strong> <em>53 </em>
                                    (9)
                                     , 2376-2389. <a href="https://doi.org/10.1021/ci400188q" title="DOI URL">https://doi.org/10.1021/ci400188q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci400188q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci400188q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DInsight%252Binto%252BCrizotinib%252BResistance%252BMechanisms%252BCaused%252Bby%252BThree%252BMutations%252Bin%252BALK%252BTyrosine%252BKinase%252Busing%252BFree%252BEnergy%252BCalculation%252BApproaches%26aulast%3DSun%26aufirst%3DHuiyong%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D28032013%26date%3D29082013%26date%3D23092013%26date%3D18082013%26volume%3D53%26issue%3D9%26spage%3D2376%26epage%3D2389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Michelle  Tran-Dubé</span>, <span class="hlFld-ContribAuthor ">Mitchell  Nambu</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Neil  Grodsky</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Shirley  Aguirre</span>, <span class="hlFld-ContribAuthor ">Max  Parker</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Li</span>, <span class="hlFld-ContribAuthor ">Helen  Zou</span>, and <span class="hlFld-ContribAuthor ">James  Christensen</span>  . </span><span class="cited-content_cbyCitation_article-title">Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (17)
                                     , 6651-6665. <a href="https://doi.org/10.1021/jm400926x" title="DOI URL">https://doi.org/10.1021/jm400926x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400926x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400926x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLessons%252Bfrom%252B%252528S%252529-6-%2525281-%2525286-%2525281-Methyl-1H-pyrazol-4-yl%252529-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-b%25255Dpyridazin-3-yl%252529ethyl%252529quinoline%252B%252528PF-04254644%252529%25252C%252Ban%252BInhibitor%252Bof%252BReceptor%252BTyrosine%252BKinase%252Bc-Met%252Bwith%252BHigh%252BProtein%252BKinase%252BSelectivity%252Bbut%252BBroad%252BPhosphodiesterase%252BFamily%252BInhibition%252BLeading%252Bto%252BMyocardial%252BDegeneration%252Bin%252BRats%26aulast%3DCui%26aufirst%3DJ.%2BJean%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D20032013%26date%3D29082013%26date%3D12092013%26date%3D14082013%26volume%3D56%26issue%3D17%26spage%3D6651%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas H.  Marsilje</span>, <span class="hlFld-ContribAuthor ">Wei  Pei</span>, <span class="hlFld-ContribAuthor ">Bei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenshuo  Lu</span>, <span class="hlFld-ContribAuthor ">Tetsuo  Uno</span>, <span class="hlFld-ContribAuthor ">Yunho  Jin</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Sungjoon  Kim</span>, <span class="hlFld-ContribAuthor ">Nanxin  Li</span>, <span class="hlFld-ContribAuthor ">Markus  Warmuth</span>, <span class="hlFld-ContribAuthor ">Yelena  Sarkisova</span>, <span class="hlFld-ContribAuthor ">Frank  Sun</span>, <span class="hlFld-ContribAuthor ">Auzon  Steffy</span>, <span class="hlFld-ContribAuthor ">AnneMarie C.  Pferdekamper</span>, <span class="hlFld-ContribAuthor ">Allen G.  Li</span>, <span class="hlFld-ContribAuthor ">Sean B.  Joseph</span>, <span class="hlFld-ContribAuthor ">Young  Kim</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Tove  Tuntland</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Cui</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Ruo  Steensma</span>, <span class="hlFld-ContribAuthor ">Yongqin  Wan</span>, <span class="hlFld-ContribAuthor ">Jiqing  Jiang</span>, <span class="hlFld-ContribAuthor ">Greg  Chopiuk</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">W. Perry  Gordon</span>, <span class="hlFld-ContribAuthor ">Wendy  Richmond</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Jonathan  Chang</span>, <span class="hlFld-ContribAuthor ">Todd  Groessl</span>, <span class="hlFld-ContribAuthor ">You-Qun  He</span>, <span class="hlFld-ContribAuthor ">Andrew  Phimister</span>, <span class="hlFld-ContribAuthor ">Alex  Aycinena</span>, <span class="hlFld-ContribAuthor ">Christian C.  Lee</span>, <span class="hlFld-ContribAuthor ">Badry  Bursulaya</span>, <span class="hlFld-ContribAuthor ">Donald S.  Karanewsky</span>, <span class="hlFld-ContribAuthor ">H. Martin  Seidel</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Harris</span>, and <span class="hlFld-ContribAuthor ">Pierre-Yves  Michellys</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (14)
                                     , 5675-5690. <a href="https://doi.org/10.1021/jm400402q" title="DOI URL">https://doi.org/10.1021/jm400402q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400402q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252BStructure%2525E2%252580%252593Activity%252BRelationships%25252C%252Band%252Bin%252BVivo%252BEfficacy%252Bof%252Bthe%252BNovel%252BPotent%252Band%252BSelective%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BInhibitor%252B5-Chloro-N2-%2525282-isopropoxy-5-methyl-4-%252528piperidin-4-yl%252529phenyl%252529-N4-%2525282-%252528isopropylsulfonyl%252529phenyl%252529pyrimidine-2%25252C4-diamine%252B%252528LDK378%252529%252BCurrently%252Bin%252BPhase%252B1%252Band%252BPhase%252B2%252BClinical%252BTrials%26aulast%3DMarsilje%26aufirst%3DThomas%2BH.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D19032013%26date%3D26062013%26date%3D25072013%26date%3D06062013%26volume%3D56%26issue%3D14%26spage%3D5675%26epage%3D5690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui-Yi  Shiao</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>, <span class="hlFld-ContribAuthor ">Chun-Wei  Chang</span>, <span class="hlFld-ContribAuthor ">Yi-Yu  Ke</span>, <span class="hlFld-ContribAuthor ">Ya-Hui  Chi</span>, <span class="hlFld-ContribAuthor ">Chang-Ying  Chu</span>, <span class="hlFld-ContribAuthor ">Hsu-Yi  Sun</span>, <span class="hlFld-ContribAuthor ">Chun-Hwa  Chen</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Ka-Shu  Fung</span>, <span class="hlFld-ContribAuthor ">Po-Chu  Kuo</span>, <span class="hlFld-ContribAuthor ">Chin-Ting  Huang</span>, <span class="hlFld-ContribAuthor ">Kai-Yen  Chang</span>, <span class="hlFld-ContribAuthor ">Cheng-Tai  Lu</span>, <span class="hlFld-ContribAuthor ">John T. A.  Hsu</span>, <span class="hlFld-ContribAuthor ">Chiung-Tong  Chen</span>, <span class="hlFld-ContribAuthor ">Weir-Torn  Jiaang</span>, <span class="hlFld-ContribAuthor ">Yu-Sheng  Chao</span>, and <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>  . </span><span class="cited-content_cbyCitation_article-title">Optimization of Ligand and Lipophilic Efficiency To Identify an in Vivo Active Furano-Pyrimidine Aurora Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (13)
                                     , 5247-5260. <a href="https://doi.org/10.1021/jm4006059" title="DOI URL">https://doi.org/10.1021/jm4006059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4006059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4006059%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252BLigand%252Band%252BLipophilic%252BEfficiency%252BTo%252BIdentify%252Ban%252Bin%252BVivo%252BActive%252BFurano-Pyrimidine%252BAurora%252BKinase%252BInhibitor%26aulast%3DShiao%26aufirst%3DHui-Yi%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D03112012%26date%3D28062013%26date%3D11072013%26volume%3D56%26issue%3D13%26spage%3D5247%26epage%3D5260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongjie  Liang</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Dengyou  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruihan  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zheng</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Cheng  Luo</span>  . </span><span class="cited-content_cbyCitation_article-title">Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (4)
                                     , 408-413. <a href="https://doi.org/10.1021/ml4000047" title="DOI URL">https://doi.org/10.1021/ml4000047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml4000047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml4000047%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAnthraquinone%252BDerivatives%252Bas%252BPotent%252BInhibitors%252Bof%252Bc-Met%252BKinase%252Band%252Bthe%252BExtracellular%252BSignaling%252BPathway%26aulast%3DLiang%26aufirst%3DZhongjie%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D04012013%26date%3D25022013%26date%3D26022013%26date%3D11042013%26date%3D25022013%26volume%3D4%26issue%3D4%26spage%3D408%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert P.  Farrell</span>, <span class="hlFld-ContribAuthor ">Maria Victoria  Silva Elipe</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Jason S.  Tedrow</span>, and <span class="hlFld-ContribAuthor ">Filisaty  Vounatsos</span>  . </span><span class="cited-content_cbyCitation_article-title">An Efficient, Regioselective Amination of 3,5-Disubstituted Pyridine N-Oxides Using Saccharin as an Ammonium Surrogate. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2013,</strong> <em>15 </em>
                                    (1)
                                     , 168-171. <a href="https://doi.org/10.1021/ol303218p" title="DOI URL">https://doi.org/10.1021/ol303218p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol303218p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol303218p%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAn%252BEfficient%25252C%252BRegioselective%252BAmination%252Bof%252B3%25252C5-Disubstituted%252BPyridine%252BN-Oxides%252BUsing%252BSaccharin%252Bas%252Ban%252BAmmonium%252BSurrogate%26aulast%3DFarrell%26aufirst%3DRobert%2BP.%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D21112012%26date%3D12122012%26date%3D04012013%26volume%3D15%26issue%3D1%26spage%3D168%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Mitchell  Nambu</span>, <span class="hlFld-ContribAuthor ">Michelle  Tran-Dubé</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Lei  Jia</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Jacqui  Hoffman</span>, <span class="hlFld-ContribAuthor ">Phuong  Le</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Gilles H.  Goetz</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neil  Grodsky</span>, <span class="hlFld-ContribAuthor ">Ya-li  Deng</span>, <span class="hlFld-ContribAuthor ">Max  Parker</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Shirley  Aguirre</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Li</span>, <span class="hlFld-ContribAuthor ">Helen  Zou</span>, and <span class="hlFld-ContribAuthor ">James  Christensen</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (18)
                                     , 8091-8109. <a href="https://doi.org/10.1021/jm300967g" title="DOI URL">https://doi.org/10.1021/jm300967g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300967g%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BClass%252Bof%252BExquisitely%252BSelective%252BMesenchymal-Epithelial%252BTransition%252BFactor%252B%252528c-MET%252529%252BProtein%252BKinase%252BInhibitors%252Band%252BIdentification%252Bof%252Bthe%252BClinical%252BCandidate%252B2-%2525284-%2525281-%252528Quinolin-6-ylmethyl%252529-1H-%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-b%25255Dpyrazin-6-yl%252529-1H-pyrazol-1-yl%252529ethanol%252B%252528PF-04217903%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DCui%26aufirst%3DJ.%2BJean%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D05072012%26date%3D10092012%26date%3D27092012%26date%3D27082012%26volume%3D55%26issue%3D18%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolun  Wang</span> and <span class="hlFld-ContribAuthor ">Joseph  Kim</span>  . </span><span class="cited-content_cbyCitation_article-title">Conformation-Specific Effects of Raf Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (17)
                                     , 7332-7341. <a href="https://doi.org/10.1021/jm300613w" title="DOI URL">https://doi.org/10.1021/jm300613w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300613w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DConformation-Specific%252BEffects%252Bof%252BRaf%252BKinase%252BInhibitors%26aulast%3DWang%26aufirst%3DXiaolun%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D03052012%26date%3D03082012%26date%3D13092012%26date%3D18072012%26volume%3D55%26issue%3D17%26spage%3D7332%26epage%3D7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard T.  Lewis</span>, <span class="hlFld-ContribAuthor ">Christiane M.  Bode</span>, <span class="hlFld-ContribAuthor ">Deborah M.  Choquette</span>, <span class="hlFld-ContribAuthor ">Michele  Potashman</span>, <span class="hlFld-ContribAuthor ">Karina  Romero</span>, <span class="hlFld-ContribAuthor ">John C.  Stellwagen</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Earl  Moore</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Linda F.  Epstein</span>, <span class="hlFld-ContribAuthor ">Renee  Emkey</span>, <span class="hlFld-ContribAuthor ">Paul S.  Andrews</span>, <span class="hlFld-ContribAuthor ">Violeta L.  Yu</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Saffran</span>, <span class="hlFld-ContribAuthor ">Man  Xu</span>, <span class="hlFld-ContribAuthor ">Allison  Drew</span>, <span class="hlFld-ContribAuthor ">Patricia  Merkel</span>, <span class="hlFld-ContribAuthor ">Steven  Szilvassy</span>, and <span class="hlFld-ContribAuthor ">Rachael L.  Brake</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (14)
                                     , 6523-6540. <a href="https://doi.org/10.1021/jm3005866" title="DOI URL">https://doi.org/10.1021/jm3005866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3005866%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Band%252BOptimization%252Bof%252Ba%252BNovel%252BClass%252Bof%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BInhibitors%252Bwith%252BPotential%252BUtility%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DLewis%26aufirst%3DRichard%2BT.%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D26042012%26date%3D10072012%26date%3D26072012%26date%3D26062012%26volume%3D55%26issue%3D14%26spage%3D6523%26epage%3D6540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Tyrchan</span>, <span class="hlFld-ContribAuthor ">Jonas  Boström</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>, <span class="hlFld-ContribAuthor ">Jon  Winter</span>, and <span class="hlFld-ContribAuthor ">Sorel  Muresan</span>  . </span><span class="cited-content_cbyCitation_article-title">Exploiting Structural Information in Patent Specifications for Key Compound Prediction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2012,</strong> <em>52 </em>
                                    (6)
                                     , 1480-1489. <a href="https://doi.org/10.1021/ci3001293" title="DOI URL">https://doi.org/10.1021/ci3001293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci3001293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci3001293%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DExploiting%252BStructural%252BInformation%252Bin%252BPatent%252BSpecifications%252Bfor%252BKey%252BCompound%252BPrediction%26aulast%3DTyrchan%26aufirst%3DChristian%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D12032012%26date%3D11062012%26date%3D25062012%26date%3D29052012%26volume%3D52%26issue%3D6%26spage%3D1480%26epage%3D1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Moosavi</span>, <span class="hlFld-ContribAuthor ">Mehdi  Khoshneviszadeh</span>, <span class="hlFld-ContribAuthor ">Motahareh  Mortazavi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>, <span class="hlFld-ContribAuthor ">Zahra  Kayani</span>, <span class="hlFld-ContribAuthor ">Luciano  Saso</span>, <span class="hlFld-ContribAuthor ">Najmeh  Edraki</span>, <span class="hlFld-ContribAuthor ">Omidreza  Firuzi</span>. </span><span class="cited-content_cbyCitation_article-title">Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-83069-4" title="DOI URL">https://doi.org/10.1038/s41598-021-83069-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-83069-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-83069-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DImidazopyridine%252Bhydrazone%252Bderivatives%252Bexert%252Bantiproliferative%252Beffect%252Bon%252Blung%252Band%252Bpancreatic%252Bcancer%252Bcells%252Band%252Bpotentially%252Binhibit%252Breceptor%252Btyrosine%252Bkinases%252Bincluding%252Bc-Met%26aulast%3DDamghani%26aufirst%3DTahereh%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna M.  Schläfli</span>, <span class="hlFld-ContribAuthor ">Igor  Tokarchuk</span>, <span class="hlFld-ContribAuthor ">Sarah  Parejo</span>, <span class="hlFld-ContribAuthor ">Susanne  Jutzi</span>, <span class="hlFld-ContribAuthor ">Sabina  Berezowska</span>, <span class="hlFld-ContribAuthor ">Nikolai  Engedal</span>, <span class="hlFld-ContribAuthor ">Mario P.  Tschan</span>. </span><span class="cited-content_cbyCitation_article-title">ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-87966-6" title="DOI URL">https://doi.org/10.1038/s41598-021-87966-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-87966-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-87966-6%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DALK%252Binhibition%252Bactivates%252BLC3B-independent%25252C%252Bprotective%252Bautophagy%252Bin%252BEML4-ALK%252Bpositive%252Blung%252Bcancer%252Bcells%26aulast%3DSchl%25C3%25A4fli%26aufirst%3DAnna%2BM.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gundula  Streubel</span>, <span class="hlFld-ContribAuthor ">Sabine  Schrepfer</span>, <span class="hlFld-ContribAuthor ">Hannah  Kallus</span>, <span class="hlFld-ContribAuthor ">Ulrike  Parnitzke</span>, <span class="hlFld-ContribAuthor ">Tanja  Wulff</span>, <span class="hlFld-ContribAuthor ">Frank  Hermann</span>, <span class="hlFld-ContribAuthor ">Matthias  Borgmann</span>, <span class="hlFld-ContribAuthor ">Svetlana  Hamm</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-88983-1" title="DOI URL">https://doi.org/10.1038/s41598-021-88983-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-88983-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-88983-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DHistone%252Bdeacetylase%252Binhibitor%252Bresminostat%252Bin%252Bcombination%252Bwith%252Bsorafenib%252Bcounteracts%252Bplatelet-mediated%252Bpro-tumoral%252Beffects%252Bin%252Bhepatocellular%252Bcarcinoma%26aulast%3DStreubel%26aufirst%3DGundula%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoran  Zhang</span>, <span class="hlFld-ContribAuthor ">Lichuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Chenglong  Gao</span>, <span class="hlFld-ContribAuthor ">Rilei  Yu</span>, <span class="hlFld-ContribAuthor ">Congmin  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore screening, molecular docking, ADMET prediction and MD simulations for identification of ALK and MEK potential dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1245 </em>, 131066. <a href="https://doi.org/10.1016/j.molstruc.2021.131066" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.131066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.131066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.131066%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DPharmacophore%252Bscreening%25252C%252Bmolecular%252Bdocking%25252C%252BADMET%252Bprediction%252Band%252BMD%252Bsimulations%252Bfor%252Bidentification%252Bof%252BALK%252Band%252BMEK%252Bpotential%252Bdual%252Binhibitors%26aulast%3DZhang%26aufirst%3DHaoran%26date%3D2021%26volume%3D1245%26spage%3D131066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor T.  Sabe</span>, <span class="hlFld-ContribAuthor ">Thandokuhle  Ntombela</span>, <span class="hlFld-ContribAuthor ">Lindiwe A.  Jhamba</span>, <span class="hlFld-ContribAuthor ">Glenn E.M.  Maguire</span>, <span class="hlFld-ContribAuthor ">Thavendran  Govender</span>, <span class="hlFld-ContribAuthor ">Tricia  Naicker</span>, <span class="hlFld-ContribAuthor ">Hendrik G.  Kruger</span>. </span><span class="cited-content_cbyCitation_article-title">Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113705. <a href="https://doi.org/10.1016/j.ejmech.2021.113705" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113705%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Btrends%252Bin%252Bcomputer%252Baided%252Bdrug%252Bdesign%252Band%252Ba%252Bhighlight%252Bof%252Bdrugs%252Bdiscovered%252Bvia%252Bcomputational%252Btechniques%25253A%252BA%252Breview%26aulast%3DSabe%26aufirst%3DVictor%2BT.%26date%3D2021%26volume%3D224%26spage%3D113705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ibrahim A.  Darwish</span>, <span class="hlFld-ContribAuthor ">Nourah Z.  Alzoman</span>, <span class="hlFld-ContribAuthor ">Jamilah M.  Alshehri</span>, <span class="hlFld-ContribAuthor ">Hany W.  Darwish</span>, <span class="hlFld-ContribAuthor ">Mohammed A.  Hamidaddin</span>, <span class="hlFld-ContribAuthor ">Ahmed Y.  Sayed</span>. </span><span class="cited-content_cbyCitation_article-title">Innovative use of σ and π electron acceptors in the development of three high throughput 96-microwell spectrophotometric assays for crizotinib. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2021,</strong> <em>259 </em>, 119884. <a href="https://doi.org/10.1016/j.saa.2021.119884" title="DOI URL">https://doi.org/10.1016/j.saa.2021.119884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2021.119884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2021.119884%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DInnovative%252Buse%252Bof%252B%2525CF%252583%252Band%252B%2525CF%252580%252Belectron%252Bacceptors%252Bin%252Bthe%252Bdevelopment%252Bof%252Bthree%252Bhigh%252Bthroughput%252B96-microwell%252Bspectrophotometric%252Bassays%252Bfor%252Bcrizotinib%26aulast%3DDarwish%26aufirst%3DIbrahim%2BA.%26date%3D2021%26volume%3D259%26spage%3D119884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Wu</span>, <span class="hlFld-ContribAuthor ">Han  Yao</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Niuniu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yangyang  Fan</span>, <span class="hlFld-ContribAuthor ">Albert S.C.  Chan</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>48 </em>, 128253. <a href="https://doi.org/10.1016/j.bmcl.2021.128253" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128253%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidines%252Bbearing%252Ba%252Bsulfoxide%252Bmoiety%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibition%252Bagents%26aulast%3DWu%26aufirst%3DFeng%26date%3D2021%26volume%3D48%26spage%3D128253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott  Raskin</span>, <span class="hlFld-ContribAuthor ">Miriam  Bornhorst</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. </span><span class="cited-content_cbyCitation_journal-name">Otolaryngologic Clinics of North America</span><span> <strong>2021,</strong> <em>54 </em>
                                    (4)
                                     , 789-801. <a href="https://doi.org/10.1016/j.otc.2021.05.004" title="DOI URL">https://doi.org/10.1016/j.otc.2021.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.otc.2021.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.otc.2021.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DOtolaryngologic%2520Clinics%2520of%2520North%2520America%26atitle%3DBiological%252BTreatments%252Bof%252BNeurofibromatosis%252BType%252B2%252Band%252BOther%252BSkull%252BBase%252BDisorders%26aulast%3DRaskin%26aufirst%3DScott%26date%3D2021%26volume%3D54%26issue%3D4%26spage%3D789%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Afsar Ali  Mian</span>, <span class="hlFld-ContribAuthor ">Isabella  Haberbosch</span>, <span class="hlFld-ContribAuthor ">Hazem  Khamaisie</span>, <span class="hlFld-ContribAuthor ">Abed  Agbarya</span>, <span class="hlFld-ContribAuthor ">Larissa  Pietsch</span>, <span class="hlFld-ContribAuthor ">Elizabeh  Eshel</span>, <span class="hlFld-ContribAuthor ">Dally  Najib</span>, <span class="hlFld-ContribAuthor ">Claudia  Chiriches</span>, <span class="hlFld-ContribAuthor ">Oliver Gerhard  Ottmann</span>, <span class="hlFld-ContribAuthor ">Oliver  Hantschel</span>, <span class="hlFld-ContribAuthor ">Ricardo M.  Biondi</span>, <span class="hlFld-ContribAuthor ">Martin  Ruthardt</span>, <span class="hlFld-ContribAuthor ">Jamal  Mahajna</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. </span><span class="cited-content_cbyCitation_journal-name">Annals of Hematology</span><span> <strong>2021,</strong> <em>100 </em>
                                    (8)
                                     , 2023-2029. <a href="https://doi.org/10.1007/s00277-020-04357-z" title="DOI URL">https://doi.org/10.1007/s00277-020-04357-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00277-020-04357-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00277-020-04357-z%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Hematology%26atitle%3DCrizotinib%252Bacts%252Bas%252BABL1%252Binhibitor%252Bcombining%252BATP-binding%252Bwith%252Ballosteric%252Binhibition%252Band%252Bis%252Bactive%252Bagainst%252Bnative%252BBCR-ABL1%252Band%252Bits%252Bresistance%252Band%252Bcompound%252Bmutants%252BBCR-ABL1T315I%252Band%252BBCR-ABL1T315I-E255K%26aulast%3DMian%26aufirst%3DAfsar%2BAli%26date%3D2021%26date%3D2021%26volume%3D100%26issue%3D8%26spage%3D2023%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Xu</span>, <span class="hlFld-ContribAuthor ">Deqiao  Sun</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Zhengsheng  Zhan</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yanyan  Shen</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113497. <a href="https://doi.org/10.1016/j.ejmech.2021.113497" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113497%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotent%252BAxl%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DXu%26aufirst%3DDandan%26date%3D2021%26volume%3D220%26spage%3D113497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swarnagowri  Nayak</span>, <span class="hlFld-ContribAuthor ">Santosh L.  Gaonkar</span>, <span class="hlFld-ContribAuthor ">Ebraheem Abdu  Musad</span>, <span class="hlFld-ContribAuthor ">Abdullah Mohammed AL  Dawsar</span>. </span><span class="cited-content_cbyCitation_article-title">1,3,4-Oxadiazole-containing hybrids as potential anticancer agents: Recent developments, mechanism of action and structure-activity relationships. </span><span class="cited-content_cbyCitation_journal-name">Journal of Saudi Chemical Society</span><span> <strong>2021,</strong> <em>25 </em>
                                    (8)
                                     , 101284. <a href="https://doi.org/10.1016/j.jscs.2021.101284" title="DOI URL">https://doi.org/10.1016/j.jscs.2021.101284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jscs.2021.101284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jscs.2021.101284%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Saudi%2520Chemical%2520Society%26atitle%3D1%25252C3%25252C4-Oxadiazole-containing%252Bhybrids%252Bas%252Bpotential%252Banticancer%252Bagents%25253A%252BRecent%252Bdevelopments%25252C%252Bmechanism%252Bof%252Baction%252Band%252Bstructure-activity%252Brelationships%26aulast%3DNayak%26aufirst%3DSwarnagowri%26date%3D2021%26volume%3D25%26issue%3D8%26spage%3D101284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline  McCarthy</span>, <span class="hlFld-ContribAuthor ">Stefano  Fedele</span>, <span class="hlFld-ContribAuthor ">Christian  Ottensmeier</span>, <span class="hlFld-ContribAuthor ">Richard J.  Shaw</span>. </span><span class="cited-content_cbyCitation_article-title">Early-Phase Interventional Trials in Oral Cancer Prevention. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (15)
                                     , 3845. <a href="https://doi.org/10.3390/cancers13153845" title="DOI URL">https://doi.org/10.3390/cancers13153845</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13153845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13153845%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DEarly-Phase%252BInterventional%252BTrials%252Bin%252BOral%252BCancer%252BPrevention%26aulast%3DMcCarthy%26aufirst%3DCaroline%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D15%26spage%3D3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey  Seow</span>, <span class="hlFld-ContribAuthor ">Sreedam C.  Das</span>, <span class="hlFld-ContribAuthor ">Rodrigo A. V.  Morales</span>, <span class="hlFld-ContribAuthor ">Ricardo  Ataide</span>, <span class="hlFld-ContribAuthor ">Bankala  Krishnarjuna</span>, <span class="hlFld-ContribAuthor ">Mitchell  Silk</span>, <span class="hlFld-ContribAuthor ">David K.  Chalmers</span>, <span class="hlFld-ContribAuthor ">Jack  Richards</span>, <span class="hlFld-ContribAuthor ">Robin F.  Anders</span>, <span class="hlFld-ContribAuthor ">Christopher A.  MacRaild</span>, <span class="hlFld-ContribAuthor ">Raymond S.  Norton</span>. </span><span class="cited-content_cbyCitation_article-title">Guiding the Immune Response to a Conserved Epitope in MSP2, an Intrinsically Disordered Malaria Vaccine Candidate. </span><span class="cited-content_cbyCitation_journal-name">Vaccines</span><span> <strong>2021,</strong> <em>9 </em>
                                    (8)
                                     , 855. <a href="https://doi.org/10.3390/vaccines9080855" title="DOI URL">https://doi.org/10.3390/vaccines9080855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/vaccines9080855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fvaccines9080855%26sid%3Dliteratum%253Aachs%26jtitle%3DVaccines%26atitle%3DGuiding%252Bthe%252BImmune%252BResponse%252Bto%252Ba%252BConserved%252BEpitope%252Bin%252BMSP2%25252C%252Ban%252BIntrinsically%252BDisordered%252BMalaria%252BVaccine%252BCandidate%26aulast%3DSeow%26aufirst%3DJeffrey%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D8%26spage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianjiang  Fu</span>, <span class="hlFld-ContribAuthor ">Xiaorui  Su</span>, <span class="hlFld-ContribAuthor ">Zhihua  Li</span>, <span class="hlFld-ContribAuthor ">Ling  Deng</span>, <span class="hlFld-ContribAuthor ">Xiawei  Liu</span>, <span class="hlFld-ContribAuthor ">Xuancheng  Feng</span>, <span class="hlFld-ContribAuthor ">Juan  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2021,</strong> <em>40 </em>
                                    (28)
                                     , 4625-4651. <a href="https://doi.org/10.1038/s41388-021-01863-w" title="DOI URL">https://doi.org/10.1038/s41388-021-01863-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-021-01863-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-021-01863-w%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DHGF%25252Fc-MET%252Bpathway%252Bin%252Bcancer%25253A%252Bfrom%252Bmolecular%252Bcharacterization%252Bto%252Bclinical%252Bevidence%26aulast%3DFu%26aufirst%3DJianjiang%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D28%26spage%3D4625%26epage%3D4651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bart  Koopman</span>, <span class="hlFld-ContribAuthor ">Harry J.M.  Groen</span>, <span class="hlFld-ContribAuthor ">Ed  Schuuring</span>, <span class="hlFld-ContribAuthor ">T. Jeroen N.  Hiltermann</span>, <span class="hlFld-ContribAuthor ">Wim  Timens</span>, <span class="hlFld-ContribAuthor ">Wilfred F.A.  den Dunnen</span>, <span class="hlFld-ContribAuthor ">Anke  van den Berg</span>, <span class="hlFld-ContribAuthor ">Arja  ter Elst</span>, <span class="hlFld-ContribAuthor ">Michel  van Kruchten</span>, <span class="hlFld-ContribAuthor ">Joost L.  Kluiver</span>, <span class="hlFld-ContribAuthor ">Birgitta I.  Hiddinga</span>, <span class="hlFld-ContribAuthor ">Lucie B.M.  Hijmering-Kappelle</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Groves</span>, <span class="hlFld-ContribAuthor ">Juliana F.  Vilacha</span>, <span class="hlFld-ContribAuthor ">Léon C.  van Kempen</span>, <span class="hlFld-ContribAuthor ">Anthonie J.  van der Wekken</span>. </span><span class="cited-content_cbyCitation_article-title">Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2021,</strong> <em>448 </em><a href="https://doi.org/10.1016/j.cllc.2021.06.011" title="DOI URL">https://doi.org/10.1016/j.cllc.2021.06.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2021.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2021.06.011%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DActionability%252Bof%252Bon-target%252BALK%252BResistance%252BMutations%252Bin%252BPatients%252BWith%252BNon-Small%252BCell%252BLung%252BCancer%25253A%252BLocal%252BExperience%252Band%252BReview%252Bof%252Bthe%252BLiterature%26aulast%3DKoopman%26aufirst%3DBart%26date%3D2021%26volume%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ossama  Daoui</span>, <span class="hlFld-ContribAuthor ">Souad  Elkhattabi</span>, <span class="hlFld-ContribAuthor ">Samir  Chtita</span>, <span class="hlFld-ContribAuthor ">Rachida  Elkhalabi</span>, <span class="hlFld-ContribAuthor ">Hsaine  Zgou</span>, <span class="hlFld-ContribAuthor ">Adil Touimi  Benjelloun</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR, molecular docking and ADMET properties in silico studies of novel 4,5,6,7-tetrahydrobenzo[D]-thiazol-2-Yl derivatives derived from dimedone as potent anti-tumor agents through inhibition of C-Met receptor tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Heliyon</span><span> <strong>2021,</strong> <em>7 </em>
                                    (7)
                                     , e07463. <a href="https://doi.org/10.1016/j.heliyon.2021.e07463" title="DOI URL">https://doi.org/10.1016/j.heliyon.2021.e07463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.heliyon.2021.e07463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.heliyon.2021.e07463%26sid%3Dliteratum%253Aachs%26jtitle%3DHeliyon%26atitle%3DQSAR%25252C%252Bmolecular%252Bdocking%252Band%252BADMET%252Bproperties%252Bin%252Bsilico%252Bstudies%252Bof%252Bnovel%252B4%25252C5%25252C6%25252C7-tetrahydrobenzo%25255BD%25255D-thiazol-2-Yl%252Bderivatives%252Bderived%252Bfrom%252Bdimedone%252Bas%252Bpotent%252Banti-tumor%252Bagents%252Bthrough%252Binhibition%252Bof%252BC-Met%252Breceptor%252Btyrosine%252Bkinase%26aulast%3DDaoui%26aufirst%3DOssama%26date%3D2021%26volume%3D7%26issue%3D7%26spage%3De07463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>168 </em>, 105579. <a href="https://doi.org/10.1016/j.phrs.2021.105579" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105579%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bphosphatidylinositol%252B3-kinase%252Binhibitors%252Bprescribed%252Bfor%252Bthe%252Btreatment%252Bof%252Bmalignancies%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2021%26volume%3D168%26spage%3D105579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahlem  Belkadi</span>, <span class="hlFld-ContribAuthor ">Samir  Kenouche</span>, <span class="hlFld-ContribAuthor ">Nadjib  Melkemi</span>, <span class="hlFld-ContribAuthor ">Ismail  Daoud</span>, <span class="hlFld-ContribAuthor ">Rachida  Djebaili</span>. </span><span class="cited-content_cbyCitation_article-title">K-means clustering analysis, ADME/pharmacokinetic prediction, MEP, and molecular docking studies of potential cytotoxic agents. </span><span class="cited-content_cbyCitation_journal-name">Structural Chemistry</span><span> <strong>2021,</strong> <em>13 </em><a href="https://doi.org/10.1007/s11224-021-01796-w" title="DOI URL">https://doi.org/10.1007/s11224-021-01796-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11224-021-01796-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11224-021-01796-w%26sid%3Dliteratum%253Aachs%26jtitle%3DStructural%2520Chemistry%26atitle%3DK-means%252Bclustering%252Banalysis%25252C%252BADME%25252Fpharmacokinetic%252Bprediction%25252C%252BMEP%25252C%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bpotential%252Bcytotoxic%252Bagents%26aulast%3DBelkadi%26aufirst%3DAhlem%26date%3D2021%26date%3D2021%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nashwa M.  Saleh</span>, <span class="hlFld-ContribAuthor ">Adel A.‐H.  Abdel‐Rahman</span>, <span class="hlFld-ContribAuthor ">Asmaa M.  Omar</span>, <span class="hlFld-ContribAuthor ">Mohamed M.  Khalifa</span>, <span class="hlFld-ContribAuthor ">Khaled  El‐Adl</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridine‐derived VEGFR‐2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>94 </em><a href="https://doi.org/10.1002/ardp.202100085" title="DOI URL">https://doi.org/10.1002/ardp.202100085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202100085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202100085%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DPyridine%2525E2%252580%252590derived%252BVEGFR%2525E2%252580%2525902%252Binhibitors%25253A%252BRational%252Bdesign%25252C%252Bsynthesis%25252C%252Banticancer%252Bevaluations%25252C%252Bin%252Bsilico%252BADMET%252Bprofile%25252C%252Band%252Bmolecular%252Bdocking%26aulast%3DSaleh%26aufirst%3DNashwa%2BM.%26date%3D2021%26date%3D2021%26volume%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Meng  Cao</span>, <span class="hlFld-ContribAuthor ">Tianming  Zhao</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>37 </em>, 116108. <a href="https://doi.org/10.1016/j.bmc.2021.116108" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116108%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bantitumor%252Bactivity%252Bof%252BBenzo%25255Bd%25255Dimidazol-containing%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Binhibitors%252Bwith%252Bmutation-combating%252Beffects%26aulast%3DLi%26aufirst%3DZheng%26date%3D2021%26volume%3D37%26spage%3D116108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm2007613&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm2007613%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-18%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=539&amp;pagesCount=6&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0021.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0022.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of <b>3</b> bound to the kinase domain of c-MET. The backbone trace of the activation loop is highlighted in cyan, and hydrogen bonds are indicated as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0023.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure overlay of <b>3</b>/c-MET (green/gray) and <b>1</b>/FGFR1K (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0024.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of 5-aryl-3-benzyloxy-2-aminopyridine scaffold for c-MET inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0025.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. First iteration 2-aminopyridines show c-MET inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. LipE plot highlights <b>14k</b>, <b>14i</b>, and <b>14c</b> as lead compounds and where close analogues reside.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. c-MET cell p(IC<sub>50</sub>) vs cLogD (blue for 5-pyrazol-4-yl, red for 5-phenyl, and yellow for other).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure and activity of pure enantiomers of <b>61</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Cocrystal structure of crizotinib bound to c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of crizotinib and <b>3</b> bound to c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4 h; (b) arylboronic ester, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 12 h; (c) 4-(2-chloroethyl)morpholine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4 h; (d) (<i>R</i>)-1-(pyrrolidin-2-ylmethyl)pyrrolidine, HOBt, EDC, DMF, 1 h; (e) Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 12 h.</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub> balloon, 10% Pd/C, methanol, 16 h; (b) NaH, DMF, 0 °C to ambient temperature, 2 h; (c) LiAlH<sub>4</sub>, THF, 0 °C to ambient temperature, 3 h; (d) Ph<sub>3</sub>PBr<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0008.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>P, DEAD, THF, 0 °C, 4 h; (b) Fe, AcOH/EtOH, reflux, 1 h; (c) NBS, ACN, 0 °C, 15 min; (d) NIS, ACN/AcOH, 0 °C, 4 h; (e) CuI, K<sub>3</sub>PO<sub>4</sub>, dodecane/cyclohexanediamine, DMSO, microwave at 150 °C, 2 h; (f) Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 12 h; (g) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, DPPF, DMF, 100 °C, 3 h; (h) EDC, HOBt, DMF, 4 h.</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0009.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 12–16 h; (b) NaH, DMF, microwave at 110 °C, 30 min; (c) Pd(dppf)Cl<sub>2</sub>, KOAc, DMSO, 80 °C, overnight; (d) Pd(dppf)Cl<sub>2</sub> or Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, CsF, DME/H<sub>2</sub>O, microwave at 120 °C, 1 h; (e) Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 85 °C, overnight; (f) trimethylsulfoxonium iodide, NaH, DMSO, 55 °C, 6 h; (g) NaH, DMF, 90 °C, 3 h.</p></p></figure><figure data-id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0010.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, DMAP, DMF, ambient temperature, 18 h; (b) Pd(dppf)Cl<sub>2</sub>, KOAc, DMSO, 80 °C, overnight; (c) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 12 h; (d) Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 87 °C, 16 h; (e) 4 N HCl in dioxane, MeOH, 1 h.</p></p></figure><figure data-id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/medium/jm-2011-007613_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0011.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Total Synthesis of Crizotinib<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2007613&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (b) NaH, DMF, 100 °C, overnight; (c) Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, KOAc, DMSO, 80 °C, 2 h; (d) Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 90 °C, 3 h; (e) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 4 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i97">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lh7zagHawbQGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_contrib-group">Krause, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as targets for cancer therapy</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMra044389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=16014887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=172-187&author=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Tyrosine+kinases+as+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets for cancer therapy</span></div><div class="casAuthors">Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the mechanisms of aberrant tyrosine kinase signaling and strategies to inhibit TKs in cancer.  It also summarizes the status of TK-directed cancer therapies, and discusses challenges and prospects for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89QOl9E0UMLVg90H21EOLACvtfcHk0lh7zagHawbQGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D&md5=0a98c8840a983300f6b0743673cf480c</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra044389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra044389%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D172%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kijima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-MET%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0lh7zagHawbQGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520c-MET%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET: structure, functions and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1023%2FA%3A1023768811842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=12884908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=309-325&author=P.+C.+Maauthor=G.+Maulikauthor=J.+Christensenauthor=R.+Salgia&title=c-MET%3A+structure%2C+functions+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met: Structure, functions and potential for therapeutic inhibition</span></div><div class="casAuthors">Ma, Patrick C.; Maulik, Gautam; Christensen, James; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Studies on signal transduction pathways have generated various promising mol. targets for therapeutic inhibition in cancer therapy.  Receptor tyrosine kinases represent an important class of such therapeutic targets.  C-Met is a receptor tyrosine kinase that has been shown to be overexpressed and/or mutated in a variety of malignancies.  A no. of c-Met activating mutations, many of which are located in the tyrosine kinase domain, have been detected in various solid tumors and have been implicated in invasion and metastasis of tumor cells.  It is known that stimulation of c-Met via its natural ligand, hepatocyte growth factor (also known as scatter factor, HGF/SF) results in a plethora of biol. and biochem. effects in the cell.  Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.  Moreover, we summarize current knowledge on various pathways of c-Met signal transduction, highlighting the central role in the cytoskeletal functions.  In this summary is included recent data in our lab. indicating that phosphorylation of focal adhesion proteins, such as paxillin, p125FAK, and PYK2, occurs in response to c-Met stimulation in lung cancer cells.  Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rIdb5Ao4a7Vg90H21EOLACvtfcHk0lh7zagHawbQGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D&md5=7b7bf60da872071a39ce313efd32fd1f</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023768811842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023768811842%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%253A%2520structure%252C%2520functions%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D309%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET as a target in human cancer and characterization of inhibitors for therapeutic intervention</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">225</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2Fj.canlet.2004.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15922853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2005&pages=1-26&author=J.+Christensenauthor=J.+Burrowsauthor=R.+Salgia&title=c-MET+as+a+target+in+human+cancer+and+characterization+of+inhibitors+for+therapeutic+intervention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention</span></div><div class="casAuthors">Christensen, James G.; Burrows, Jon; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-26</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, Imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers.  A unique member of the RTK family, c-Met, also represents an intriguing target for cancer therapy that is yet to be explored in a clin. setting.  The proto-oncogene, c-Met, encodes the high-affinity receptor for hepatocyte growth factor (HGF) or scatter factor (SF).  C-Met and HGF are each required for normal mammalian development and have been shown to be particularly important in cell migration, morphogenic differentiation, and organization of three-dimensional tubular structures (e.g. renal tubular cells, gland formation, etc.) as well as cell growth and angiogenesis.  Both c-Met and HGF have been shown to be deregulated in and to correlate with poor prognosis in a no. of major human cancers.  New data describing the constitutive phosphorylation of c-Met in a no. of human tumors is presented here along with a variety of mechanisms by which c-Met can become activated, including mutation and gene amplification.  In support of the clin. data implicating c-Met activation in the pathogenesis of human cancers, introduction of c-Met and HGF (or mutant c-Met) into cells conferred the properties of motility, invasiveness, and tumorigenicity to the transformed cells.  Conversely, the inhibition of c-Met with a variety of receptor antagonists inhibited the motility, invasiveness, and tumorigenicity of human tumor cell lines.  Consistent with this observation, small-mol. inhibitors of c-Met were developed that antagonized c-Met/HGF-dependent phenotypes and tumor growth in mouse models.  This review will address the potential for development of c-Met inhibitors for treatment of human cancers with particular emphasis on recent findings with small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojTbSn0ouMILVg90H21EOLACvtfcHk0lilkhQ7uJpH1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D&md5=106b145cbf442e9fec9667817697658d</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%2520as%2520a%2520target%2520in%2520human%2520cancer%2520and%2520characterization%2520of%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D225%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_contrib-group">Benvenuti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">The met receptor tyrosine kinase in invasion and metastasis</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fjcp.21183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=17607709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=316-325&author=S.+Benvenutiauthor=P.+M.+Comoglio&title=The+met+receptor+tyrosine+kinase+in+invasion+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The MET receptor tyrosine kinase in invasion and metastasis</span></div><div class="casAuthors">Benvenuti, Silvia; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Various cytokines and sol. growth factors upon interaction with their membrane receptors are responsible for inducing cellular proliferation, differentiation, movement, and protection from anoikis (a planned suicide activated by normal cells in absence of attachment to neighboring cells or extracellular matrix (EMC)).  Among those sol. factors a major position is exerted by hepatocyte growth factor (HGF) together with its receptor MET and macrophage-stimulating protein (MSP) in cooperation with its receptor RON.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1QrqNHPoSM7Vg90H21EOLACvtfcHk0lilkhQ7uJpH1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM&md5=8994572071201c78fd2df1b504ab1a4e</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21183%26sid%3Dliteratum%253Aachs%26aulast%3DBenvenuti%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DThe%2520met%2520receptor%2520tyrosine%2520kinase%2520in%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_contrib-group">Knudsen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Showering c-MET-dependent cancers with drugs</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lilkhQ7uJpH1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_contrib-group">Cheng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1200%2FJCO.20.6.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=11896103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1544-1550&author=H.-L.+Chengauthor=B.+Trinkauthor=T.-S.+Tzaiauthor=H.-S.+Liuauthor=S.-H.+Chanauthor=C.-L.+Hoauthor=D.+Sidranskyauthor=N.-H.+Chow&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+transitional+cell+carcinoma+of+the+urinary+bladder%3A+a+comparison+with+p53+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation</span></div><div class="casAuthors">Cheng, Hong-Lin; Trink, Barry; Tzai, Tzong-Shin; Liu, Hsiao-Sheng; Chan, Shih-Huang; Ho, Chung-Liang; Sidransky, David; Chow, Nan-Haw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1550</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis.  Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clin. significance of Met in human bladder cancer.  Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines.  Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients).  Results: Expression of c-met mRNA tended to pos. correlate with differentiation of cancer cell lines in the absence of point mutation.  High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and neg. expression in 103 cases (72.5%).  Expression of Met was pos. assocd. with histol. grade, stage classification, tumor size, and nodular tumor growth (P < .05, resp.); however, it was not related to TP53 status.  Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P < .05, resp.).  Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, resp.).  Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53.  Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfd5r45qOJLVg90H21EOLACvtfcHk0ljRkezVxMMYTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D&md5=2b9b03134c74318b533f82908304a28e</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.6.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.6.1544%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DTrink%26aufirst%3DB.%26aulast%3DTzai%26aufirst%3DT.-S.%26aulast%3DLiu%26aufirst%3DH.-S.%26aulast%3DChan%26aufirst%3DS.-H.%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DN.-H.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520urinary%2520bladder%253A%2520a%2520comparison%2520with%2520p53%2520nuclear%2520accumulation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1544%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_contrib-group">Lengyel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resau, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harneck, N.</span><span> </span><span class="NLM_article-title">c-MET overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fijc.20598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15455388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1Km" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2005&pages=678-682&author=E.+Lengyelauthor=D.+Prechtelauthor=J.+H.+Resauauthor=K.+Gaugerauthor=A.+Welkauthor=K.+Lindemannauthor=G.+Salantiauthor=T.+Richterauthor=B.+Knudsenauthor=G.+F.+Vande+Woudeauthor=N.+Harneck&title=c-MET+overexpression+in+node-positive+breast+cancer+identifies+patients+with+poor+clinical+outcome+independent+of+Her2%2Fneu"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span></div><div class="casAuthors">Lengyel, Ernst; Prechtel, Dieter; Resau, James H.; Gauger, Katja; Welk, Anita; Lindemann, Kristina; Salanti, Georgia; Richter, Thomas; Knudsen, Beatrice; Vande Woude, George F.; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-682</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis.  In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochem. and confocal immunofluorescence.  Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade.  Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression.  Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addn. to Her2/neu.  Median disease-free survival in patients with c-Met overexpressing tumors was 8 mo compared to 53 mo when c-Met expression was low (p = 0.037; RR = 3.0).  This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate anal.  In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further anal. in a larger cohort of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx-vk_XMTZ6LVg90H21EOLACvtfcHk0ljRkezVxMMYTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1Km&md5=d1d709a602edbff17ee9240e05cb8412</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1002%2Fijc.20598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20598%26sid%3Dliteratum%253Aachs%26aulast%3DLengyel%26aufirst%3DE.%26aulast%3DPrechtel%26aufirst%3DD.%26aulast%3DResau%26aufirst%3DJ.%2BH.%26aulast%3DGauger%26aufirst%3DK.%26aulast%3DWelk%26aufirst%3DA.%26aulast%3DLindemann%26aufirst%3DK.%26aulast%3DSalanti%26aufirst%3DG.%26aulast%3DRichter%26aufirst%3DT.%26aulast%3DKnudsen%26aufirst%3DB.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DHarneck%26aufirst%3DN.%26atitle%3Dc-MET%2520overexpression%2520in%2520node-positive%2520breast%2520cancer%2520identifies%2520patients%2520with%2520poor%2520clinical%2520outcome%2520independent%2520of%2520Her2%252Fneu%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D113%26spage%3D678%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_contrib-group">Lo Muzio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coccia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capogreco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campisi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carinci, F.</span><span> </span><span class="NLM_article-title">Effect of c-MET expression on survival in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1159%2F000092716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=116-121&author=L.+Lo+Muzioauthor=A.+Farinaauthor=C.+Rubiniauthor=E.+Cocciaauthor=M.+Capogrecoauthor=G.+Colellaauthor=R.+Leonardiauthor=G.+Campisiauthor=F.+Carinci&title=Effect+of+c-MET+expression+on+survival+in+head+and+neck+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1159%2F000092716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000092716%26sid%3Dliteratum%253Aachs%26aulast%3DLo%2BMuzio%26aufirst%3DL.%26aulast%3DFarina%26aufirst%3DA.%26aulast%3DRubini%26aufirst%3DC.%26aulast%3DCoccia%26aufirst%3DE.%26aulast%3DCapogreco%26aufirst%3DM.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DLeonardi%26aufirst%3DR.%26aulast%3DCampisi%26aufirst%3DG.%26aulast%3DCarinci%26aufirst%3DF.%26atitle%3DEffect%2520of%2520c-MET%2520expression%2520on%2520survival%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2006%26volume%3D27%26spage%3D116%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3d"><span><span class="NLM_contrib-group">Sawada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radjabi, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kistner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkyilmaz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, E.</span><span> </span><span class="NLM_article-title">c-MET overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1670</span><span class="NLM_x">–</span> <span class="NLM_lpage">1679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1670-1679&author=K.+Sawadaauthor=A.+E.+Radjabiauthor=N.+Shinomiyaauthor=E.+Kistnerauthor=H.+Kennyauthor=A.+R.+Beckerauthor=M.+A.+Turkyilmazauthor=R.+Salgiaauthor=S.+D.+Yamadaauthor=G.+F.+Vande+Woudeauthor=M.+S.+Tretiakovaauthor=E.+Lengyel&title=c-MET+overexpression+is+a+prognostic+factor+in+ovarian+cancer+and+an+effective+target+for+inhibition+of+peritoneal+dissemination+and+invasion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DRadjabi%26aufirst%3DA.%2BE.%26aulast%3DShinomiya%26aufirst%3DN.%26aulast%3DKistner%26aufirst%3DE.%26aulast%3DKenny%26aufirst%3DH.%26aulast%3DBecker%26aufirst%3DA.%2BR.%26aulast%3DTurkyilmaz%26aufirst%3DM.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DYamada%26aufirst%3DS.%2BD.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DLengyel%26aufirst%3DE.%26atitle%3Dc-MET%2520overexpression%2520is%2520a%2520prognostic%2520factor%2520in%2520ovarian%2520cancer%2520and%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520peritoneal%2520dissemination%2520and%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1670%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3e"><span><span class="NLM_contrib-group">Drebber, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldus, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollschweiler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienes, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hölscher, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mönig, S. P.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18497953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1477-1483&author=U.+Drebberauthor=S.+E.+Baldusauthor=B.+Noldenauthor=G.+Grassauthor=E.+Bollschweilerauthor=H.+P.+Dienesauthor=A.+H.+H%C3%B6lscherauthor=S.+P.+M%C3%B6nig&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+gastric+carcinoma+compared+to+p53+and+p21+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3eR"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span></div><div class="casAuthors">Drebber Uta; Baldus Stephan E; Nolden Britt; Grass Guido; Bollschweiler Elfriede; Dienes Hans P; Holscher Arnulf H; Monig Stefan P</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1477-83</span>
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    </div><div class="casAbstract">The purpose of this study was to clarify the relationship of the immunohistochemical expression of c-met, p53 and p21 with clinicopathological parameters and prognosis in gastric carcinomas.  We analyzed specimens from 114 gastric cancer patients (median age 64 years, range: 33-86) who underwent gastrectomy with lymphadenectomy.  Specimens were categorized according to the tumor differentiation, based on UICC, WHO, Lauren, Ming and Goseki classifications.  Specimens were examined immunohistochemically with antibodies against c-met, p53 and p21.  The expression was evaluated semiquantitatively and correlated with the clinicopathological parameters.  The c-met staining pattern was positive in 73.7%.  P53 and p21 were positive in 86.8 and 67.5%, respectively.  No significant correlation between c-met or p21 expression and the clinicopathological parameters was seen.  A significant increase of p53 expression was observed in stage pT3 and -4.  The overexpression of c-met and p53 was significantly associated with a poor prognosis in the univariate survival analysis.  In the multivariate analysis this impact was maintained for c-met.  P21 proved to be a significant prognostic factor in the multivariate analysis.  Our data suggest that the overexpression of c-met and p21 may represent independent prognostic factors in gastric carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcwNSw0zEj49-cVm4E2RlLfW6udTcc2eYxrpD2jIqn77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D&md5=5f503921226de1902468d1526a7322e7</span></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrebber%26aufirst%3DU.%26aulast%3DBaldus%26aufirst%3DS.%2BE.%26aulast%3DNolden%26aufirst%3DB.%26aulast%3DGrass%26aufirst%3DG.%26aulast%3DBollschweiler%26aufirst%3DE.%26aulast%3DDienes%26aufirst%3DH.%2BP.%26aulast%3DH%25C3%25B6lscher%26aufirst%3DA.%2BH.%26aulast%3DM%25C3%25B6nig%26aufirst%3DS.%2BP.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520gastric%2520carcinoma%2520compared%2520to%2520p53%2520and%2520p21%2520nuclear%2520accumulation%26jtitle%3DOncol.%2520Rep.%26date%3D2008%26volume%3D19%26spage%3D1477%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bischof, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2312</span><span class="NLM_x">–</span> <span class="NLM_lpage">2325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1128%2FMCB.17.4.2312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=9121481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADyaK2sXhvFOhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=2312-2325&author=D.+Bischofauthor=K.+Pulfordauthor=D.+Y.+Masonauthor=S.+W.+Morris&title=Role+of+the+nucleophosmin+%28NPM%29+portion+of+the+non-Hodgkin%E2%80%99s+lymphoma-associated+NPM-anaplastic+lymphoma+kinase+fusion+protein+in+oncogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis</span></div><div class="casAuthors">Bischof, Daniela; Pulford, Karen; Mason, David Y.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2312-2325</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NPM-ALK fusion gene, formed by the t(2;5)(p23;q35) translocation in non-Hodgkin's lymphoma, encodes a 75-kDa hybrid protein that contains the amino-terminal 117 amino acid residues of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase).  Here, the authors demonstrate the transforming ability of NPM-ALK and show that oncogenesis by the chimeric protein requires the activation of its kinase function as a result of oligomerization mediated by the NPM segment.  Sedimentation gradient expts. revealed that NPM-ALK forms in vivo multimeric complexes of approx. 200 kDa or greater that also contain normal NPM.  Cell fractionation studies of the t(2;5) translocation-contg. lymphoma cell line SUP-M2 showed NPM-ALK to be localized within both the cytoplasmic and nuclear compartments.  Immunostaining performed with both polyclonal and monoclonal anti-ALK antibodies confirmed the dual location of the oncoprotein and also indicated that NPM-ALK is abundant within both the nucleoplasm and the nucleolus.  An intact NPM segment is absolutely required for NPM-ALK-mediated oncogenesis, as indicated by the authors' observation that three different NPM-ALK mutant proteins lacking nonoverlapping portions of the NPM segment were each unable to form complexes, lacked kinase activity in vivo, and failed to transform cells.  However, NPM could be functionally replaced in the fusion protein with the portion of the unrelated translocated promoter region (TPR) protein that activates the TPR-MET fusion kinase by mediating dimerization through its leucine zipper motif.  This engineered TPR-ALK hybrid protein, which transformed cells almost as efficiently as NPM-ALK, was localized solely within the cytoplasm of cells.  These data indicate that the nuclear and nucleolar localization of NPM-ALK, which probably occur because of transport via the shuttling activity of NPM, is not required for oncogenesis.  Further, the activation of the truncated ALK protein by a completely heterologous oligomerization domain suggests that the functionally important role of the NPM segment of NPM-ALK in transformation is restricted to the formation of kinase-active oligomers and does not involve the alteration of normal NPM functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzwe8k7qW59rVg90H21EOLACvtfcHk0li08sLy5vLvQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhvFOhsLo%253D&md5=5530ead614a941232bcff372ee7fae4b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2FMCB.17.4.2312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.17.4.2312%26sid%3Dliteratum%253Aachs%26aulast%3DBischof%26aufirst%3DD.%26aulast%3DPulford%26aufirst%3DK.%26aulast%3DMason%26aufirst%3DD.%2BY.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DRole%2520of%2520the%2520nucleophosmin%2520%2528NPM%2529%2520portion%2520of%2520the%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma-associated%2520NPM-anaplastic%2520lymphoma%2520kinase%2520fusion%2520protein%2520in%2520oncogenesis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D2312%26epage%3D2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Palmer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernersson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, B.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: signalling in development and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">420</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+lymphoma+kinase%3A+signalling+in+development+and+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520signalling%2520in%2520development%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=Q.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+MacNeillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.-L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signaling+identifies+oncogenic+kinases+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacNeill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signaling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">A mouse model for EML4-ALK-positive lung cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">19893</span><span class="NLM_x">–</span> <span class="NLM_lpage">19897</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=19893-19897&author=M.+Sodaauthor=S.+Takadaauthor=K.+Takeuchiauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=T.+Uenoauthor=H.+Harutaauthor=T.+Hamadaauthor=Y.+Yamashitaauthor=Y.+Ishikawaauthor=Y.+Sugiyamaauthor=H.+Mano&title=A+mouse+model+for+EML4-ALK-positive+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DA%2520mouse%2520model%2520for%2520EML4-ALK-positive%2520lung%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D19893%26epage%3D19897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Caren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinsson, I.</span><span> </span><span class="NLM_article-title">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">416</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Carenauthor=F.+Abelauthor=P.+Kognerauthor=I.+Martinsson&title=High+incidence+of+DNA+mutations+and+gene+amplifications+of+the+ALK+gene+in+advanced+sporadic+neuroblastoma+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaren%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DI.%26atitle%3DHigh%2520incidence%2520of%2520DNA%2520mutations%2520and%2520gene%2520amplifications%2520of%2520the%2520ALK%2520gene%2520in%2520advanced%2520sporadic%2520neuroblastoma%2520tumors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of <i>ALK</i> as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugieres, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alain Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Alain+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lh8-e-1QcTPPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DAlain%2BPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=Li.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DLi.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9e"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanael S. Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan W. Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provides a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Frohlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Nathanael+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Stephan+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provides+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DNathanael%2BS.%2BGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DStephan%2BW.%2BMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provides%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=B.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-MET%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ligtaN0BdUQQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DB.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-MET%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+Altonauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-MET%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0ligtaN0BdUQQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-MET%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Classon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3389</span><span class="NLM_x">–</span> <span class="NLM_lpage">3395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F0008-5472.CAN-07-6186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18451166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3389-3395&author=U.+McDermottauthor=A.+J.+Iafrateauthor=N.+S.+Grayauthor=T.+Shiodaauthor=M.+Classonauthor=S.+Maheswaranauthor=W.+Zhouauthor=H.+G.+Choiauthor=S.+L.+Smithauthor=L.+Dowellauthor=L.+E.+Ulkusauthor=G.+Kuhlmannauthor=P.+Greningerauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=J.+Settleman&title=Genomic+alterations+of+anaplastic+lymphoma+kinase+may+sensitize+tumors+to+anaplastic+lymphoma+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3389-3395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective kinase inhibitors have had a substantial impact on the field of medical oncol.  Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.  We have established an automated platform for examg. the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant.  Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.  This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.  ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.  Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.  Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.  These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtwwG7vhYTbVg90H21EOLACvtfcHk0ligtaN0BdUQQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D&md5=5168e6ce3ea650df3722dbd4f1aa53ea</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6186%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DClasson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DS.%2BL.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DKuhlmann%26aufirst%3DG.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGenomic%2520alterations%2520of%2520anaplastic%2520lymphoma%2520kinase%2520may%2520sensitize%2520tumors%2520to%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3389%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=S.+Sistlaauthor=T.+L.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lj-511TOTRj3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DS.%26aulast%3DLuu%26aufirst%3DT.%2BL.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_contrib-group">Cui, J. J.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cui%2C+J.+J.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_contrib-group">Cui, J.; Zhang, R.; Shen, H.; Chu, J. Y.; Zhang, F.-J.; Koenig, M.; Do, S. H.; Li, X.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Preparation of 4-Aryl Substituted Indolinones as Protein Kinase Signal Transduction Modulators for Inhibiting Abnormal Cell Proliferation</span>. PCT Int. Appl. WO2002055517,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=R.+Zhang&author=H.+Shen&author=J.+Y.+Chu&author=F.-J.+Zhang&author=M.+Koenig&author=S.+H.+Do&author=X.+Li&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+4-Aryl+Substituted+Indolinones+as+Protein+Kinase+Signal+Transduction+Modulators+for+Inhibiting+Abnormal+Cell+Proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25204-Aryl%2520Substituted%2520Indolinones%2520as%2520Protein%2520Kinase%2520Signal%2520Transduction%2520Modulators%2520for%2520Inhibiting%2520Abnormal%2520Cell%2520Proliferation%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_contrib-group">Cui, J.; Ramphal, Y.; Liang, C.; Sun, L.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Preparation of 5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone Derivatives as Kinase Inhibitors</span>. PCT Int. Appl. WO2002096361,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=Y.+Ramphal&author=C.+Liang&author=L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+5-Aralkylsulfonyl-3-%28pyrrol-2-ylmethylidene%29-2-indolinone+Derivatives+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25205-Aralkylsulfonyl-3-%2528pyrrol-2-ylmethylidene%2529-2-indolinone%2520Derivatives%2520as%2520Kinase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornea, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correiac, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owena, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompsona, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trana, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttc, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngc, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneaauthor=A.+M.+Correiacauthor=D.+R.+Owenaauthor=L.+R.+Thompsonaauthor=I.+Tranaauthor=M.+F.+Tuttcauthor=T.+Youngc&title=Rapid+assessment+of+a+novel+series+of+selective+CB2+agonists+using+parallel+synthesis+protocols%3A+a+lipophilic+efficiency+%28LipE%29+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lj-511TOTRj3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHornea%26aufirst%3DV.%2BA.%26aulast%3DCorreiac%26aufirst%3DA.%2BM.%26aulast%3DOwena%26aufirst%3DD.%2BR.%26aulast%3DThompsona%26aufirst%3DL.%2BR.%26aulast%3DTrana%26aufirst%3DI.%26aulast%3DTuttc%26aufirst%3DM.%2BF.%26aulast%3DYoungc%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB2%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520a%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and lipophilic ligand efficiency (LipE or LLE) in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+lipophilic+ligand+efficiency+%28LipE+or+LLE%29+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520lipophilic%2520ligand%2520efficiency%2520%2528LipE%2520or%2520LLE%2529%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiewlich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Li</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=14617781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=1085-1092&author=X.+Wangauthor=P.+Leauthor=C.+Liangauthor=J.+Chanauthor=D.+Kiewlichauthor=T.+Millerauthor=D.+Harrisauthor=Li+Sunauthor=A.+Riceauthor=S.+Vasileauthor=R.+A.+Blakeauthor=A.+R.+Howlettauthor=N.+Patelauthor=G.+McMahonauthor=K.+E.+Lipson&title=Potent+and+selective+inhibitors+of+the+Met+%5Bhepatocyte+growth+factor%2Fscatter+factor+%28HGF%2FSF%29+receptor%5D+tyrosine+kinase+block+HGF%2FSF-induced+tumor+cell+growth+and+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span></div><div class="casAuthors">Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; Blake, Robert A.; Howlett, Anthony R.; Patel, Neela; McMahon, Gerald; Lipson, Kenneth E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met, mediates various cellular responses on activation with its ligand, including proliferation, survival, motility, invasion, and tubular morphogenesis.  Met expression is frequently up-regulated in sarcomas and carcinomas.  Exptl. evidence suggests that Met activation correlates with poor clin. outcome and the likelihood of metastasis.  Therefore, inhibitors of Met tyrosine kinase may be useful for the treatment of a wide variety of cancers that have spread from the primary site.  We have discovered potent and selective pyrrole-indolinone Met kinase inhibitors and characterized them for their ability to inhibit HGF/SF-induced cellular responses in vitro.  These compds. inhibit HGF/SF-induced receptor phosphorylation in a dose-dependent manner.  They also inhibit the HGF/SF-induced motility and invasion of epithelial and carcinoma cells.  Therefore, these compds. represent a class of prototype small mols. that selectively inhibit the Met kinase and could lead to identification of compds. with potential therapeutic utility in treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVAQRRxT_J1rVg90H21EOLACvtfcHk0lhNPc1hYXcZBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D&md5=3b3141600b15ed4f9c97d86fb7ade81d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DKiewlich%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DLi%26aulast%3DRice%26aufirst%3DA.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DHowlett%26aufirst%3DA.%2BR.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520Met%2520%255Bhepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520%2528HGF%252FSF%2529%2520receptor%255D%2520tyrosine%2520kinase%2520block%2520HGF%252FSF-induced%2520tumor%2520cell%2520growth%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D1085%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruganti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruslim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramphal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET kinase inhibits c-MET-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7345</span><span class="NLM_x">–</span> <span class="NLM_lpage">7355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7345-7355&author=J.+G.+Christensenauthor=R.+Schreckauthor=J.+Burrowsauthor=P.+Kurugantiauthor=E.+Chanauthor=P.+Leauthor=J.+Chenauthor=X.+Wangauthor=L.+Ruslimauthor=R.+Blakeauthor=K.+E.+Lipsonauthor=J.+Ramphalauthor=S.+Doauthor=J.+J.+Cuiauthor=J.+M.+Cherringtonauthor=D.+B.+Mendel&title=A+selective+small+molecule+inhibitor+of+c-MET+kinase+inhibits+c-MET-dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antimutor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DKuruganti%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRuslim%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%2520kinase%2520inhibits%2520c-MET-dependent%2520phenotypes%2520in%2520vitro%2520and%2520exhibits%2520cytoreductive%2520antimutor%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7345%26epage%3D7355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_contrib-group">Hov, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utne Holt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baade Rø, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerli, U.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjorth-Hansen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baykov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waage, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Børset, M.</span><span> </span><span class="NLM_article-title">A selective c-MET inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">6686</span><span class="NLM_x">–</span> <span class="NLM_lpage">6694</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1078-0432.CCR-04-0874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15475459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Ohsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=6686-6694&author=H.+Hovauthor=R.+Utne+Holtauthor=T.+Baade+R%C3%B8author=U.-M.+Fagerliauthor=H.+Hjorth-Hansenauthor=V.+Baykovauthor=J.+G.+Christensenauthor=A.+Waageauthor=A.+Sundanauthor=M.+B%C3%B8rset&title=A+selective+c-MET+inhibitor+blocks+an+autocrine+hepatocyte+growth+factor+growth+loop+in+ANBL-6+cells+and+prevents+migration+and+adhesion+of+myeloma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells</span></div><div class="casAuthors">Hov, Hakon; Holt, Randi Utne; Ro, Torstein Baade; Fagerli, Unn-Merete; Hjorth-Hansen, Henrik; Baykov, Vadim; Christensen, James G.; Waage, Anders; Sundan, Anders; Borset, Magne</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6686-6694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors wanted to examine the role of the hepatocyte growth factor (HGF) receptor c-Met in multiple myeloma by applying a novel selective small mol. tyrosine kinase inhibitor, PHA-665752, directed against the receptor.  Four biol. sequels of HGF related to multiple myeloma were studied: (1) proliferation of myeloma cells, (2) secretion of interleukin-11 from osteogenic cells, (3) migration of myeloma cells, and (4) adhesion of myeloma cells to fibronectin.  The authors also examd. effects of the c-Met inhibitor on intracellular signaling pathways in myeloma cells.  PHA-665752 effectively blocked the biol. responses to HGF in all assays, with 50% inhibition at 5 to 15 nmol/L concn. and complete inhibition at around 100 nmol/L.  PHA-665752 inhibited phosphorylation of several tyrosine residues in c-Met (Tyr1003, Tyr1230/1234/1235, and Tyr1349), blocked HGF-mediated activation of Akt and p44/42 mitogen-activated protein kinase, and prevented the adaptor mol. Gab1 from complexing with c-Met.  In the HGF-producing myeloma cell line ANBL-6, PHA-665752 revealed an autocrine HGF-c-Met-mediated growth loop.  The inhibitor also blocked proliferation of purified primary myeloma cells, suggesting that autocrine HGF-c-Met-driven growth loops are important for progression of multiple myeloma.  Collectively, these findings support the role of c-Met and HGF in the proliferation, migration, and adhesion of myeloma cells and identify c-Met kinase as a therapeutic target for treatment of patients with multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhIE0e1cVIbVg90H21EOLACvtfcHk0lhNPc1hYXcZBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Ohsr8%253D&md5=f92327485713764358a8cfe9607a61ec</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0874%26sid%3Dliteratum%253Aachs%26aulast%3DHov%26aufirst%3DH.%26aulast%3DUtne%2BHolt%26aufirst%3DR.%26aulast%3DBaade%2BR%25C3%25B8%26aufirst%3DT.%26aulast%3DFagerli%26aufirst%3DU.-M.%26aulast%3DHjorth-Hansen%26aufirst%3DH.%26aulast%3DBaykov%26aufirst%3DV.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWaage%26aufirst%3DA.%26aulast%3DSundan%26aufirst%3DA.%26aulast%3DB%25C3%25B8rset%26aufirst%3DM.%26atitle%3DA%2520selective%2520c-MET%2520inhibitor%2520blocks%2520an%2520autocrine%2520hepatocyte%2520growth%2520factor%2520growth%2520loop%2520in%2520ANBL-6%2520cells%2520and%2520prevents%2520migration%2520and%2520adhesion%2520of%2520myeloma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D6686%26epage%3D6694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngchul Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce E. Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Youngchul+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.-M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Bruce+E.+Johnsonauthor=L.+C.+Cantleyauthor=A.+Pasiauthor=P.+A.+J%C3%A4nne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lgUc2r7Nva6VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYoungchul%2BSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBruce%2BE.%2BJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DPasi%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_contrib-group">Smolen, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohapatra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barmettler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sgroi, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Amplification of Met may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">2316</span><span class="NLM_x">–</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=2316-2321&author=G.+A.+Smolenauthor=R.+Sordellaauthor=B.+Muirauthor=G.+Mohapatraauthor=A.+Barmettlerauthor=H.+Archibaldauthor=W.+J.+Kimauthor=R.+A.+Okimotoauthor=D.+W.+Bellauthor=D.+C.+Sgroiauthor=J.+G.+Christensenauthor=J.+Settlemanauthor=D.+A.+Haber&title=Amplification+of+Met+may+identify+a+subset+of+cancers+with+extreme+sensitivity+to+the+selective+tyrosine+kinase+inhibitor+PHA-665752"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DG.%2BA.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DMuir%26aufirst%3DB.%26aulast%3DMohapatra%26aufirst%3DG.%26aulast%3DBarmettler%26aufirst%3DA.%26aulast%3DArchibald%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.%2BJ.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSgroi%26aufirst%3DD.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DAmplification%2520of%2520Met%2520may%2520identify%2520a%2520subset%2520of%2520cancers%2520with%2520extreme%2520sensitivity%2520to%2520the%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520PHA-665752%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D2316%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2312</span><span class="NLM_x">–</span> <span class="NLM_lpage">2319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1078-0432.CCR-04-1708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15788682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2312-2319&author=P.+C.+Maauthor=E.+Schaeferauthor=J.+G.+Christensenauthor=R.+Salgia&title=A+selective+small+molecule+c-MET+inhibitor%2C+PHA665752%2C+cooperates+with+rapamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin</span></div><div class="casAuthors">Ma, Patrick C.; Schaefer, Erik; Christensen, James G.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2319</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">c-MET is believed to be an attractive receptor target for mol. therapeutic inhibition.  TPR-MET, a constitutively active oncogenic variant of MET, serves as excellent model for testing c-MET inhibitors.  Here, we characterized a small mol. c-MET inhibitor, PHA665752, and tested its cooperation with the mammalian target of rapamycin inhibitor as potential targeted therapy.  The effect of PHA665752 treatment was detd. on cell growth, motility and migration, apoptosis, and cell-cycle arrest of TPR-MET-transformed cells.  Moreover, the effect of PHA665752 on the phosphorylation on MET, as well as its downstream effectors, p-AKT and p-S6K, was also detd.  Finally, growth of TPR-MET-transformed cells was tested in the presence of PHA665752 and rapamycin.  H441 non-small cell lung cancer (NSCLC) cells (with activated c-Met) were also tested against both PHA665752 and rapamycin.  PHA665752 specifically inhibited cell growth in BaF3.  TPR-MET cells (IC50 < 0.06 μmol/L), induced apoptosis and cell cycle arrest.  Constitutive cell motility and migration of the BaF3.  TPR-MET cells was also inhibited.  PHA665752 inhibited specific phosphorylation of TPR-MET as well as phosphorylation of downstream targets of the mammalian target of rapamycin pathway.  When combined with PHA665752, rapamycin showed cooperative inhibition to reduce growth of BaF3.  TPR-MET- and c-MET-expressing H441 NSCLC cells.  PHA665752 is a potent small mol.-selective c-MET inhibitor and is highly active against TPR-MET-transformed cells both biol. and biochem.  PHA665752 is also active against H441 NSCLC cells.  The c-MET inhibitor can cooperate with rapamycin in therapeutic inhibition of NSCLC, and in vivo studies of this combination against c-MET expressing cancers would be merited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ6fVYSbU8ibVg90H21EOLACvtfcHk0lhsRWW6b_cDlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFaju7c%253D&md5=9e69f0253f675f4a1aeb96c115e2e420</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1708%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DA%2520selective%2520small%2520molecule%2520c-MET%2520inhibitor%252C%2520PHA665752%252C%2520cooperates%2520with%2520rapamycin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2312%26epage%3D2319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18d"><span><span class="NLM_contrib-group">Puri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khramtsov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetzel, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karczmar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">3529</span><span class="NLM_x">–</span> <span class="NLM_lpage">3534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=3529-3534&author=N.+Puriauthor=A.+Khramtsovauthor=S.+Ahmedauthor=V.+Nallasuraauthor=J.+T.+Hetzelauthor=R.+Jagadeeswaranauthor=G.+Karczmarauthor=R.+Salgia&title=A+selective+small+molecule+inhibitor+of+c-MET%2C+PHA665752%2C+inhibits+tumorigenicity+and+angiogenesis+in+mouse+lung+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DN.%26aulast%3DKhramtsov%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DHetzel%26aufirst%3DJ.%2BT.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKarczmar%26aufirst%3DG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%252C%2520PHA665752%252C%2520inhibits%2520tumorigenicity%2520and%2520angiogenesis%2520in%2520mouse%2520lung%2520cancer%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D3529%26epage%3D3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18e"><span><span class="NLM_contrib-group">Chattopadhyay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Naggar, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayman, G. L.</span><span> </span><span class="NLM_article-title">Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma</span> <span class="citation_source-journal">Head Neck</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fhed.20816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=991-1000&author=C.+Chattopadhyayauthor=A.+K.+El-Naggarauthor=M.+D.+Williamsauthor=G.+L.+Clayman&title=Small+molecule+c-MET+inhibitor+PHA665752%3A+effect+on+cell+growth+and+motility+in+papillary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1002%2Fhed.20816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhed.20816%26sid%3Dliteratum%253Aachs%26aulast%3DChattopadhyay%26aufirst%3DC.%26aulast%3DEl-Naggar%26aufirst%3DA.%2BK.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DClayman%26aufirst%3DG.%2BL.%26atitle%3DSmall%2520molecule%2520c-MET%2520inhibitor%2520PHA665752%253A%2520effect%2520on%2520cell%2520growth%2520and%2520motility%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DHead%2520Neck%26date%3D2007%26volume%3D30%26spage%3D991%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18f"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wislez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izzo, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurie, J. M.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET, PHA-665752, reverses lung premalignancy induced by mutant <i>K-ras</i></span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18f&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1158%2F1535-7163.MCT-07-2045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18f&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=18413809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18f&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=952-960&author=Y.+Yangauthor=M.+Wislezauthor=N.+Fujimotoauthor=L.+Prudkinauthor=J.+G.+Izzoauthor=F.+Unoauthor=L.+Jiauthor=E.+Amyauthor=A.+E.+Hannaauthor=R.+R.+Langleyauthor=D.+Liuauthor=F.+M.+Johnsonauthor=I.+Wistubaauthor=J.+M.+Kurie&title=A+selective+small+molecule+inhibitor+of+c-MET%2C+PHA-665752%2C+reverses+lung+premalignancy+induced+by+mutant+K-ras"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18fR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras</span></div><div class="casAuthors">Yang, Yanan; Wislez, Marie; Fujimoto, Nobukazu; Prudkin, Ludmila; Izzo, Julie G.; Uno, Futoshi; Ji, Lin; Hanna, Amy E.; Langley, Robert R.; Liu, Diane; Johnson, Faye M.; Wistuba, Ignacio; Kurie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-960</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase has been implicated in cellular transformation induced by mutant Ras, a commonly activated proto-oncogene in non-small cell lung cancer (NSCLC).  However, the role of c-Met has not been defined in K-ras-mutant NSCLC, a disease for which no effective targeted therapeutic options currently exist.  To acquire a greater understanding of its role, we used genetic and pharmacol. approaches to inhibit c-Met in mice and cultured cells.  In KrasLA1 mice, which develop premalignant lung lesions that progress to multifocal lung adenocarcinomas owing to somatic mutations in K-ras, c-Met was expressed in multiple cell types within premalignant lung lesions, and high concns. of HGF were detected in bronchoalveolar lavage samples.  Short-term treatment with PHA-665752, a c-Met inhibitor, decreased the nos. of premalignant lung lesions and induced apoptosis in tumor cells and vascular endothelial cells within lesions.  In cell culture, PHA-665752 induced apoptosis of a lung adenocarcinoma cell line derived from KrasLA1 mice (LKR-13) and a murine lung endothelial cell line (MEC).  C-Met depletion by siRNA transfection induced apoptosis of MECs but not LKR-13 cells.  Collectively, these findings suggest that apoptosis was an on-target effect of PHA-665752 in MECs but not in LKR-13 cells.  We conclude that PHA-665752 inhibited lung tumorigenesis in KrasLA1 mice and may provide a novel therapeutic approach to the prevention of K-ras-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lgtND1nnfbVg90H21EOLACvtfcHk0lhsRWW6b_cDlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gmsb0%253D&md5=0d2ee01079be38dc194598c659bde3b5</span></div><a href="/servlet/linkout?suffix=cit18f&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2045%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWislez%26aufirst%3DM.%26aulast%3DFujimoto%26aufirst%3DN.%26aulast%3DPrudkin%26aufirst%3DL.%26aulast%3DIzzo%26aufirst%3DJ.%2BG.%26aulast%3DUno%26aufirst%3DF.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DAmy%26aufirst%3DE.%26aulast%3DHanna%26aufirst%3DA.%2BE.%26aulast%3DLangley%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DF.%2BM.%26aulast%3DWistuba%26aufirst%3DI.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%252C%2520PHA-665752%252C%2520reverses%2520lung%2520premalignancy%2520induced%2520by%2520mutant%2520K-ras%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D952%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cui, J. J.</span> Unpublished results. PHA-665752 was discovered as a potent and selective c-MET kinase inhibitor. Because of the high lipophilicity and large molecular weight, PHA-665752 demonstrated high metabolic clearance (CL = 77 (mL/min)/kg in rat in vivo PK study), low permeability, and a pH dependent solubility. PHA-665752 was originally positioned as a preclinic candidate with an intravenous drug profile. However, the low solubility at pH 7.4 (0.9 μg/mL) prevented PHA-665752 as a potential intravenous drug candidate for clinical applications.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cui%2C+J.+J.+Unpublished+results.+PHA-665752+was+discovered+as+a+potent+and+selective+c-MET+kinase+inhibitor.+Because+of+the+high+lipophilicity+and+large+molecular+weight%2C+PHA-665752+demonstrated+high+metabolic+clearance+%28CL+%3D+77+%28mL%2Fmin%29%2Fkg+in+rat+in+vivo+PK+study%29%2C+low+permeability%2C+and+a+pH+dependent+solubility.+PHA-665752+was+originally+positioned+as+a+preclinic+candidate+with+an+intravenous+drug+profile.+However%2C+the+low+solubility+at+pH+7.4+%280.9+%CE%BCg%2FmL%29+prevented+PHA-665752+as+a+potential+intravenous+drug+candidate+for+clinical+applications."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">–</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0lhuet3ThzU4HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1126%2Fscience.276.5314.955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=9139660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=955-960&author=M.+Mohammadiauthor=G.+McMahonauthor=Li.+Sunauthor=C.+Tangauthor=P.+Hirthauthor=B.+K.+Yehauthor=S.+R.+Hubbardauthor=J.+Schlessinger&title=Structures+of+the+tyrosine+kinase+domain+of+fibroblast+growth+factor+receptor+in+complex+with+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors</span></div><div class="casAuthors">Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5314</span>),
    <span class="NLM_cas:pages">955-960</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones).  Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases.  Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were detd.  The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes.  The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop.  This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwP7A-FMgDLVg90H21EOLACvtfcHk0lhuet3ThzU4HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1ans7w%253D&md5=fdbedba79850d11771677e6d25f3842f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5314.955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5314.955%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DLi.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DYeh%26aufirst%3DB.%2BK.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520in%2520complex%2520with%2520inhibitors%26jtitle%3DScience%26date%3D1997%26volume%3D276%26spage%3D955%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">LE = [–<i>RT</i> log(<i>K</i><sub>i</sub> or IC<sub>50</sub>)]/number of heavy atoms.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cui, J. J.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cui%2C+J.+J.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">–</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+c-MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520c-MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Structure-Based Design and Characterization of Axitinib</span>. In  <span class="citation_source-book">Kinase Inhibitor Drugs</span>; <span class="NLM_contrib-group">Li, R.; Stafford, J. A.</span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2F9780470524961.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=167-200&author=R.+S.+Kaniaauthor=R.+Li&author=J.+A.+Stafford&title=Kinase+Inhibitor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F9780470524961.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470524961.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DStructure-Based%2520Design%2520and%2520Characterization%2520of%2520Axitinib%26btitle%3DKinase%2520Inhibitor%2520Drugs%26aulast%3DLi%26aufirst%3DR.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2009%26spage%3D167%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wagh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peace, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, S. E.</span><span> </span><span class="NLM_article-title">Met-related receptor tyrosine kinase Ron in tumor growth and metastasis</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=1-33&author=P.+K.+Waghauthor=B.+E.+Peaceauthor=S.+E.+Waltz&title=Met-related+receptor+tyrosine+kinase+Ron+in+tumor+growth+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWagh%26aufirst%3DP.%2BK.%26aulast%3DPeace%26aufirst%3DB.%2BE.%26aulast%3DWaltz%26aufirst%3DS.%2BE.%26atitle%3DMet-related%2520receptor%2520tyrosine%2520kinase%2520Ron%2520in%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2008%26volume%3D100%26spage%3D1%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Accornero, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, M.</span><span> </span><span class="NLM_article-title">The scatter factor signaling pathways as therapeutic associated target in cancer treatment</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2692</span><span class="NLM_x">–</span> <span class="NLM_lpage">2712</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.2174%2F092986710791859261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2692-2712&author=P.+Accorneroauthor=L.+M.+Pavoneauthor=M.+Baratta&title=The+scatter+factor+signaling+pathways+as+therapeutic+associated+target+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F092986710791859261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791859261%26sid%3Dliteratum%253Aachs%26aulast%3DAccornero%26aufirst%3DP.%26aulast%3DPavone%26aufirst%3DL.%2BM.%26aulast%3DBaratta%26aufirst%3DM.%26atitle%3DThe%2520scatter%2520factor%2520signaling%2520pathways%2520as%2520therapeutic%2520associated%2520target%2520in%2520cancer%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2692%26epage%3D2712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_contrib-group">Cheng, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N. H.</span><span> </span><span class="NLM_article-title">Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1906</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1038%2Fsj.bjc.6602593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=15870710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=1906-1914&author=H.+L.+Chengauthor=H.+S.+Liuauthor=Y.+J.+Linauthor=H.+H.+Chenauthor=P.+Y.+Hsuauthor=T.+Y.+Changauthor=C.+L.+Hoauthor=T.+S.+Tzaiauthor=N.+H.+Chow&title=Co-expression+of+RON+and+MET+is+a+prognostic+indicator+for+patients+with+transitional-cell+carcinoma+of+the+bladder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder</span></div><div class="casAuthors">Cheng, H-L.; Liu, H-S.; Lin, Y-J.; Chen, H. H-W.; Hsu, P-Y.; Chang, T-Y.; Ho, C-L.; Tzai, T-S.; Chow, N-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1906-1914</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recepteur d'Origine Nantais (RON) is a distinct receptor tyrosine kinase in the c-met proto-oncogene family.  We examd. the mutational and expression patterns of RON in eight human uroepithelial cell lines.  Biol. effects of RON overexpression on cancer cells were investigated in vitro, and the prognostic significance of RON and/or c-met protein (MET) expression was analyzed in a bladder cancer cohort (n=183).  There was no evidence of mutation in the kinase domain of RON.  Overexpression of RON using an inducible Tet-off system induced increased cell proliferation, motility, and antiapoptosis.  Immunohistochem. anal. showed that RON was overexpressed in 60 cases (32.8%) of primary tumors, with 14 (23.3%) showing a high level of expression.  Recepteur d'Origine Nantais expression was pos. assocd. with histol. grading, larger size, nonpapillary contour, and tumor stage (all P<0.01).  In addn., MET was overexpressed in 82 cases (44.8%).  Co-expressed RON and MET was significantly assocd. with decreased overall survival (P=0.005) or metastasis-free survival (P=0.01) in 35 cases (19.1%).  Recepteur d'Origine Nantais-assocd. signalling may play an important role in the progression of human bladder cancer.  Evaluation of RON and MET expression status may identify a subset of bladder-cancer patients who require more intensive treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy3Jc9r7lea7Vg90H21EOLACvtfcHk0lgTgk-72s8n9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D&md5=2da682ab6fe899da8b0b959e6c86d0e4</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602593%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BL.%26aulast%3DLiu%26aufirst%3DH.%2BS.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DH.%2BH.%26aulast%3DHsu%26aufirst%3DP.%2BY.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DHo%26aufirst%3DC.%2BL.%26aulast%3DTzai%26aufirst%3DT.%2BS.%26aulast%3DChow%26aufirst%3DN.%2BH.%26atitle%3DCo-expression%2520of%2520RON%2520and%2520MET%2520is%2520a%2520prognostic%2520indicator%2520for%2520patients%2520with%2520transitional-cell%2520carcinoma%2520of%2520the%2520bladder%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D1906%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_contrib-group">Catenacci, D. V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hashani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanteti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Dinali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasina, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brägelmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanicola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grushko, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olopade, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgi, R.</span><span> </span><span class="NLM_article-title">RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.4161%2Fcbt.12.1.15747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=21543897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2hsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=9-46&author=D.+V.+T.+Catenacciauthor=G.+Cervantesauthor=S.+Yalaauthor=E.+A.+Nelsonauthor=E.+El-Hashaniauthor=R.+Kantetiauthor=M.+El+Dinaliauthor=R.+Hasinaauthor=J.+Br%C3%A4gelmannauthor=T.+Seiwertauthor=M.+Sanicolaauthor=L.+Hendersonauthor=T.+A.+Grushkoauthor=O.+Olopadeauthor=T.+Karrisonauthor=Y.-J.+Bangauthor=W.+H.+Kimauthor=M.+Tretiakovaauthor=E.+Vokesauthor=D.+A.+Frankauthor=H.+L.+Kindlerauthor=H.+Huetauthor=R.+Salgi&title=RON+%28MST1R%29+is+a+novel+prognostic+marker+and+therapeutic+target+for+gastroesophageal+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma</span></div><div class="casAuthors">Catenacci, Daniel V. T.; Cervantes, Gustavo; Yala, Soheil; Nelson, Erik A.; El-Hashani, Essam; Kanteti, Rajani; El Dinali, Mohamed; Hasina, Rifat; Bragelmann, Johannes; Seiwert, Tanguy; Sanicola, Michele; Henderson, Les; Grushko, Tatyana A.; Olopade, Olufunmilayo; Karrison, Theodore; Bang, Yung-Jue; Kim, Woo Ho; Tretiakova, Maria; Vokes, Everett; Frank, David A.; Kindler, Hedy L.; Huet, Heather; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-46</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">RON (MST1R) is one of two members of the MET receptor tyrosine kinase family, along with parent receptor MET.  RON has a putative role in several cancers, but its expression and function is poorly characterized in gastroesophageal adenocarcinoma.  A recognized functional role of MET tyrosine kinase in gastroesophageal cancer has led to early phase clin. trials using MET inhibitors, with unimpressive results.  Therefore, the role of RON in gastroesophageal cancer, as well as its role in cooperative signaling with MET and as a mechanism of resistance to MET inhibition, was studied in gastroesophageal tissues and cell lines.  By IHC, RON was highly overexpressed in 74% of gastroesophageal samples (n = 94) and overexpression was prognostic of poor survival (p = 0.008); RON and MET co-expression occurred in 43% of samples and was prognostic of worst survival (p = 0.03).  High MST1R gene copy no. by quant. polymerase chain reaction and confirmed by fluorescence in situ hybridization and/or array comparative genomic hybridization, was seen in 35.5% (16/45) of cases.  High MST1R gene copy no. correlated with poor survival (p = 0.01), and was assocd. with high MET and ERBB2 gene copy no.  A novel somatic MST1R juxtamembrane mutation R1018G was found in 11% of samples.  RON signaling was functional in cell lines, activating downstream effector STAT3, and resulted in increased viability over controls.  RON and MET co-stimulation assays led to enhanced malignant phenotypes over stimulation of either receptor alone.  Growth inhibition as evidenced by viability and apoptosis assays was optimal using novel blocking monoclonal antibodies to both RON and MET, vs. either alone.  SU11274, a classic MET small mol. tyrosine kinase inhibitor, blocked signaling of both receptors and proved synergistic when combined with STAT3 inhibition (combination index <1).  These preclin. studies define RON as an important novel prognostic marker and therapeutic target for gastroesophageal cancer warranting further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIwsWP_-5oL7Vg90H21EOLACvtfcHk0lgTgk-72s8n9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2hsL4%253D&md5=3a5218b61d602dfddab721e62ec43353</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.4161%2Fcbt.12.1.15747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.12.1.15747%26sid%3Dliteratum%253Aachs%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%2BT.%26aulast%3DCervantes%26aufirst%3DG.%26aulast%3DYala%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DEl-Hashani%26aufirst%3DE.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DEl%2BDinali%26aufirst%3DM.%26aulast%3DHasina%26aufirst%3DR.%26aulast%3DBr%25C3%25A4gelmann%26aufirst%3DJ.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DSanicola%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DGrushko%26aufirst%3DT.%2BA.%26aulast%3DOlopade%26aufirst%3DO.%26aulast%3DKarrison%26aufirst%3DT.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DTretiakova%26aufirst%3DM.%26aulast%3DVokes%26aufirst%3DE.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26aulast%3DHuet%26aufirst%3DH.%26aulast%3DSalgi%26aufirst%3DR.%26atitle%3DRON%2520%2528MST1R%2529%2520is%2520a%2520novel%2520prognostic%2520marker%2520and%2520therapeutic%2520target%2520for%2520gastroesophageal%2520adenocarcinoma%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2011%26volume%3D12%26spage%3D9%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_contrib-group">Drexler, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gignac, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Wasielewski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirks, W. G.</span><span> </span><span class="NLM_article-title">Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1533</span><span class="NLM_x">–</span> <span class="NLM_lpage">1559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=1533-1559&author=H.+G.+Drexlerauthor=S.+M.+Gignacauthor=R.+von+Wasielewskiauthor=M.+Wernerauthor=W.+G.+Dirks&title=Pathobiology+of+NPM-ALK+and+variant+fusion+genes+in+anaplastic+large+cell+lymphoma+and+other+lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26aulast%3DGignac%26aufirst%3DS.%2BM.%26aulast%3Dvon%2BWasielewski%26aufirst%3DR.%26aulast%3DWerner%26aufirst%3DM.%26aulast%3DDirks%26aufirst%3DW.%2BG.%26atitle%3DPathobiology%2520of%2520NPM-ALK%2520and%2520variant%2520fusion%2520genes%2520in%2520anaplastic%2520large%2520cell%2520lymphoma%2520and%2520other%2520lymphomas%26jtitle%3DLeukemia%26date%3D2000%26volume%3D14%26spage%3D1533%26epage%3D1559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedeutour, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Wolf-Peeters, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span> </span><span class="NLM_article-title">Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1002%2Fgcc.10033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=12112524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2002&pages=354-362&author=J.+Coolsauthor=I.+Wlodarskaauthor=R.+Somersauthor=N.+Mentensauthor=F.+Pedeutourauthor=B.+Maesauthor=C.+De+Wolf-Peetersauthor=P.+Pauwelsauthor=A.+Hagemeijerauthor=P.+Marynen&title=Identification+of+novel+fusion+partners+of+ALK%2C+the+anaplastic+lymphoma+kinase%2C+in+anaplastic+large-cell+lymphoma+and+inflammatory+myofibroblastic+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Cools, Jan; Wlodarska, Iwona; Somers, Riet; Mentens, Nicole; Pedeutour, Florence; Maes, Brigitte; De Wolf-Peeters, Christiane; Pauwels, Patrick; Hagemeijer, Anne; Marynen, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">ALK-pos. anaplastic large-cell lymphoma (ALCL) has been recognized as a distinct type of lymphoma in the heterogeneous group of T/Null-ALCL.  While most of the ALK-pos. ALCL (ALKomas) are characterized by the presence of the NPM-ALK fusion protein, the product of the t(2;5)(p23;q35), 10-20% of ALKomas contain variant ALK fusions, including ATIC-ALK, TFG-ALK, CLTC-ALK (previously designated CLTCL-ALK), TMP3-ALK, and MSN-ALK.  TMP3-ALK and TMP4-ALK fusions also have been detected in inflammatory myofibroblastic tumors (IMTs), making clear that aberrations of the ALK gene are not assocd. exclusively with the pathogenesis of ALK-pos. ALCL.  Here the authors report results of mol. studies on two lymphoma cases and one IMT case with variant rearrangements of ALK.  The authors' study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA 1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).  These results confirm the recurrent involvement of ALK in IMT and further demonstrate the diversity of ALK fusion partners, with the ability to homodimerize as a common characteristic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXRK_iZnUkNrVg90H21EOLACvtfcHk0ljKW1ZaJU9UiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D&md5=5e15ec7d207444665354c7f08d2620fc</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1002%2Fgcc.10033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.10033%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DSomers%26aufirst%3DR.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DPedeutour%26aufirst%3DF.%26aulast%3DMaes%26aufirst%3DB.%26aulast%3DDe%2BWolf-Peeters%26aufirst%3DC.%26aulast%3DPauwels%26aufirst%3DP.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520fusion%2520partners%2520of%2520ALK%252C%2520the%2520anaplastic%2520lymphoma%2520kinase%252C%2520in%2520anaplastic%2520large-cell%2520lymphoma%2520and%2520inflammatory%2520myofibroblastic%2520tumor%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2002%26volume%3D34%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Viaud, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamoneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savelon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillaumet, G.</span><span> </span><span class="NLM_article-title">Synthesis of 6-substituted 2-phenyloxazolo[4,5-<i>b</i>]pyridines</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2799</span><span class="NLM_x">–</span> <span class="NLM_lpage">2809</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1995&pages=2799-2809&author=M.-C.+Viaudauthor=P.+Jamoneauauthor=L.+Savelonauthor=G.+Guillaumet&title=Synthesis+of+6-substituted+2-phenyloxazolo%5B4%2C5-b%5Dpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DViaud%26aufirst%3DM.-C.%26aulast%3DJamoneau%26aufirst%3DP.%26aulast%3DSavelon%26aufirst%3DL.%26aulast%3DGuillaumet%26aufirst%3DG.%26atitle%3DSynthesis%2520of%25206-substituted%25202-phenyloxazolo%255B4%252C5-b%255Dpyridines%26jtitle%3DHeterocycles%26date%3D1995%26volume%3D41%26spage%3D2799%26epage%3D2809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Suh, Y.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J.-S.</span><span> </span><span class="NLM_article-title">Concise and versatile syntheses of <i>N</i>-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1998&pages=239-242&author=Y.-G.+Suhauthor=D.-Y.+Shinauthor=K.-H.+Choauthor=J.-S.+Ryu&title=Concise+and+versatile+syntheses+of+N-arylalkylpiperidines+as+potential+intermediates+for+4-anilidopiperidine+analgesics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuh%26aufirst%3DY.-G.%26aulast%3DShin%26aufirst%3DD.-Y.%26aulast%3DCho%26aufirst%3DK.-H.%26aulast%3DRyu%26aufirst%3DJ.-S.%26atitle%3DConcise%2520and%2520versatile%2520syntheses%2520of%2520N-arylalkylpiperidines%2520as%2520potential%2520intermediates%2520for%25204-anilidopiperidine%2520analgesics%26jtitle%3DHeterocycles%26date%3D1998%26volume%3D48%26spage%3D239%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Carlos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metselaar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruithof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span> </span><span class="NLM_article-title">Biotransformation-mediated synthesis of (1<i>S</i>)-1-(2,6-dichloro-3-fluorophenyl)ethanol in enantiomerically pure form</span> <span class="citation_source-journal">Tetrahedron: Asymmetry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=2408-2412&author=A.+Carlosauthor=C.+A.+Martinezauthor=E.+Kellerauthor=R.+Meijerauthor=G.+Metselaarauthor=G.+Kruithofauthor=C.+Mooreauthor=P.-P.+Kung&title=Biotransformation-mediated+synthesis+of+%281S%29-1-%282%2C6-dichloro-3-fluorophenyl%29ethanol+in+enantiomerically+pure+form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlos%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DC.%2BA.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DMeijer%26aufirst%3DR.%26aulast%3DMetselaar%26aufirst%3DG.%26aulast%3DKruithof%26aufirst%3DG.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DKung%26aufirst%3DP.-P.%26atitle%3DBiotransformation-mediated%2520synthesis%2520of%2520%25281S%2529-1-%25282%252C6-dichloro-3-fluorophenyl%2529ethanol%2520in%2520enantiomerically%2520pure%2520form%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D2010%26volume%3D21%26spage%3D2408%26epage%3D2412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaptason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span> </span><span class="NLM_article-title">Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically-based pharmacokinetic modeling versus traditional one-compartment model</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=383-393&author=S.+Yamazakiauthor=J.+Skaptasonauthor=D.+Romeroauthor=S.+Vekichauthor=H.+M.+Jonesauthor=W.+Tanauthor=K.+Wilnerauthor=T.+Koudriakova&title=Prediction+of+oral+pharmacokinetics+of+cMet+kinase+inhibitors+in+humans%3A+physiologically-based+pharmacokinetic+modeling+versus+traditional+one-compartment+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DVekich%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DPrediction%2520of%2520oral%2520pharmacokinetics%2520of%2520cMet%2520kinase%2520inhibitors%2520in%2520humans%253A%2520physiologically-based%2520pharmacokinetic%2520modeling%2520versus%2520traditional%2520one-compartment%2520model%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D383%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaptason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetic–pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available c-MET kinase inhibitor in human tumor xenograft mouse models</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1267-1274&author=S.+Yamazakiauthor=J.+Skaptasonauthor=D.+Romeroauthor=J.+H.+Leeauthor=H.+Y.+Zouauthor=J.+G.+Christensenauthor=J.+R.+Koupauthor=B.+J.+Smithauthor=T.+Koudriakova&title=Pharmacokinetic%E2%80%93pharmacodynamic+modeling+of+biomarker+response+and+tumor+growth+inhibition+to+an+orally+available+c-MET+kinase+inhibitor+in+human+tumor+xenograft+mouse+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DKoup%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DPharmacokinetic%25E2%2580%2593pharmacodynamic%2520modeling%2520of%2520biomarker%2520response%2520and%2520tumor%2520growth%2520inhibition%2520to%2520an%2520orally%2520available%2520c-MET%2520kinase%2520inhibitor%2520in%2520human%2520tumor%2520xenograft%2520mouse%2520models%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1267%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell-lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&author=E.+L.+Kwakauthor=Y.-J.+Bangauthor=R.+Camidgeauthor=A.+T.+Shawauthor=B+Solomonauthor=R.+G.+Makiauthor=S.-H.+I.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.-H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell-lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0liy1d9-tPULTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DCamidge%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.-H.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell-lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_contrib-group">Butrynski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornick, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Cin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhanwar, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMoa1007056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=20979472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1727-1733&author=J.+E.+Butrynskiauthor=D.+R.+D%E2%80%99Adamoauthor=J.+L.+Hornickauthor=P.+Dal+Cinauthor=C.+R.+Antonescuauthor=S.+C.+Jhanwarauthor=M.+Ladanyiauthor=M.+Capellettiauthor=S.+J.+Rodigauthor=N.+Ramaiyaauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=K.+D.+Wilnerauthor=J.+G.+Christensenauthor=P.+A.+J%C3%A4nneauthor=R.+G.+Makiauthor=G.+D.+Demetriauthor=G.+I.+Shapiro&title=Crizotinib+in+ALK-rearranged+inflammatory+myofibroblastic+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Butrynski, James E.; D'Adamo, David R.; Hornick, Jason L.; Dal Cin, Paola; Antonescu, Cristina R.; Jhanwar, Suresh C.; Ladanyi, Marc; Capelletti, Marzia; Rodig, Scott J.; Ramaiya, Nikhil; Kwak, Eunice L.; Clark, Jeffrey W.; Wilner, Keith D.; Christensen, James G.; Janne, Pasi A.; Maki, Robert G.; Demetri, George D.; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1727-1733</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate.  Approx. half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression.  We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no obsd. activity in another patient without the ALK translocation.  These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeQPUocISij7Vg90H21EOLACvtfcHk0liy1d9-tPULTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FI&md5=757a1bfa766ea47507542afb93387895</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007056%26sid%3Dliteratum%253Aachs%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%2BR.%26aulast%3DHornick%26aufirst%3DJ.%2BL.%26aulast%3DDal%2BCin%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DJhanwar%26aufirst%3DS.%2BC.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DRamaiya%26aufirst%3DN.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCrizotinib%2520in%2520ALK-rearranged%2520inflammatory%2520myofibroblastic%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1727%26epage%3D1733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogliani, E. M.</span><span> </span><span class="NLM_article-title">Crizotinib in large cell anaplastic lymphoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">776</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1056%2FNEJMc1013224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=21345110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A280%3ADC%252BC3M3hsVOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=775-776&author=C.+Gambacorti-Passeriniauthor=C.+Messaauthor=E.+M.+Pogliani&title=Crizotinib+in+large+cell+anaplastic+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in anaplastic large-cell lymphoma</span></div><div class="casAuthors">Gambacorti-Passerini Carlo; Messa Cristina; Pogliani Enrico M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">775-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS57pbSZcjKy5I8NvIb08rbfW6udTcc2eblPMZ0daawBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3hsVOntg%253D%253D&md5=34f64413ae3c80d4faac17d07c05284e</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1013224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1013224%26sid%3Dliteratum%253Aachs%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMessa%26aufirst%3DC.%26aulast%3DPogliani%26aufirst%3DE.%2BM.%26atitle%3DCrizotinib%2520in%2520large%2520cell%2520anaplastic%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D775%26epage%3D776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_contrib-group">Ou, S. -H. I.; Kwak, E. L.; Siwak-Tapp, C.; Dy, J.; Bergethon, K.; Clark, J. W.; Camidge, D. R.; Solomon, B. J.; Maki, R. G.; Bang, Y. -J.; Kim, D. -W; Christensen, J.; Tan, W.; Wilner, K. D.; Salgia, R.; Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-Small Cell Lung Cancer Patient with de novo <i>MET</i> Amplification</span>. J. Thorac. Oncol.<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Fjm2007613&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Fjm2007613&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Fjm2007613&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+-H.+I.+Ou&author=E.+L.+Kwak&author=C.+Siwak-Tapp&author=J.+Dy&author=K.+Bergethon&author=J.+W.+Clark&author=D.+R.+Camidge&author=B.+J.+Solomon&author=R.+G.+Maki&author=Y.+-J.+Bang&author=D.+-W+Kim&author=J.+Christensen&author=W.+Tan&author=K.+D.+Wilner&author=R.+Salgia&author=A.+J.+Iafrate&title=Activity+of+Crizotinib+%28PF02341066%29%2C+a+Dual+Mesenchymal-Epithelial+Transition+%28MET%29+and+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor%2C+in+a+Non-Small+Cell+Lung+Cancer+Patient+with+de+novo+MET+Amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2eblPMZ0daawBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2B-H.%2BI.%26atitle%3DActivity%2520of%2520Crizotinib%2520%2528PF02341066%2529%252C%2520a%2520Dual%2520Mesenchymal-Epithelial%2520Transition%2520%2528MET%2529%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%252C%2520in%2520a%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Patient%2520with%2520de%2520novo%2520MET%2520Amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_contrib-group">Chi, A. S.; Kwak, E. L.; Clark, J. W.; Wang, D. L.; Louis, D. N.; Iafrate, A. J.; Batchelor, T.</span><span> </span><span class="NLM_article-title">Clinical Improvement and Rapid Radiographic Regression Induced by a MET Inhibitor in a Patient with MET-Amplified Glioblastoma</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 2072.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+S.+Chi&author=E.+L.+Kwak&author=J.+W.+Clark&author=D.+L.+Wang&author=D.+N.+Louis&author=A.+J.+Iafrate&author=T.+Batchelor&title=Clinical+Improvement+and+Rapid+Radiographic+Regression+Induced+by+a+MET+Inhibitor+in+a+Patient+with+MET-Amplified+Glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%2BS.%26atitle%3DClinical%2520Improvement%2520and%2520Rapid%2520Radiographic%2520Regression%2520Induced%2520by%2520a%2520MET%2520Inhibitor%2520in%2520a%2520Patient%2520with%2520MET-Amplified%2520Glioblastoma%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36c"><span><span class="NLM_contrib-group">Lennerz, J. K.; Kwak, E. L.; Michael, M.; Fox, S. B.; Ackerman, A.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y.; Clark, J. W.; Solomon, B. J.; Iafrate, A., J.</span><span> </span><span class="NLM_article-title">Identification of a Small and Lethal Subgroup of Esophagogastric Adenocarcinoma with Evidence of Responsiveness to Crizotinib by MET Amplification</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 4130.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+K.+Lennerz&author=E.+L.+Kwak&author=M.+Michael&author=S.+B.+Fox&author=A.+Ackerman&author=K.+Bergethon&author=G.+Y.+Lauwers&author=J.+G.+Christensen&author=K.+D.+Wilner&author=D.+A.+Haber&author=R.+Salgia&author=Y.+Bang&author=J.+W.+Clark&author=B.+J.+Solomon&author=A.%2C+J.+Iafrate&title=Identification+of+a+Small+and+Lethal+Subgroup+of+Esophagogastric+Adenocarcinoma+with+Evidence+of+Responsiveness+to+Crizotinib+by+MET+Amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26atitle%3DIdentification%2520of%2520a%2520Small%2520and%2520Lethal%2520Subgroup%2520of%2520Esophagogastric%2520Adenocarcinoma%2520with%2520Evidence%2520of%2520Responsiveness%2520to%2520Crizotinib%2520by%2520MET%2520Amplification%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj','PDB','2wgj'); return false;">PDB: 2wgj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2xp2','PDB','2xp2'); return false;">PDB: 2xp2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm','PDB','2wkm'); return false;">PDB: 2wkm</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm2007613&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm2007613%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-18%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm2007613" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f3e629ef24c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
